doc_id stringlengths 12 18 | text stringlengths 71 5.65k | annotations_brat stringlengths 54 5.63k | tokens listlengths 12 1.16k | token_starts listlengths 12 1.16k | token_ends listlengths 12 1.16k | labels listlengths 12 1.16k | ner_tags listlengths 12 1.16k |
|---|---|---|---|---|---|---|---|
MDIEC/20221103_175 | In primary care pediatric settings, the EPDS and its shorter subscales have potential for use as effective depression screening tools. | T1 method 3 34 primary care pediatric settings
T2 method 40 44 EPDS
T3 method 107 133 depression screening tools
R1 hyponym_of Arg1:T2 Arg2:T3
| [
"In",
"primary",
"care",
"pediatric",
"settings",
",",
"the",
"EPDS",
"and",
"its",
"shorter",
"subscales",
"have",
"potential",
"for",
"use",
"as",
"effective",
"depression",
"screening",
"tools",
"."
] | [
0,
3,
11,
16,
26,
34,
36,
40,
45,
49,
53,
61,
71,
76,
86,
90,
94,
97,
107,
118,
128,
133
] | [
2,
10,
15,
25,
34,
35,
39,
44,
48,
52,
60,
70,
75,
85,
89,
93,
96,
106,
117,
127,
133,
134
] | [
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"O",
"O",
"B-method",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"O"
] | [
0,
9,
10,
10,
10,
0,
0,
9,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
10,
0
] |
MDIEC/33743882 | Register-based metrics of years lived with disability associated with mental and substance use disorders: a register-based cohort study in Denmark. BACKGROUND Mental disorders account for a substantial proportion of the years lived with disability (YLDs) globally. These estimates have generally been calculated top down... | T0 disease 70 104 mental and substance use disorders
T1 Health_factors 26 53 years lived with disability
T3 method 108 135 register-based cohort study
T4 method 0 22 Register-based metrics
T5 disease 159 175 Mental disorders
T7 Health_factors 220 247 years lived with disability
T8 disease 462 496 mental and substance u... | [
"Register",
"-",
"based",
"metrics",
"of",
"years",
"lived",
"with",
"disability",
"associated",
"with",
"mental",
"and",
"substance",
"use",
"disorders",
":",
"a",
"register",
"-",
"based",
"cohort",
"study",
"in",
"Denmark",
".",
"BACKGROUND",
"Mental",
"dis... | [
0,
8,
9,
15,
23,
26,
32,
38,
43,
54,
65,
70,
77,
81,
91,
95,
104,
106,
108,
116,
117,
123,
130,
136,
139,
146,
148,
159,
166,
176,
184,
188,
190,
202,
213,
216,
220,
226,
232,
237,
248,
249,
253,
255,
263,
265,
271,
281,
... | [
8,
9,
14,
22,
25,
31,
37,
42,
53,
64,
69,
76,
80,
90,
94,
104,
105,
107,
116,
117,
122,
129,
135,
138,
146,
147,
158,
165,
175,
183,
187,
189,
201,
212,
215,
219,
225,
231,
236,
247,
249,
253,
254,
263,
264,
270,
280,
285,... | [
"B-method",
"I-method",
"I-method",
"I-method",
"O",
"B-Health_factors",
"I-Health_factors",
"I-Health_factors",
"I-Health_factors",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"I-met... | [
9,
10,
10,
10,
0,
1,
2,
2,
2,
0,
0,
3,
4,
4,
4,
4,
0,
0,
9,
10,
10,
10,
10,
0,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
1,
2,
2,
2,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
0,
0,
0,
0,
0,
... |
MDIEC/15292631 | QT interval and QT dispersion in eating disorders. BACKGROUND Eating disorders are thought to be risk factors for cardiac sudden death secondary to arrhythmia. Results in previous studies on QT interval and QT dispersion, markers of fatal arrhythmia, have been inconsistent. METHODS We prospectively examined 179 femal... | T0 disease 33 49 eating disorders
T1 signs 0 11 QT interval
T2 disease 62 78 Eating disorders
T3 disease 114 134 cardiac sudden death
T4 disease 148 158 arrhythmia
T6 disease 233 249 fatal arrhythmia
T8 signs 191 202 QT interval
T11 Health_factors 368 371 old
T12 method 403 418 DSM-IV criteria
T14 Health_factors 466 47... | [
"QT",
"interval",
"and",
"QT",
"dispersion",
"in",
"eating",
"disorders",
".",
"BACKGROUND",
"Eating",
"disorders",
"are",
"thought",
"to",
"be",
"risk",
"factors",
"for",
"cardiac",
"sudden",
"death",
"secondary",
"to",
"arrhythmia",
".",
"Results",
"in",
"pr... | [
0,
3,
12,
16,
19,
30,
33,
40,
49,
51,
62,
69,
79,
83,
91,
94,
97,
102,
110,
114,
122,
129,
135,
145,
148,
158,
160,
168,
171,
180,
188,
191,
194,
203,
207,
210,
220,
222,
230,
233,
239,
249,
251,
256,
261,
273,
277,
285,
... | [
2,
11,
15,
18,
29,
32,
39,
49,
50,
61,
68,
78,
82,
90,
93,
96,
101,
109,
113,
121,
128,
134,
144,
147,
158,
159,
167,
170,
179,
187,
190,
193,
202,
206,
209,
220,
221,
229,
232,
238,
249,
250,
255,
260,
273,
274,
284,
287,... | [
"B-signs",
"I-signs",
"O",
"B-signs",
"I-signs",
"O",
"B-disease",
"I-disease",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"B-signs",
... | [
15,
16,
0,
15,
16,
0,
3,
4,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
3,
4,
4,
0,
0,
3,
0,
0,
0,
0,
0,
0,
15,
16,
0,
15,
16,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
3,
4,
0,
0,
0,
0,
0,
0,
1,
0,
... |
MDIEC/20221103_11 | RESULTS: Depressed subjects who were not treated with antidepressant medications had lower levels of VZV-CMI following administration of zoster vaccine than nondepressed controls or depressed subjects receiving antidepressants even when antidepressant medications failed to alter depressive symptom severity (P<.005). | T1 disease 9 18 Depressed
T3 drug 54 80 antidepressant medications
T4 drug 237 263 antidepressant medications
T6 drug 137 151 zoster vaccine
T9 disease 182 191 depressed
T10 drug 211 226 antidepressants
T11 disease 280 298 depressive symptom
T5 physiology 101 108 VZV-CMI
R1 characteristic_of Arg1:T5 Arg2:T1
R2 treatme... | [
"RESULTS",
":",
"Depressed",
"subjects",
"who",
"were",
"not",
"treated",
"with",
"antidepressant",
"medications",
"had",
"lower",
"levels",
"of",
"VZV",
"-",
"CMI",
"following",
"administration",
"of",
"zoster",
"vaccine",
"than",
"nondepressed",
"controls",
"or"... | [
0,
7,
9,
19,
28,
32,
37,
41,
49,
54,
69,
81,
85,
91,
98,
101,
104,
105,
109,
119,
134,
137,
144,
152,
157,
170,
179,
182,
192,
201,
211,
227,
232,
237,
252,
264,
271,
274,
280,
291,
299,
308,
309,
310,
311,
312,
315,
316
] | [
7,
8,
18,
27,
31,
36,
40,
48,
53,
68,
80,
84,
90,
97,
100,
104,
105,
108,
118,
133,
136,
143,
151,
156,
169,
178,
181,
191,
200,
210,
226,
231,
236,
251,
263,
270,
273,
279,
290,
298,
307,
309,
310,
311,
312,
315,
316,
317... | [
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"B-drug",
"I-drug",
"O",
"O",
"O",
"O",
"B-physiology",
"I-physiology",
"I-physiology",
"O",
"O",
"O",
"B-drug",
"I-drug",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"B-drug",
"O",
"O",
"B-drug",
... | [
0,
0,
3,
0,
0,
0,
0,
0,
0,
5,
6,
0,
0,
0,
0,
11,
12,
12,
0,
0,
0,
5,
6,
0,
0,
0,
0,
3,
0,
0,
5,
0,
0,
5,
6,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
0
] |
MDIEC/32348643 | Association between Mental Disorders and Subsequent Medical Conditions. BACKGROUND Persons with mental disorders are at a higher risk than the general population for the subsequent development of certain medical conditions. METHODS We used a population-based cohort from Danish national registries that included data o... | T1 disease 20 36 Mental Disorders
T2 disease 96 112 mental disorders
T3 disease 505 521 mental disorders
T4 disease 722 738 mental disorders
T5 disease 822 838 mental disorders
T6 disease 1007 1022 mental disorder
T7 disease 1168 1183 mental disorder
T8 disease 1270 1286 mental disorders
T9 disease 1364 1379 mental dis... | [
"Association",
"between",
"Mental",
"Disorders",
"and",
"Subsequent",
"Medical",
"Conditions",
".",
"BACKGROUND",
"Persons",
"with",
"mental",
"disorders",
"are",
"at",
"a",
"higher",
"risk",
"than",
"the",
"general",
"population",
"for",
"the",
"subsequent",
"dev... | [
0,
12,
20,
27,
37,
41,
52,
60,
70,
72,
83,
91,
96,
103,
113,
117,
120,
122,
129,
134,
139,
143,
151,
162,
166,
170,
181,
193,
196,
204,
212,
222,
226,
234,
237,
242,
244,
254,
255,
261,
268,
273,
280,
289,
300,
305,
314,
3... | [
11,
19,
26,
36,
40,
51,
59,
70,
71,
82,
90,
95,
102,
112,
116,
119,
121,
128,
133,
138,
142,
150,
161,
165,
169,
180,
192,
195,
203,
211,
222,
223,
233,
236,
241,
243,
254,
255,
260,
267,
272,
279,
288,
299,
304,
313,
318,
... | [
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
... | [
0,
0,
3,
4,
0,
0,
3,
4,
0,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
1,
2,
0,
0,
0,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
9,
10,
10,
10,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
... |
MDIEC/20221103_47 | Imaging and postmortem brain studies in depressed human subjects, in combination with animal behavioral models of depression, have identified a number of different cellular events, intracellular signaling pathways, proteins, and target genes that are modulated by stress and are potentially vital mediators of antidepres... | T1 method 0 36 Imaging and postmortem brain studies
T2 disease 40 49 depressed
T3 method 86 110 animal behavioral models
T4 disease 114 124 depression
T6 physiology 181 213 intracellular signaling pathways
T9 disease 264 270 stress
T11 physiology 310 331 antidepressant action
T5 disease 164 179 cellular events
R1 assoc... | [
"Imaging",
"and",
"postmortem",
"brain",
"studies",
"in",
"depressed",
"human",
"subjects",
",",
"in",
"combination",
"with",
"animal",
"behavioral",
"models",
"of",
"depression",
",",
"have",
"identified",
"a",
"number",
"of",
"different",
"cellular",
"events",
... | [
0,
8,
12,
23,
29,
37,
40,
50,
56,
64,
66,
69,
81,
86,
93,
104,
111,
114,
124,
126,
131,
142,
144,
151,
154,
164,
173,
179,
181,
195,
205,
213,
215,
223,
225,
229,
236,
242,
247,
251,
261,
264,
271,
275,
279,
291,
297,
307,... | [
7,
11,
22,
28,
36,
39,
49,
55,
64,
65,
68,
80,
85,
92,
103,
110,
113,
124,
125,
130,
141,
143,
150,
153,
163,
172,
179,
180,
194,
204,
213,
214,
223,
224,
228,
235,
241,
246,
250,
260,
263,
270,
274,
278,
290,
296,
306,
30... | [
"B-method",
"I-method",
"I-method",
"I-method",
"I-method",
"O",
"B-disease",
"B-Health_factors",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"B-physiology",
... | [
9,
10,
10,
10,
10,
0,
3,
1,
0,
0,
0,
0,
0,
9,
10,
10,
0,
3,
0,
0,
0,
0,
0,
0,
0,
3,
4,
0,
11,
12,
12,
0,
0,
0,
0,
0,
7,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
0,
11,
12,
0
] |
MDIEC/20221103_181 | RESULTS: RMT treatment was associated with significant clinical improvement in depression scores at 8th week (Hamilton depression rating scale scores (Mean +- SEM) from 21.5 +- 2.44 to 14.31 +- 2.25, p <= 0.05). | T1 method 9 22 RMT treatment
T2 disease 79 89 depression
T3 method 110 149 Hamilton depression rating scale scores
R1 treatment_for Arg1:T1 Arg2:T2
T4 method 159 162 SEM
R2 help_diagnose Arg1:T3 Arg2:T2
| [
"RESULTS",
":",
"RMT",
"treatment",
"was",
"associated",
"with",
"significant",
"clinical",
"improvement",
"in",
"depression",
"scores",
"at",
"8th",
"week",
"(",
"Hamilton",
"depression",
"rating",
"scale",
"scores",
"(",
"Mean",
"+",
"-",
"SEM",
")",
"from",... | [
0,
7,
9,
13,
23,
27,
38,
43,
55,
64,
76,
79,
90,
97,
100,
104,
109,
110,
119,
130,
137,
143,
150,
151,
156,
157,
159,
162,
164,
169,
171,
172,
174,
175,
177,
178,
179,
182,
185,
187,
188,
191,
192,
194,
195,
196,
198,
200,... | [
7,
8,
12,
22,
26,
37,
42,
54,
63,
75,
78,
89,
96,
99,
103,
108,
110,
118,
129,
136,
142,
149,
151,
155,
157,
158,
162,
163,
168,
171,
172,
173,
175,
176,
178,
179,
181,
184,
187,
188,
190,
192,
193,
195,
196,
198,
199,
201... | [
"O",
"O",
"B-method",
"I-method",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"I-method",
"O",
"O",
"O",
"O",
"B-method",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
... | [
0,
0,
9,
10,
0,
0,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
9,
10,
10,
10,
10,
0,
0,
0,
0,
9,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
MDIEC/20221103_129 | Controversy: Repetitive transcranial magnetic stimulation or transcranial direct current stimulation shows efficacy in treating psychiatric diseases (depression, mania, schizophrenia, obsessive-complusive disorder, panic, posttraumatic stress disorder). | T1 method 13 57 Repetitive transcranial magnetic stimulation
T2 disease 128 148 psychiatric diseases
T3 disease 150 160 depression
T4 disease 162 167 mania
T5 disease 169 182 schizophrenia
T6 disease 184 213 obsessive-complusive disorder
T7 disease 215 220 panic
T8 disease 222 251 posttraumatic stress disorder
T9 metho... | [
"Controversy",
":",
"Repetitive",
"transcranial",
"magnetic",
"stimulation",
"or",
"transcranial",
"direct",
"current",
"stimulation",
"shows",
"efficacy",
"in",
"treating",
"psychiatric",
"diseases",
"(",
"depression",
",",
"mania",
",",
"schizophrenia",
",",
"obsess... | [
0,
11,
13,
24,
37,
46,
58,
61,
74,
81,
89,
101,
107,
116,
119,
128,
140,
149,
150,
160,
162,
167,
169,
182,
184,
193,
194,
205,
213,
215,
220,
222,
236,
243,
251,
252
] | [
11,
12,
23,
36,
45,
57,
60,
73,
80,
88,
100,
106,
115,
118,
127,
139,
148,
150,
160,
161,
167,
168,
182,
183,
193,
194,
204,
213,
214,
220,
221,
235,
242,
251,
252,
253
] | [
"O",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"B-disease",
"O",
"B-disease",
"O",
"B-disease",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-dise... | [
0,
0,
9,
10,
10,
10,
0,
9,
10,
10,
10,
0,
0,
0,
0,
3,
4,
0,
3,
0,
3,
0,
3,
0,
3,
4,
4,
4,
0,
3,
0,
3,
4,
4,
0,
0
] |
MDIEC/11187420 | Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia. Patients with serious psychiatric disorders are frequently treated by primary care physicians, who may have difficulty keeping up with recent advances in psychiatry. This paper presents an updated synopsis for three major psyc... | T0 disease 45 55 depression
T1 disease 57 73 bipolar disorder
T2 disease 79 92 schizophrenia
T3 method 0 40 Psychopharmacologic treatment strategies
T4 disease 108 137 serious psychiatric disorders
T6 Health_factors 164 187 primary care physicians
T7 method 248 258 psychiatry
T9 disease 316 337 psychiatric illnesses
T1... | [
"Psychopharmacologic",
"treatment",
"strategies",
"for",
"depression",
",",
"bipolar",
"disorder",
",",
"and",
"schizophrenia",
".",
"Patients",
"with",
"serious",
"psychiatric",
"disorders",
"are",
"frequently",
"treated",
"by",
"primary",
"care",
"physicians",
",",
... | [
0,
20,
30,
41,
45,
55,
57,
65,
73,
75,
79,
92,
94,
103,
108,
116,
128,
138,
142,
153,
161,
164,
172,
177,
187,
189,
193,
197,
202,
213,
221,
224,
229,
236,
245,
248,
258,
260,
265,
271,
280,
283,
291,
300,
304,
310,
316,
3... | [
19,
29,
40,
44,
55,
56,
64,
73,
74,
78,
92,
93,
102,
107,
115,
127,
137,
141,
152,
160,
163,
171,
176,
187,
188,
192,
196,
201,
212,
220,
223,
228,
235,
244,
247,
258,
259,
264,
270,
279,
282,
290,
299,
303,
309,
315,
327,
... | [
"B-method",
"I-method",
"I-method",
"O",
"B-disease",
"O",
"B-disease",
"I-disease",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"I-Health_factors",
"O",
"O",
"O",
"O",
... | [
9,
10,
10,
0,
3,
0,
3,
4,
0,
0,
3,
0,
0,
0,
3,
4,
4,
0,
0,
0,
0,
1,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
0,
3,
4,
0,
3,
4,
0,
0,
3,
0,
0,
0,
0,
0,
9,
... |
MDIEC/34416346 | Sub-regional hippocampal volumes in first-episode drug-naive major depression disorder. Hippocampal volume reduction was reported to underlie depressive symptomatology, however, the evidence to date remains inconsistent. For the complex intrinsic organization of hippocampus, the hippocampal volumes can be further divid... | T1 disease 36 86 first-episode drug-naive major depression disorder
T2 disease 142 167 depressive symptomatology
T3 disease 469 494 major depressive disorder
T4 disease 496 499 MDD
T5 disease 542 570 first-episode drug-naive MDD
T6 disease 1002 1005 MDD
T7 disease 1088 1091 MDD
T8 disease 1304 1307 MDD
T9 disease 1401 ... | [
"Sub",
"-",
"regional",
"hippocampal",
"volumes",
"in",
"first",
"-",
"episode",
"drug",
"-",
"naive",
"major",
"depression",
"disorder",
".",
"Hippocampal",
"volume",
"reduction",
"was",
"reported",
"to",
"underlie",
"depressive",
"symptomatology",
",",
"however"... | [
0,
3,
4,
13,
25,
33,
36,
41,
42,
50,
54,
55,
61,
67,
78,
86,
88,
100,
107,
117,
121,
130,
133,
142,
153,
167,
169,
176,
178,
182,
191,
194,
199,
207,
219,
221,
225,
229,
237,
247,
260,
263,
274,
276,
280,
292,
300,
304,
... | [
3,
4,
12,
24,
32,
35,
41,
42,
49,
54,
55,
60,
66,
77,
86,
87,
99,
106,
116,
120,
129,
132,
141,
152,
167,
168,
176,
177,
181,
190,
193,
198,
206,
219,
220,
224,
228,
236,
246,
259,
262,
274,
275,
279,
291,
299,
303,
306,
... | [
"B-signs",
"I-signs",
"I-signs",
"I-signs",
"I-signs",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"B-signs",
"I-signs",
"I-signs",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
... | [
15,
16,
16,
16,
16,
0,
3,
4,
4,
4,
4,
4,
4,
4,
4,
0,
15,
16,
16,
0,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
13,
0,
0,
15,
16,
0,
0,
0,
0,
0,
0,
0,
13,
14,
0,
0,
0,
0,
0,
0,
... |
MDIEC/10029644 | Effects of family history and place and season of birth on the risk of schizophrenia. BACKGROUND Although a family history of schizophrenia is the best-established risk factor for schizophrenia, environmental factors such as the place and season of birth may also be important. METHODS Using data from the Civil Regist... | T0 disease 71 84 schizophrenia
T1 Health_factors 11 25 family history
T4 Health_factors 30 55 place and season of birth
T6 disease 180 193 schizophrenia
T8 Health_factors 195 216 environmental factors
T11 Health_factors 229 254 place and season of birth
T13 Health_factors 108 139 family history of schizophrenia
T14 met... | [
"Effects",
"of",
"family",
"history",
"and",
"place",
"and",
"season",
"of",
"birth",
"on",
"the",
"risk",
"of",
"schizophrenia",
".",
"BACKGROUND",
"Although",
"a",
"family",
"history",
"of",
"schizophrenia",
"is",
"the",
"best",
"-",
"established",
"risk",
... | [
0,
8,
11,
18,
26,
30,
36,
40,
47,
50,
56,
59,
63,
68,
71,
84,
86,
97,
106,
108,
115,
123,
126,
140,
143,
147,
151,
152,
164,
169,
176,
180,
193,
195,
209,
217,
222,
225,
229,
235,
239,
246,
249,
255,
259,
264,
267,
276,
... | [
7,
10,
17,
25,
29,
35,
39,
46,
49,
55,
58,
62,
67,
70,
84,
85,
96,
105,
107,
114,
122,
125,
139,
142,
146,
151,
152,
163,
168,
175,
179,
193,
194,
208,
216,
221,
224,
228,
234,
238,
245,
248,
254,
258,
263,
266,
276,
277,
... | [
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"B-Health_factors",
"I-Health_factors",
"I-Health_factors",
"I-Health_factors",
"I-Health_factors",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"I-Health_factors",
"I-H... | [
0,
0,
1,
2,
0,
1,
2,
2,
2,
2,
0,
0,
0,
0,
3,
0,
0,
0,
0,
1,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
3,
0,
1,
2,
0,
0,
0,
1,
2,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
10,
10,
10,
0,
0,
0,
0,
9,... |
MDIEC/32828165 | Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. BACKGROUND Most individuals with schizophrenia-spectrum disorders have relapses, which increase the risk of morbidity and mortality. Because n... | T0 disease 0 17 Psychosis relapse
T1 disease 98 130 schizophrenia-spectrum disorders
T3 drug 40 77 long-acting injectable antipsychotics
T5 method 135 176 individual participant data meta-analysis
T7 disease 211 243 schizophrenia-spectrum disorders
T8 Health_factors 249 257 relapses
T9 disease 286 295 morbidity
T10 dis... | [
"Psychosis",
"relapse",
"during",
"treatment",
"with",
"long",
"-",
"acting",
"injectable",
"antipsychotics",
"in",
"individuals",
"with",
"schizophrenia",
"-",
"spectrum",
"disorders",
":",
"an",
"individual",
"participant",
"data",
"meta",
"-",
"analysis",
".",
... | [
0,
10,
18,
25,
35,
40,
44,
45,
52,
63,
78,
81,
93,
98,
111,
112,
121,
130,
132,
135,
146,
158,
163,
167,
168,
176,
178,
189,
194,
206,
211,
224,
225,
234,
244,
249,
257,
259,
265,
274,
278,
283,
286,
296,
300,
309,
311,
31... | [
9,
17,
24,
34,
39,
44,
45,
51,
62,
77,
80,
92,
97,
111,
112,
120,
130,
131,
134,
145,
157,
162,
167,
168,
176,
177,
188,
193,
205,
210,
224,
225,
233,
243,
248,
257,
258,
264,
273,
277,
282,
285,
295,
299,
309,
310,
318,
3... | [
"B-disease",
"I-disease",
"O",
"O",
"O",
"B-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"O",
"O",
"O",
"O",
... | [
3,
4,
0,
0,
0,
5,
6,
6,
6,
6,
0,
0,
0,
3,
4,
4,
4,
0,
0,
9,
10,
10,
10,
10,
10,
0,
0,
0,
0,
0,
3,
4,
4,
4,
0,
1,
0,
0,
0,
0,
0,
0,
3,
0,
3,
0,
0,
1,
2,
2,
2,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
3... |
MDIEC/13678875 | Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. BACKGROUND Results of array studies have suggested abnormalities in expression of lipid and myelin-related genes in schizophrenia. Here, we investigated oligodendrocyte-specific and myelination-associated gene expression in schizophrenia and bipolar aff... | T1 disease 0 27 Oligodendrocyte dysfunction
T2 disease 31 44 schizophrenia
T3 disease 49 65 bipolar disorder
T4 disease 183 196 schizophrenia
T8 gene 149 179 lipid and myelin-related genes
T10 method 89 102 array studies
T12 disease 291 304 schizophrenia
T13 disease 309 335 bipolar affective disorder
T15 physiology 220... | [
"Oligodendrocyte",
"dysfunction",
"in",
"schizophrenia",
"and",
"bipolar",
"disorder",
".",
"BACKGROUND",
"Results",
"of",
"array",
"studies",
"have",
"suggested",
"abnormalities",
"in",
"expression",
"of",
"lipid",
"and",
"myelin",
"-",
"related",
"genes",
"in",
... | [
0,
16,
28,
31,
45,
49,
57,
65,
67,
78,
86,
89,
95,
103,
108,
118,
132,
135,
146,
149,
155,
159,
165,
166,
174,
180,
183,
196,
198,
202,
204,
207,
220,
235,
236,
245,
249,
260,
261,
272,
277,
288,
291,
305,
309,
317,
327,
3... | [
15,
27,
30,
44,
48,
56,
65,
66,
77,
85,
88,
94,
102,
107,
117,
131,
134,
145,
148,
154,
158,
165,
166,
173,
179,
182,
196,
197,
202,
203,
206,
219,
235,
236,
244,
248,
260,
261,
271,
276,
287,
290,
304,
308,
316,
326,
335,
... | [
"B-disease",
"I-disease",
"O",
"B-disease",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"O",
"O",
"O",
"O",
"O",
"O",
"B-gene",
"I-gene",
"I-gene",
"I-gene",
"I-gene",
"I-gene",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
... | [
3,
4,
0,
3,
0,
3,
4,
0,
0,
0,
0,
9,
10,
0,
0,
0,
0,
0,
0,
7,
8,
8,
8,
8,
8,
0,
3,
0,
0,
0,
0,
0,
11,
12,
12,
12,
12,
12,
12,
12,
12,
0,
3,
0,
3,
4,
4,
0,
0,
0,
0,
0,
0,
0,
9,
10,
10,
0,
0,
0,
0,
... |
MDIEC/33971098 | Depression. Most psychiatric care is delivered in primary care settings, where depression is the most common presenting psychiatric symptom. Given the high prevalence of depression worldwide and the well-established consequences of untreated depression, the ability of primary care clinicians to effectively diagnose and... | T1 disease 0 10 Depression
T2 disease 79 89 depression
T3 disease 170 180 depression
T4 disease 242 252 depression
T5 disease 430 455 major depressive disorder
T6 method 50 62 primary care
T7 Health_factors 269 292 primary care clinicians
T10 method 17 33 psychiatric care
T9 disease 120 139 psychiatric symptom
R1 hypon... | [
"Depression",
".",
"Most",
"psychiatric",
"care",
"is",
"delivered",
"in",
"primary",
"care",
"settings",
",",
"where",
"depression",
"is",
"the",
"most",
"common",
"presenting",
"psychiatric",
"symptom",
".",
"Given",
"the",
"high",
"prevalence",
"of",
"depress... | [
0,
10,
12,
17,
29,
34,
37,
47,
50,
58,
63,
71,
73,
79,
90,
93,
97,
102,
109,
120,
132,
139,
141,
147,
151,
156,
167,
170,
181,
191,
195,
199,
203,
204,
216,
229,
232,
242,
252,
254,
258,
266,
269,
277,
282,
293,
296,
308,
... | [
10,
11,
16,
28,
33,
36,
46,
49,
57,
62,
71,
72,
78,
89,
92,
96,
101,
108,
119,
131,
139,
140,
146,
150,
155,
166,
169,
180,
190,
194,
198,
203,
204,
215,
228,
231,
241,
252,
253,
257,
265,
268,
276,
281,
292,
295,
307,
316... | [
"B-disease",
"O",
"O",
"B-method",
"I-method",
"O",
"O",
"O",
"B-method",
"I-method",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"... | [
3,
0,
0,
9,
10,
0,
0,
0,
9,
10,
0,
0,
0,
3,
0,
0,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
1,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
... |
MDIEC/26873185 | Childhood maltreatment and unfavourable clinical outcomes in bipolar disorder: a systematic review and meta-analysis. BACKGROUND Bipolar disorder affects up to one in 25 individuals and identification of early risk indicators of negative outcomes could facilitate early detection of patients with greatest clinical needs... | T0 disease 61 77 bipolar disorder
T1 Health_factors 0 22 Childhood maltreatment
T2 Health_factors 40 57 clinical outcomes
T3 method 81 98 systematic review
T4 method 103 116 meta-analysis
T6 disease 129 145 Bipolar disorder
T8 Health_factors 229 246 negative outcomes
T9 disease 445 461 bipolar disorder
T10 Health_facto... | [
"Childhood",
"maltreatment",
"and",
"unfavourable",
"clinical",
"outcomes",
"in",
"bipolar",
"disorder",
":",
"a",
"systematic",
"review",
"and",
"meta",
"-",
"analysis",
".",
"BACKGROUND",
"Bipolar",
"disorder",
"affects",
"up",
"to",
"one",
"in",
"25",
"indivi... | [
0,
10,
23,
27,
40,
49,
58,
61,
69,
77,
79,
81,
92,
99,
103,
107,
108,
116,
118,
129,
137,
146,
154,
157,
160,
164,
167,
170,
182,
186,
201,
204,
210,
215,
226,
229,
238,
247,
253,
264,
270,
280,
283,
292,
297,
306,
315,
32... | [
9,
22,
26,
39,
48,
57,
60,
68,
77,
78,
80,
91,
98,
102,
107,
108,
116,
117,
128,
136,
145,
153,
156,
159,
163,
166,
169,
181,
185,
200,
203,
209,
214,
225,
228,
237,
246,
252,
263,
269,
279,
282,
291,
296,
305,
314,
320,
3... | [
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"B-disease",
"I-disease",
"O",
"O",
"B-method",
"I-method",
"O",
"B-method",
"I-method",
"I-method",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
... | [
1,
2,
0,
0,
1,
2,
0,
3,
4,
0,
0,
9,
10,
0,
9,
10,
10,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
2,
0,
0,
1,
2,
... |
MDIEC/20221122_9 | Dual neurokinin(1) antagonists/5-HT reuptake inhibitors (SRIs) and melanocortin(4) antagonists/SRIs should display advantages over their selective counterparts, and histamine H(3) antagonists/SRIs, GABA(B) antagonists/SRIs, glutamatergic/SRIs, and cholinergic agents/SRIs may counter the compromised cognitive function o... | T1 drug 31 55 5-HT reuptake inhibitors
T2 drug 198 222 GABA(B) antagonists/SRIs
T6 disease 288 318 compromised cognitive function
T7 drug 57 61 SRIs
R1 abbreviation_for Arg1:T7 Arg2:T1
T8 drug 0 30 Dual neurokinin(1) antagonists
T9 drug 67 99 melanocortin(4) antagonists/SRIs
T11 drug 165 196 histamine H(3) antagonists... | [
"Dual",
"neurokinin",
"(",
"1",
")",
"antagonists",
"/",
"5",
"-",
"HT",
"reuptake",
"inhibitors",
"(",
"SRIs",
")",
"and",
"melanocortin",
"(",
"4",
")",
"antagonists",
"/",
"SRIs",
"should",
"display",
"advantages",
"over",
"their",
"selective",
"counterpa... | [
0,
5,
15,
16,
17,
19,
30,
31,
32,
33,
36,
45,
56,
57,
61,
63,
67,
79,
80,
81,
83,
94,
95,
100,
107,
115,
126,
131,
137,
147,
159,
161,
165,
175,
176,
177,
178,
180,
191,
192,
196,
198,
202,
203,
204,
206,
217,
218,
222,
... | [
4,
15,
16,
17,
18,
30,
31,
32,
33,
35,
44,
55,
57,
61,
62,
66,
79,
80,
81,
82,
94,
95,
99,
106,
114,
125,
130,
136,
146,
159,
160,
164,
174,
176,
177,
178,
179,
191,
192,
196,
197,
202,
203,
204,
205,
217,
218,
222,
223,... | [
"B-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"O",
"B-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"O",
"B-drug",
"O",
"O",
"B-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",... | [
5,
6,
6,
6,
6,
6,
0,
5,
6,
6,
6,
6,
0,
5,
0,
0,
5,
6,
6,
6,
6,
6,
6,
0,
0,
0,
0,
0,
0,
0,
0,
0,
5,
6,
6,
6,
6,
6,
6,
6,
0,
5,
6,
6,
6,
6,
6,
6,
0,
5,
6,
6,
0,
0,
5,
6,
6,
6,
0,
0,
0,
3,
4,
4... |
MDIEC/31371720 | Obsessive-compulsive disorder. Obsessive-compulsive disorder (OCD) is a highly prevalent and chronic condition that is associated with substantial global disability. OCD is the key example of the 'obsessive-compulsive and related disorders', a group of conditions which are now classified together in the Diagnostic and ... | T0 disease 0 29 Obsessive-compulsive disorder
T1 disease 31 60 Obsessive-compulsive disorder
T2 disease 62 65 OCD
T3 disease 154 164 disability
T5 disease 93 110 chronic condition
T6 disease 166 169 OCD
T7 disease 197 239 obsessive-compulsive and related disorders
T8 method 305 373 Diagnostic and Statistical Manual of ... | [
"Obsessive",
"-",
"compulsive",
"disorder",
".",
"Obsessive",
"-",
"compulsive",
"disorder",
"(",
"OCD",
")",
"is",
"a",
"highly",
"prevalent",
"and",
"chronic",
"condition",
"that",
"is",
"associated",
"with",
"substantial",
"global",
"disability",
".",
"OCD",
... | [
0,
9,
10,
21,
29,
31,
40,
41,
52,
61,
62,
65,
67,
70,
72,
79,
89,
93,
101,
111,
116,
119,
130,
135,
147,
154,
164,
166,
170,
173,
177,
181,
189,
192,
196,
197,
206,
207,
218,
222,
230,
239,
240,
242,
244,
250,
253,
264,
... | [
9,
10,
20,
29,
30,
40,
41,
51,
60,
62,
65,
66,
69,
71,
78,
88,
92,
100,
110,
115,
118,
129,
134,
146,
153,
164,
165,
169,
172,
176,
180,
188,
191,
195,
197,
206,
207,
217,
221,
229,
239,
240,
241,
243,
249,
252,
263,
269,
... | [
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"B-disease",
"O",
"O",
"O... | [
3,
4,
4,
4,
0,
3,
4,
4,
4,
0,
3,
0,
0,
0,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
3,
0,
3,
0,
0,
0,
0,
0,
0,
0,
3,
4,
4,
4,
4,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
10,
10,
10,
10,
10,
10,
... |
MDIEC/20221103_130 | Both unilateral and bilateral subthalamic (STN) deep brain stimulation (DBS) effectively treat the motor symptoms of PD, but questions remain regarding the impact of unilateral STN DBS on non-motor symptoms, such as depression. | T1 region 43 46 STN
T3 method 48 70 deep brain stimulation
T4 method 72 75 DBS
T6 disease 99 113 motor symptoms
T9 method 166 184 unilateral STN DBS
T10 disease 188 206 non-motor symptoms
T11 disease 216 226 depression
R1 abbreviation_for Arg1:T4 Arg2:T3
T12 region 30 41 subthalamic
R2 abbreviation_for Arg1:T1 Arg2:T1... | [
"Both",
"unilateral",
"and",
"bilateral",
"subthalamic",
"(",
"STN",
")",
"deep",
"brain",
"stimulation",
"(",
"DBS",
")",
"effectively",
"treat",
"the",
"motor",
"symptoms",
"of",
"PD",
",",
"but",
"questions",
"remain",
"regarding",
"the",
"impact",
"of",
... | [
0,
5,
16,
20,
30,
42,
43,
46,
48,
53,
59,
71,
72,
75,
77,
89,
95,
99,
105,
114,
117,
119,
121,
125,
135,
142,
152,
156,
163,
166,
177,
181,
185,
188,
191,
192,
198,
206,
208,
213,
216,
226
] | [
4,
15,
19,
29,
41,
43,
46,
47,
52,
58,
70,
72,
75,
76,
88,
94,
98,
104,
113,
116,
119,
120,
124,
134,
141,
151,
155,
162,
165,
176,
180,
184,
187,
191,
192,
197,
206,
207,
212,
215,
226,
227
] | [
"O",
"B-region",
"I-region",
"I-region",
"I-region",
"O",
"B-region",
"O",
"B-method",
"I-method",
"I-method",
"O",
"B-method",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
... | [
0,
13,
14,
14,
14,
0,
13,
0,
9,
10,
10,
0,
9,
0,
0,
0,
0,
3,
4,
0,
3,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
10,
0,
3,
4,
4,
4,
0,
0,
0,
3,
0
] |
MDIEC/20221103_63 | This enhanced [(18)F]FLT-PET imaging technique with probenecid can be used to assess the dynamic alteration of neurogenic activity in the adult mammalian brain and may also provide a means for objective diagnosis of depression and monitoring of the therapeutic effect of antidepressant treatment. | T1 method 5 46 enhanced [(18)F]FLT-PET imaging technique
T2 drug 52 62 probenecid
T3 physiology 111 130 neurogenic activity
T5 region 138 159 adult mammalian brain
T7 disease 216 226 depression
T10 method 271 295 antidepressant treatment
R1 help_diagnose Arg1:T1 Arg2:T3
R2 located_in Arg1:T3 Arg2:T5
R3 help_diagnose ... | [
"This",
"enhanced",
"[",
"(",
"18",
")",
"F",
"]",
"FLT",
"-",
"PET",
"imaging",
"technique",
"with",
"probenecid",
"can",
"be",
"used",
"to",
"assess",
"the",
"dynamic",
"alteration",
"of",
"neurogenic",
"activity",
"in",
"the",
"adult",
"mammalian",
"bra... | [
0,
5,
14,
15,
16,
18,
19,
20,
21,
24,
25,
29,
37,
47,
52,
63,
67,
70,
75,
78,
85,
89,
97,
108,
111,
122,
131,
134,
138,
144,
154,
160,
164,
168,
173,
181,
183,
189,
193,
203,
213,
216,
227,
231,
242,
245,
249,
261,
268,
... | [
4,
13,
15,
16,
18,
19,
20,
21,
24,
25,
28,
36,
46,
51,
62,
66,
69,
74,
77,
84,
88,
96,
107,
110,
121,
130,
133,
137,
143,
153,
159,
163,
167,
172,
180,
182,
188,
192,
202,
212,
215,
226,
230,
241,
244,
248,
260,
267,
270... | [
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"O",
"B-drug",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-physiology",
"I-physiology",
"O",
"O",
"B-region... | [
0,
9,
10,
10,
10,
10,
10,
10,
10,
10,
10,
10,
10,
0,
5,
0,
0,
0,
0,
0,
0,
0,
0,
0,
11,
12,
0,
0,
13,
14,
14,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
0,
0,
9,
10,
0
] |
MDIEC/20221122_17 | We found significant correlations between PHQ-8 scores and angina frequency (SAQ-AF, r=-0.28), physical limitation (SAQ-PL, r=-0.32) and disease perception (SAQ-DS r=-0.37, all P<0.001), which remained significant after adjustment for clinical characteristics, CAD severity, and anti-depressant use. | T2 method 42 47 PHQ-8
T3 disease 59 65 angina
T4 disease 137 155 disease perception
T13 Health_factors 235 259 clinical characteristics
T14 drug 279 294 anti-depressant
R1 associated_with Arg1:T2 Arg2:T3
T1 disease 95 114 physical limitation
T5 method 77 83 SAQ-AF
T6 disease 261 264 CAD
T7 method 116 122 SAQ-PL
T8 met... | [
"We",
"found",
"significant",
"correlations",
"between",
"PHQ",
"-",
"8",
"scores",
"and",
"angina",
"frequency",
"(",
"SAQ",
"-",
"AF",
",",
"r",
"=",
"-",
"0",
".",
"28",
")",
",",
"physical",
"limitation",
"(",
"SAQ",
"-",
"PL",
",",
"r",
"=",
"... | [
0,
3,
9,
21,
34,
42,
45,
46,
48,
55,
59,
66,
76,
77,
80,
81,
83,
85,
86,
87,
88,
89,
90,
92,
93,
95,
104,
115,
116,
119,
120,
122,
124,
125,
126,
127,
128,
129,
131,
133,
137,
145,
156,
157,
160,
161,
164,
165,
166,
16... | [
2,
8,
20,
33,
41,
45,
46,
47,
54,
58,
65,
75,
77,
80,
81,
83,
84,
86,
87,
88,
89,
90,
92,
93,
94,
103,
114,
116,
119,
120,
122,
123,
125,
126,
127,
128,
129,
131,
132,
136,
144,
155,
157,
160,
161,
163,
165,
166,
167,
... | [
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"O",
"O",
"B-disease",
"O",
"O",
"B-method",
"I-method",
"I-method",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"B-method",
"I-method",
"I-method",
"O",
"O",
... | [
0,
0,
0,
0,
0,
9,
10,
10,
0,
0,
3,
0,
0,
9,
10,
10,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
0,
9,
10,
10,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
0,
9,
10,
10,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
... |
MDIEC/20221103_155 | OBJECTIVES: This study examined national trends in 12-month prevalence of major depressive episodes (MDEs) in adolescents and young adults overall and in different sociodemographic groups, as well as trends in depression treatment between 2005 and 2014. | T2 disease 74 99 major depressive episodes
T3 Health_factors 110 121 adolescents
T4 Health_factors 126 138 young adults
T5 Health_factors 164 187 sociodemographic groups
T6 disease 210 220 depression
T1 disease 101 105 MDEs
R1 abbreviation_for Arg1:T1 Arg2:T2
R2 occurs_in Arg1:T1 Arg2:T3
R3 occurs_in Arg1:T1 Arg2:T4 ... | [
"OBJECTIVES",
":",
"This",
"study",
"examined",
"national",
"trends",
"in",
"12",
"-",
"month",
"prevalence",
"of",
"major",
"depressive",
"episodes",
"(",
"MDEs",
")",
"in",
"adolescents",
"and",
"young",
"adults",
"overall",
"and",
"in",
"different",
"sociod... | [
0,
10,
12,
17,
23,
32,
41,
48,
51,
53,
54,
60,
71,
74,
80,
91,
100,
101,
105,
107,
110,
122,
126,
132,
139,
147,
151,
154,
164,
181,
187,
189,
192,
197,
200,
207,
210,
221,
231,
239,
244,
248,
252
] | [
10,
11,
16,
22,
31,
40,
47,
50,
53,
54,
59,
70,
73,
79,
90,
99,
101,
105,
106,
109,
121,
125,
131,
138,
146,
150,
153,
163,
180,
187,
188,
191,
196,
199,
206,
209,
220,
230,
238,
243,
247,
252,
253
] | [
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"B-disease",
"O",
"O",
"B-Health_factors",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
... | [
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
4,
0,
3,
0,
0,
1,
0,
1,
2,
0,
0,
0,
0,
1,
2,
0,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
0
] |
MDIEC/32296353 | Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review. Depression is a major public health problem that affects approximately 4.4% of the global population. Since conventional pharmacotherapies and psychotherapies are on... | T1 drug 29 39 Psilocybin
T2 drug 102 112 Psilocybin
T3 disease 133 143 Depression
T4 disease 155 165 Depression
T5 drug 483 493 psilocybin
T6 disease 824 834 depression
T7 drug 882 892 psilocybin
T8 disease 1102 1127 major depression disorder
T9 drug 1615 1625 psilocybin
T10 method 1845 1847 MM
T11 drug 2033 2043 psilo... | [
"Depression",
",",
"Mindfulness",
",",
"and",
"Psilocybin",
":",
"Possible",
"Complementary",
"Effects",
"of",
"Mindfulness",
"Meditation",
"and",
"Psilocybin",
"in",
"the",
"Treatment",
"of",
"Depression",
".",
"A",
"Review",
".",
"Depression",
"is",
"a",
"majo... | [
0,
10,
12,
23,
25,
29,
39,
41,
50,
64,
72,
75,
87,
98,
102,
113,
116,
120,
130,
133,
143,
145,
147,
153,
155,
166,
169,
171,
177,
184,
191,
199,
204,
212,
226,
227,
228,
229,
231,
234,
238,
245,
255,
257,
263,
276,
294,
29... | [
10,
11,
23,
24,
28,
39,
40,
49,
63,
71,
74,
86,
97,
101,
112,
115,
119,
129,
132,
143,
144,
146,
153,
154,
165,
168,
170,
176,
183,
190,
198,
203,
211,
225,
227,
228,
229,
230,
233,
237,
244,
255,
256,
262,
275,
293,
297,
... | [
"B-disease",
"O",
"B-method",
"O",
"O",
"B-drug",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"O",
"B-drug",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"I-Health_factors",
... | [
3,
0,
9,
0,
0,
5,
0,
0,
0,
0,
0,
9,
10,
0,
5,
0,
0,
0,
0,
3,
0,
0,
0,
0,
3,
0,
0,
0,
1,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
0,
9,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
... |
MDIEC/30192101 | Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis. Psychological treatments are increasingly regarded as useful interventions for schizophrenia. However, a comprehensive evaluation of the available evidence is lacking and the benefit of psychological i... | T0 disease 59 72 schizophrenia
T1 method 0 27 Psychological interventions
T2 method 74 91 systematic review
T3 method 96 117 network meta-analysis
T4 disease 38 55 positive symptoms
T5 disease 198 211 schizophrenia
T6 method 119 143 Psychological treatments
T7 method 180 193 interventions
T9 method 305 332 psychologica... | [
"Psychological",
"interventions",
"to",
"reduce",
"positive",
"symptoms",
"in",
"schizophrenia",
":",
"systematic",
"review",
"and",
"network",
"meta",
"-",
"analysis",
".",
"Psychological",
"treatments",
"are",
"increasingly",
"regarded",
"as",
"useful",
"interventio... | [
0,
14,
28,
31,
38,
47,
56,
59,
72,
74,
85,
92,
96,
104,
108,
109,
117,
119,
133,
144,
148,
161,
170,
173,
180,
194,
198,
211,
213,
220,
222,
224,
238,
249,
252,
256,
266,
275,
278,
286,
290,
294,
302,
305,
319,
333,
337,
3... | [
13,
27,
30,
37,
46,
55,
58,
72,
73,
84,
91,
95,
103,
108,
109,
117,
118,
132,
143,
147,
160,
169,
172,
179,
193,
197,
211,
212,
220,
221,
223,
237,
248,
251,
255,
265,
274,
277,
285,
289,
293,
301,
304,
318,
332,
336,
345,
... | [
"B-method",
"I-method",
"O",
"O",
"B-disease",
"I-disease",
"O",
"B-disease",
"O",
"B-method",
"I-method",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"O",
"B-method",
"I-method",
"O",
"O",
"O",
"O",
"O",
"B-method",
"O",
"B-disease",
"O",
"O",
"O",... | [
9,
10,
0,
0,
3,
4,
0,
3,
0,
9,
10,
0,
9,
10,
10,
10,
0,
9,
10,
0,
0,
0,
0,
0,
9,
0,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
0,
0,
0,
3,
4,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
... |
MDIEC/20221103_58 | In recent years, deep brain stimulation (DBS) has evolved as a potential tool to modulate pathological neural activity; stimulation of the subgenual cingulate (Cg25) has been shown to reduce depressive symptoms, including anhedonia. | T1 method 17 39 deep brain stimulation
T2 method 41 44 DBS
T4 physiology 90 118 pathological neural activity
T7 region 139 158 subgenual cingulate
T8 disease 191 210 depressive symptoms
T9 disease 222 231 anhedonia
R1 abbreviation_for Arg1:T2 Arg2:T1
R2 associated_with Arg1:T2 Arg2:T4
R3 associated_with Arg1:T1 Arg2:... | [
"In",
"recent",
"years",
",",
"deep",
"brain",
"stimulation",
"(",
"DBS",
")",
"has",
"evolved",
"as",
"a",
"potential",
"tool",
"to",
"modulate",
"pathological",
"neural",
"activity",
";",
"stimulation",
"of",
"the",
"subgenual",
"cingulate",
"(",
"Cg25",
"... | [
0,
3,
10,
15,
17,
22,
28,
40,
41,
44,
46,
50,
58,
61,
63,
73,
78,
81,
90,
103,
110,
118,
120,
132,
135,
139,
149,
159,
160,
164,
166,
170,
175,
181,
184,
191,
202,
210,
212,
222,
231
] | [
2,
9,
15,
16,
21,
27,
39,
41,
44,
45,
49,
57,
60,
62,
72,
77,
80,
89,
102,
109,
118,
119,
131,
134,
138,
148,
158,
160,
164,
165,
169,
174,
180,
183,
190,
201,
210,
211,
221,
231,
232
] | [
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"O",
"B-method",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-physiology",
"I-physiology",
"I-physiology",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"I-method",
"O",
"B-region",
"O",
"O"... | [
0,
0,
0,
0,
9,
10,
10,
0,
9,
0,
0,
0,
0,
0,
0,
0,
0,
0,
11,
12,
12,
0,
9,
10,
10,
10,
10,
0,
13,
0,
0,
0,
0,
0,
0,
3,
4,
0,
0,
3,
0
] |
MDIEC/31569326 | Lifestyle interventions for mental health. BACKGROUND: Mental illness is the single most common reason for patient visits to a general practitioner (GP). Prevalent mental illnesses include major depression disorder and dysthymia, anxiety disorders, bipolar disorders and schizophrenia. Patients with severe mental illnes... | T2 disease 55 69 Mental illness
T3 disease 164 180 mental illnesses
T4 disease 189 214 major depression disorder
T5 disease 219 228 dysthymia
T6 disease 230 247 anxiety disorders
T7 disease 249 266 bipolar disorders
T8 disease 271 284 schizophrenia
T9 disease 300 321 severe mental illness
T10 disease 604 620 mental ill... | [
"Lifestyle",
"interventions",
"for",
"mental",
"health",
".",
"BACKGROUND",
":",
"Mental",
"illness",
"is",
"the",
"single",
"most",
"common",
"reason",
"for",
"patient",
"visits",
"to",
"a",
"general",
"practitioner",
"(",
"GP",
")",
".",
"Prevalent",
"mental... | [
0,
10,
24,
28,
35,
41,
43,
53,
55,
62,
70,
73,
77,
84,
89,
96,
103,
107,
115,
122,
125,
127,
135,
148,
149,
151,
152,
154,
164,
171,
181,
189,
195,
206,
215,
219,
228,
230,
238,
247,
249,
257,
267,
271,
284,
286,
295,
300,... | [
9,
23,
27,
34,
41,
42,
53,
54,
61,
69,
72,
76,
83,
88,
95,
102,
106,
114,
121,
124,
126,
134,
147,
149,
151,
152,
153,
163,
170,
180,
188,
194,
205,
214,
218,
228,
229,
237,
247,
248,
256,
266,
270,
284,
285,
294,
299,
306... | [
"B-method",
"I-method",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"B-Health_factors",
"O",
"O",
"O",
"B-disease",
... | [
9,
10,
0,
1,
2,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
2,
0,
1,
0,
0,
0,
3,
4,
0,
3,
4,
4,
0,
3,
0,
3,
4,
0,
3,
4,
0,
3,
0,
0,
0,
3,
4,
4,
0,
0,
1,
2,
2,
2,
2,
2,
2,
2,
0,
0,
0,
... |
MDIEC/20221103_50 | Additionally, this individually targeted rTMS can be integrated with cognitive interventions designed to activate the neural circuitry associated with promotion vs. prevention, thus allowing the neuroplasticity induced by the rTMS to benefit the systems likely to be involved in remediating depression. | T1 method 41 45 rTMS
T2 method 226 230 rTMS
T3 method 69 92 cognitive interventions
T4 region 118 134 neural circuitry
T7 physiology 195 210 neuroplasticity
T8 disease 291 301 depression
R1 associated_with Arg1:T7 Arg2:T2
R2 associated_with Arg1:T3 Arg2:T4
| [
"Additionally",
",",
"this",
"individually",
"targeted",
"rTMS",
"can",
"be",
"integrated",
"with",
"cognitive",
"interventions",
"designed",
"to",
"activate",
"the",
"neural",
"circuitry",
"associated",
"with",
"promotion",
"vs",
".",
"prevention",
",",
"thus",
"... | [
0,
12,
14,
19,
32,
41,
46,
50,
53,
64,
69,
79,
93,
102,
105,
114,
118,
125,
135,
146,
151,
161,
163,
165,
175,
177,
182,
191,
195,
211,
219,
222,
226,
231,
234,
242,
246,
254,
261,
264,
267,
276,
279,
291,
301
] | [
12,
13,
18,
31,
40,
45,
49,
52,
63,
68,
78,
92,
101,
104,
113,
117,
124,
134,
145,
150,
160,
163,
164,
175,
176,
181,
190,
194,
210,
218,
221,
225,
230,
233,
241,
245,
253,
260,
263,
266,
275,
278,
290,
301,
302
] | [
"O",
"O",
"O",
"O",
"O",
"B-method",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"O",
"O",
"O",
"O",
"B-region",
"I-region",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-physiology",
"O",
"O",
"O",
"B-method",
"O",
"O",
"O",
"O",
"O",... | [
0,
0,
0,
0,
0,
9,
0,
0,
0,
0,
9,
10,
0,
0,
0,
0,
13,
14,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
11,
0,
0,
0,
9,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
0
] |
MDIEC/20221122_120 | Obesity, educational attainment, body image, binge eating, physical health, psychological characteristics and interpersonal effectiveness were consistently associated with the relationship between obesity and depression. | T1 disease 0 7 Obesity
T3 Health_factors 9 31 educational attainment
T4 Health_factors 33 43 body image
T5 disease 45 57 binge eating
T6 Health_factors 59 74 physical health
T7 Health_factors 76 105 psychological characteristics
T9 disease 197 204 obesity
T10 disease 209 219 depression
T11 Health_factors 110 137 interp... | [
"Obesity",
",",
"educational",
"attainment",
",",
"body",
"image",
",",
"binge",
"eating",
",",
"physical",
"health",
",",
"psychological",
"characteristics",
"and",
"interpersonal",
"effectiveness",
"were",
"consistently",
"associated",
"with",
"the",
"relationship",... | [
0,
7,
9,
21,
31,
33,
38,
43,
45,
51,
57,
59,
68,
74,
76,
90,
106,
110,
124,
138,
143,
156,
167,
172,
176,
189,
197,
205,
209,
219
] | [
7,
8,
20,
31,
32,
37,
43,
44,
50,
57,
58,
67,
74,
75,
89,
105,
109,
123,
137,
142,
155,
166,
171,
175,
188,
196,
204,
208,
219,
220
] | [
"B-disease",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"B-disease",
"I-disease",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"O... | [
3,
0,
1,
2,
0,
1,
2,
0,
3,
4,
0,
1,
2,
0,
1,
2,
0,
1,
2,
0,
0,
0,
0,
0,
0,
0,
3,
0,
3,
0
] |
MDIEC/9193383 | Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-nave patients. BACKGROUND There have been reports that patients with schizophrenia have decreased metabolic activity in prefrontal cortex. However, findings have been confounded by medication effects, chronic illness, and difficulties of... | T0 disease 0 14 Hypofrontality
T1 disease 18 31 schizophrenia
T2 Health_factors 71 96 neuroleptic-nave patients
T4 disease 33 67 distributed dysfunctional circuits
T5 disease 152 165 schizophrenia
T6 region 203 220 prefrontal cortex
T7 physiology 181 199 metabolic activity
T8 disease 284 299 chronic illness
T9 drug 264... | [
"Hypofrontality",
"in",
"schizophrenia",
":",
"distributed",
"dysfunctional",
"circuits",
"in",
"neuroleptic",
"-",
"nave",
"patients",
".",
"BACKGROUND",
"There",
"have",
"been",
"reports",
"that",
"patients",
"with",
"schizophrenia",
"have",
"decreased",
"metabolic"... | [
0,
15,
18,
31,
33,
45,
59,
68,
71,
82,
83,
88,
96,
98,
109,
115,
120,
125,
133,
138,
147,
152,
166,
171,
181,
191,
200,
203,
214,
220,
222,
229,
231,
240,
245,
250,
261,
264,
275,
282,
284,
292,
299,
301,
305,
318,
321,
33... | [
14,
17,
31,
32,
44,
58,
67,
70,
82,
83,
87,
96,
97,
108,
114,
119,
124,
132,
137,
146,
151,
165,
170,
180,
190,
199,
202,
213,
220,
221,
229,
230,
239,
244,
249,
260,
263,
274,
282,
283,
291,
299,
300,
304,
317,
320,
332,
... | [
"B-disease",
"O",
"B-disease",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"B-Health_factors",
"I-Health_factors",
"I-Health_factors",
"I-Health_factors",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"B-physiology",
"I-physiology",
"O",... | [
3,
0,
3,
0,
3,
4,
4,
0,
1,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
0,
0,
11,
12,
0,
13,
14,
0,
0,
0,
0,
0,
0,
0,
0,
5,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
15,
16,
16,
0,
9,
... |
MDIEC/20221122_47 | Because orphan nuclear receptor estrogen-related receptor gamma (ERRgamma) plays a role in the differentiation of neuronal cells, we investigated whether an ERRgamma ligand enhances adult neurogenesis and regulates depressive behavior in a LRRK2-G2019S-associated mouse model of PD. | T2 physiology 182 200 adult neurogenesis
T3 disease 215 234 depressive behavior
T4 physiology 95 128 differentiation of neuronal cells
T5 gene 8 31 orphan nuclear receptor
T6 gene 32 63 estrogen-related receptor gamma
T7 gene 65 73 ERRgamma
R1 abbreviation_for Arg1:T7 Arg2:T6
R4 associated_with Arg1:T6 Arg2:T4
R5 ass... | [
"Because",
"orphan",
"nuclear",
"receptor",
"estrogen",
"-",
"related",
"receptor",
"gamma",
"(",
"ERRgamma",
")",
"plays",
"a",
"role",
"in",
"the",
"differentiation",
"of",
"neuronal",
"cells",
",",
"we",
"investigated",
"whether",
"an",
"ERRgamma",
"ligand",
... | [
0,
8,
15,
23,
32,
40,
41,
49,
58,
64,
65,
73,
75,
81,
83,
88,
91,
95,
111,
114,
123,
128,
130,
133,
146,
154,
157,
166,
173,
182,
188,
201,
205,
215,
226,
235,
238,
240,
245,
246,
252,
253,
264,
270,
276,
279,
281
] | [
7,
14,
22,
31,
40,
41,
48,
57,
63,
65,
73,
74,
80,
82,
87,
90,
94,
110,
113,
122,
128,
129,
132,
145,
153,
156,
165,
172,
181,
187,
200,
204,
214,
225,
234,
237,
239,
245,
246,
252,
253,
263,
269,
275,
278,
281,
282
] | [
"O",
"B-gene",
"I-gene",
"I-gene",
"B-gene",
"I-gene",
"I-gene",
"I-gene",
"I-gene",
"O",
"B-gene",
"O",
"O",
"O",
"O",
"O",
"O",
"B-physiology",
"I-physiology",
"I-physiology",
"I-physiology",
"O",
"O",
"O",
"O",
"O",
"B-drug",
"I-drug",
"O",
"B-physiology"... | [
0,
7,
8,
8,
7,
8,
8,
8,
8,
0,
7,
0,
0,
0,
0,
0,
0,
11,
12,
12,
12,
0,
0,
0,
0,
0,
5,
6,
0,
11,
12,
0,
0,
3,
4,
0,
0,
9,
10,
10,
10,
10,
10,
10,
0,
3,
0
] |
MDIEC/33303583 | Poverty, depression, and anxiety: Causal evidence and mechanisms. Why are people who live in poverty disproportionately affected by mental illness? We review the interdisciplinary evidence of the bidirectional causal relationship between poverty and common mental illnesses-depression and anxiety-and the underlying mech... | T0 Health_factors 0 7 Poverty
T1 disease 9 19 depression
T2 disease 25 32 anxiety
T3 disease 132 146 mental illness
T4 Health_factors 93 100 poverty
T5 Health_factors 238 245 poverty
T6 disease 257 273 mental illnesses
T7 disease 274 284 depression
T8 disease 289 296 anxiety
T11 disease 348 362 mental illness
T12 Healt... | [
"Poverty",
",",
"depression",
",",
"and",
"anxiety",
":",
"Causal",
"evidence",
"and",
"mechanisms",
".",
"Why",
"are",
"people",
"who",
"live",
"in",
"poverty",
"disproportionately",
"affected",
"by",
"mental",
"illness",
"?",
"We",
"review",
"the",
"interdis... | [
0,
7,
9,
19,
21,
25,
32,
34,
41,
50,
54,
64,
66,
70,
74,
81,
85,
90,
93,
101,
120,
129,
132,
139,
146,
148,
151,
158,
162,
180,
189,
192,
196,
210,
217,
230,
238,
246,
250,
257,
264,
273,
274,
285,
289,
296,
297,
301,
30... | [
7,
8,
19,
20,
24,
32,
33,
40,
49,
53,
64,
65,
69,
73,
80,
84,
89,
92,
100,
119,
128,
131,
138,
146,
147,
150,
157,
161,
179,
188,
191,
195,
209,
216,
229,
237,
245,
249,
256,
263,
273,
274,
284,
288,
296,
297,
300,
304,
... | [
"B-Health_factors",
"O",
"B-disease",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Health_factors",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B... | [
1,
0,
3,
0,
0,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
3,
4,
0,
3,
0,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
0,
1,
0,
0,
1,
0,
0,
0... |
MDIEC/30366684 | Rheumatoid arthritis and depression: an inflammatory perspective. The coexistence of immune-mediated inflammatory diseases with depression has long been recognised. Data that illustrate the intimate associations between peripheral and brain immune responses raise the possibility of shared pathophysiological mechanisms.... | T1 disease 0 20 Rheumatoid arthritis
T2 disease 25 35 depression
T3 disease 70 138 coexistence of immune-mediated inflammatory diseases with depression
T5 disease 727 743 physical disease
T6 disease 807 827 rheumatoid arthritis
T7 disease 832 842 depression
T8 disease 1080 1087 fatigue
T9 disease 1177 1187 depression
T... | [
"Rheumatoid",
"arthritis",
"and",
"depression",
":",
"an",
"inflammatory",
"perspective",
".",
"The",
"coexistence",
"of",
"immune",
"-",
"mediated",
"inflammatory",
"diseases",
"with",
"depression",
"has",
"long",
"been",
"recognised",
".",
"Data",
"that",
"illus... | [
0,
11,
21,
25,
35,
37,
40,
53,
64,
66,
70,
82,
85,
91,
92,
101,
114,
123,
128,
139,
143,
148,
153,
163,
165,
170,
175,
186,
190,
199,
212,
220,
231,
235,
241,
248,
258,
264,
268,
280,
283,
290,
309,
319,
321,
327,
340,
348... | [
10,
20,
24,
35,
36,
39,
52,
64,
65,
69,
81,
84,
91,
92,
100,
113,
122,
127,
138,
142,
147,
152,
163,
164,
169,
174,
185,
189,
198,
211,
219,
230,
234,
240,
247,
257,
263,
267,
279,
282,
289,
308,
319,
320,
326,
339,
347,
3... | [
"B-disease",
"I-disease",
"O",
"B-disease",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O... | [
3,
4,
0,
3,
0,
0,
3,
0,
0,
0,
3,
4,
4,
4,
4,
4,
4,
4,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
11,
12,
12,
12,
12,
0,
0,
0,
0,
0,
11,
12,
0,
0,
0,
0,
0,
0,
0,
0,
7,
8,
0,
11,
12,
0,
7,
8,
0,
0,
0,... |
MDIEC/28034075 | Use of Medications for Treating Anxiety and Depression in Cancer Survivors in the United States. Purpose This study used population-based data to estimate the percentage of cancer survivors in the United States reporting current medication use for anxiety and depression and to characterize the survivors taking this typ... | T0 disease 32 39 Anxiety
T1 disease 44 54 Depression
T2 Health_factors 58 74 Cancer Survivors
T3 Health_factors 0 18 Use of Medications
T4 Health_factors 173 189 cancer survivors
T5 disease 248 255 anxiety
T6 disease 260 270 depression
T7 drug 229 239 medication
T8 drug 325 335 medication
T11 method 121 142 population-... | [
"Use",
"of",
"Medications",
"for",
"Treating",
"Anxiety",
"and",
"Depression",
"in",
"Cancer",
"Survivors",
"in",
"the",
"United",
"States",
".",
"Purpose",
"This",
"study",
"used",
"population",
"-",
"based",
"data",
"to",
"estimate",
"the",
"percentage",
"of... | [
0,
4,
7,
19,
23,
32,
40,
44,
55,
58,
65,
75,
78,
82,
89,
95,
97,
105,
110,
116,
121,
131,
132,
138,
143,
146,
155,
159,
170,
173,
180,
190,
193,
197,
204,
211,
221,
229,
240,
244,
248,
256,
260,
271,
275,
278,
291,
295,
... | [
3,
6,
18,
22,
31,
39,
43,
54,
57,
64,
74,
77,
81,
88,
95,
96,
104,
109,
115,
120,
131,
132,
137,
142,
145,
154,
158,
169,
172,
179,
189,
192,
196,
203,
210,
220,
228,
239,
243,
247,
255,
259,
270,
274,
277,
290,
294,
304,
... | [
"B-Health_factors",
"I-Health_factors",
"I-Health_factors",
"O",
"O",
"B-disease",
"O",
"B-disease",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"O",
"O",
"O",
"O",
"... | [
1,
2,
2,
0,
0,
3,
0,
3,
0,
1,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
10,
10,
0,
0,
0,
0,
0,
1,
2,
0,
0,
0,
0,
0,
0,
5,
0,
0,
3,
0,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
5,
0,
0,
0,
5,
0,
0,
1,
2,
0,
0,
... |
MDIEC/20221122_60 | Recent studies have both offered and contested the proposition that lowering plasma cholesterol by diet and medications increases suicide, homicide, and depression. | T2 drug 77 95 plasma cholesterol
T4 Health_factors 139 147 homicide
T5 disease 153 163 depression
T1 Health_factors 99 103 diet
T3 disease 130 137 suicide
T6 drug 108 119 medications
R1 risk_factor_of Arg1:T2 Arg2:T3
R2 risk_factor_of Arg1:T2 Arg2:T4
R3 risk_factor_of Arg1:T2 Arg2:T5
R4 associated_with Arg1:T2 Arg2:... | [
"Recent",
"studies",
"have",
"both",
"offered",
"and",
"contested",
"the",
"proposition",
"that",
"lowering",
"plasma",
"cholesterol",
"by",
"diet",
"and",
"medications",
"increases",
"suicide",
",",
"homicide",
",",
"and",
"depression",
"."
] | [
0,
7,
15,
20,
25,
33,
37,
47,
51,
63,
68,
77,
84,
96,
99,
104,
108,
120,
130,
137,
139,
147,
149,
153,
163
] | [
6,
14,
19,
24,
32,
36,
46,
50,
62,
67,
76,
83,
95,
98,
103,
107,
119,
129,
137,
138,
147,
148,
152,
163,
164
] | [
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-drug",
"I-drug",
"O",
"B-Health_factors",
"O",
"B-drug",
"O",
"B-disease",
"O",
"B-Health_factors",
"O",
"O",
"B-disease",
"O"
] | [
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
5,
6,
0,
1,
0,
5,
0,
3,
0,
1,
0,
0,
3,
0
] |
MDIEC/21159375 | Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial. BACKGROUND Depression and anxiety disorders are common mental disorders worldwide. The MANAS trial aimed to test the effectiveness of an inter... | T0 Health_factors 40 62 lay health counsellors
T1 disease 67 99 depressive and anxiety disorders
T2 method 20 32 intervention
T3 method 103 115 primary care
T5 method 141 176 cluster randomised controlled trial
T6 disease 204 221 anxiety disorders
T7 disease 233 249 mental disorders
T8 Health_factors 335 357 lay health... | [
"Effectiveness",
"of",
"an",
"intervention",
"led",
"by",
"lay",
"health",
"counsellors",
"for",
"depressive",
"and",
"anxiety",
"disorders",
"in",
"primary",
"care",
"in",
"Goa",
",",
"India",
"(",
"MANAS",
")",
":",
"a",
"cluster",
"randomised",
"controlled"... | [
0,
14,
17,
20,
33,
37,
40,
44,
51,
63,
67,
78,
82,
90,
100,
103,
111,
116,
119,
122,
124,
130,
131,
136,
137,
139,
141,
149,
160,
171,
176,
178,
189,
200,
204,
212,
222,
226,
233,
240,
250,
259,
261,
265,
271,
277,
283,
28... | [
13,
16,
19,
32,
36,
39,
43,
50,
62,
66,
77,
81,
89,
99,
102,
110,
115,
118,
122,
123,
129,
131,
136,
137,
138,
140,
148,
159,
170,
176,
177,
188,
199,
203,
211,
221,
225,
232,
239,
249,
259,
260,
264,
270,
276,
282,
285,
2... | [
"O",
"O",
"O",
"B-method",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"I-Health_factors",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"B-method",
"I-method",
"O",
"O",
"O",
"O",
"O",
"B-method",
"O",
"O",
"O",
"B-method",
"I-method",
"... | [
0,
0,
0,
9,
0,
0,
1,
2,
2,
0,
3,
4,
4,
4,
0,
9,
10,
0,
0,
0,
0,
0,
9,
0,
0,
0,
9,
10,
10,
10,
0,
0,
3,
0,
3,
4,
0,
0,
3,
4,
0,
0,
0,
9,
10,
0,
0,
0,
0,
0,
0,
0,
9,
0,
0,
1,
2,
2,
0,
9,
10,
10,
... |
MDIEC/20221122_56 | The overall anxiolytic properties of tianeptine in patients with coexisting depression and anxiety appear to be similar to those of amitriptyline, imipramine and fluoxetine and may be superior to those of maprotiline, although submaximal dosages of amitriptyline and maprotiline were used. | T2 disease 65 98 coexisting depression and anxiety
T4 drug 132 145 amitriptyline
T5 drug 249 262 amitriptyline
T6 drug 147 157 imipramine
T7 drug 162 172 fluoxetine
T8 drug 205 216 maprotiline
T9 drug 267 278 maprotiline
T10 physiology 12 33 anxiolytic properties
T11 drug 37 47 tianeptine
R2 treatment_for Arg1:T11 Arg2... | [
"The",
"overall",
"anxiolytic",
"properties",
"of",
"tianeptine",
"in",
"patients",
"with",
"coexisting",
"depression",
"and",
"anxiety",
"appear",
"to",
"be",
"similar",
"to",
"those",
"of",
"amitriptyline",
",",
"imipramine",
"and",
"fluoxetine",
"and",
"may",
... | [
0,
4,
12,
23,
34,
37,
48,
51,
60,
65,
76,
87,
91,
99,
106,
109,
112,
120,
123,
129,
132,
145,
147,
158,
162,
173,
177,
181,
184,
193,
196,
202,
205,
216,
218,
227,
238,
246,
249,
263,
267,
279,
284,
288
] | [
3,
11,
22,
33,
36,
47,
50,
59,
64,
75,
86,
90,
98,
105,
108,
111,
119,
122,
128,
131,
145,
146,
157,
161,
172,
176,
180,
183,
192,
195,
201,
204,
216,
217,
226,
237,
245,
248,
262,
266,
278,
283,
288,
289
] | [
"O",
"O",
"B-physiology",
"I-physiology",
"O",
"B-drug",
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-drug",
"O",
"B-drug",
"O",
"B-drug",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-drug",
"O",
... | [
0,
0,
11,
12,
0,
5,
0,
0,
0,
3,
4,
4,
4,
0,
0,
0,
0,
0,
0,
0,
5,
0,
5,
0,
5,
0,
0,
0,
0,
0,
0,
0,
5,
0,
0,
0,
0,
0,
5,
0,
5,
0,
0,
0
] |
MDIEC/20221103_76 | The findings are in concert with antidepressant effects of NMDA-receptor antagonists and the hypotheses that impaired astroglial functions contribute to the pathogenesis of affective disorders. | T1 physiology 33 55 antidepressant effects
T2 drug 59 84 NMDA-receptor antagonists
T3 disease 109 138 impaired astroglial functions
T5 disease 173 192 affective disorders
T4 disease 157 169 pathogenesis
R1 associated_with Arg1:T3 Arg2:T5
| [
"The",
"findings",
"are",
"in",
"concert",
"with",
"antidepressant",
"effects",
"of",
"NMDA",
"-",
"receptor",
"antagonists",
"and",
"the",
"hypotheses",
"that",
"impaired",
"astroglial",
"functions",
"contribute",
"to",
"the",
"pathogenesis",
"of",
"affective",
"... | [
0,
4,
13,
17,
20,
28,
33,
48,
56,
59,
63,
64,
73,
85,
89,
93,
104,
109,
118,
129,
139,
150,
153,
157,
170,
173,
183,
192
] | [
3,
12,
16,
19,
27,
32,
47,
55,
58,
63,
64,
72,
84,
88,
92,
103,
108,
117,
128,
138,
149,
152,
156,
169,
172,
182,
192,
193
] | [
"O",
"O",
"O",
"O",
"O",
"O",
"B-physiology",
"I-physiology",
"O",
"B-drug",
"I-drug",
"I-drug",
"I-drug",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"B-disease",
"O",
"B-disease",
"I-disease",
"O"
] | [
0,
0,
0,
0,
0,
0,
11,
12,
0,
5,
6,
6,
6,
0,
0,
0,
0,
3,
4,
4,
0,
0,
0,
3,
0,
3,
4,
0
] |
MDIEC/10865302 | Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. CONTEXT Generalized anxiety disorder (GAD) is a chronic disorder that is associated with debilitating psychic and somatic symptoms. Venlafaxine extended-release (XR) ca... | T0 drug 12 49 venlafaxine extended-release capsules
T1 disease 83 111 generalized anxiety disorder
T3 method 123 150 randomized controlled trial
T5 Health_factors 53 77 nondepressed outpatients
T6 disease 160 188 Generalized anxiety disorder
T7 disease 190 193 GAD
T8 disease 200 216 chronic disorder
T9 disease 241 282 ... | [
"Efficacy",
"of",
"venlafaxine",
"extended",
"-",
"release",
"capsules",
"in",
"nondepressed",
"outpatients",
"with",
"generalized",
"anxiety",
"disorder",
":",
"A",
"6",
"-",
"month",
"randomized",
"controlled",
"trial",
".",
"CONTEXT",
"Generalized",
"anxiety",
... | [
0,
9,
12,
24,
32,
33,
41,
50,
53,
66,
78,
83,
95,
103,
111,
113,
115,
116,
117,
123,
134,
145,
150,
152,
160,
172,
180,
189,
190,
193,
195,
198,
200,
208,
217,
222,
225,
236,
241,
254,
262,
266,
274,
282,
284,
296,
304,
30... | [
8,
11,
23,
32,
33,
40,
49,
52,
65,
77,
82,
94,
102,
111,
112,
114,
116,
117,
122,
133,
144,
150,
151,
159,
171,
179,
188,
190,
193,
194,
197,
199,
207,
216,
221,
224,
235,
240,
253,
261,
265,
273,
282,
283,
295,
304,
305,
... | [
"O",
"O",
"B-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"O"... | [
0,
0,
5,
6,
6,
6,
6,
0,
1,
2,
0,
3,
4,
4,
0,
0,
0,
0,
0,
9,
10,
10,
0,
0,
3,
4,
4,
0,
3,
0,
0,
0,
3,
4,
0,
0,
0,
0,
3,
4,
4,
4,
4,
0,
5,
6,
6,
6,
6,
6,
6,
6,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
... |
MDIEC/30934083 | Generalized Anxiety Disorder. Generalized anxiety disorder (GAD) is a common and disabling illness that is often underdiagnosed and undertreated. Patients with GAD are at increased risk for suicide as well as cardiovascular-related events and death. Most patients can be diagnosed and managed by primary care physicians.... | T0 disease 0 28 Generalized Anxiety Disorder
T1 disease 30 58 Generalized anxiety disorder
T2 disease 60 63 GAD
T3 disease 70 98 common and disabling illness
T4 disease 160 163 GAD
T5 disease 209 248 cardiovascular-related events and death
T6 disease 190 197 suicide
T10 Health_factors 296 319 primary care physicians
T1... | [
"Generalized",
"Anxiety",
"Disorder",
".",
"Generalized",
"anxiety",
"disorder",
"(",
"GAD",
")",
"is",
"a",
"common",
"and",
"disabling",
"illness",
"that",
"is",
"often",
"underdiagnosed",
"and",
"undertreated",
".",
"Patients",
"with",
"GAD",
"are",
"at",
"... | [
0,
12,
20,
28,
30,
42,
50,
59,
60,
63,
65,
68,
70,
77,
81,
91,
99,
104,
107,
113,
128,
132,
144,
146,
155,
160,
164,
168,
171,
181,
186,
190,
198,
201,
206,
209,
223,
224,
232,
239,
243,
248,
250,
255,
264,
268,
271,
281,
... | [
11,
19,
28,
29,
41,
49,
58,
60,
63,
64,
67,
69,
76,
80,
90,
98,
103,
106,
112,
127,
131,
144,
145,
154,
159,
163,
167,
170,
180,
185,
189,
197,
200,
205,
208,
223,
224,
231,
238,
242,
248,
249,
254,
263,
267,
270,
280,
284... | [
"B-disease",
"I-disease",
"I-disease",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"B-disease",
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"B-... | [
3,
4,
4,
0,
3,
4,
4,
0,
3,
0,
0,
0,
3,
4,
4,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
3,
0,
0,
0,
3,
4,
4,
4,
4,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
2,
2,
0,
0,
0,
3,
4,
4,
4,
4,
4,
0,
0... |
MDIEC/20221103_80 | CONCLUSIONS: Varenicline appears to improve the chances of achieving at least 3 months of smoking abstinence in smokers with substance use disorders trying to stop, compared with transdermal nicotine patches, the effect being independent of history of depressive disorder. | T1 drug 13 24 Varenicline
T2 Health_factors 112 119 smokers
T3 disease 125 148 substance use disorders
T4 drug 179 207 transdermal nicotine patches
T6 Health_factors 241 271 history of depressive disorder
T8 Health_factors 90 108 smoking abstinence
R1 occurs_in Arg1:T2 Arg2:T3
R2 treatment_for Arg1:T1 Arg2:T8
R3 occu... | [
"CONCLUSIONS",
":",
"Varenicline",
"appears",
"to",
"improve",
"the",
"chances",
"of",
"achieving",
"at",
"least",
"3",
"months",
"of",
"smoking",
"abstinence",
"in",
"smokers",
"with",
"substance",
"use",
"disorders",
"trying",
"to",
"stop",
",",
"compared",
... | [
0,
11,
13,
25,
33,
36,
44,
48,
56,
59,
69,
72,
78,
80,
87,
90,
98,
109,
112,
120,
125,
135,
139,
149,
156,
159,
163,
165,
174,
179,
191,
200,
207,
209,
213,
220,
226,
238,
241,
249,
252,
263,
271
] | [
11,
12,
24,
32,
35,
43,
47,
55,
58,
68,
71,
77,
79,
86,
89,
97,
108,
111,
119,
124,
134,
138,
148,
155,
158,
163,
164,
173,
178,
190,
199,
207,
208,
212,
219,
225,
237,
240,
248,
251,
262,
271,
272
] | [
"O",
"O",
"B-drug",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"B-Health_factors",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"B-drug",
"I-drug",
"I-drug",
"O"... | [
0,
0,
5,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
2,
0,
1,
0,
3,
4,
4,
0,
0,
0,
0,
0,
0,
5,
6,
6,
0,
0,
0,
0,
0,
0,
1,
2,
2,
2,
0
] |
MDIEC/20221103_1 | Since the discovery that a single dose of ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, had rapid and long-lasting antidepressant effects, there has been increased interest in using NMDAR modulators in the pharmacotherapy of depression. | T1 drug 42 50 ketamine
T2 gene 55 84 N-methyl-D-aspartate receptor
T3 gene 86 91 NMDAR
T4 drug 199 215 NMDAR modulators
T6 physiology 109 154 rapid and long-lasting antidepressant effects
T8 method 223 238 pharmacotherapy
T9 disease 242 252 depression
R1 abbreviation_for Arg1:T3 Arg2:T2
T10 drug 55 103 N-methyl-D-aspa... | [
"Since",
"the",
"discovery",
"that",
"a",
"single",
"dose",
"of",
"ketamine",
",",
"an",
"N",
"-",
"methyl",
"-",
"D",
"-",
"aspartate",
"receptor",
"(",
"NMDAR",
")",
"antagonist",
",",
"had",
"rapid",
"and",
"long",
"-",
"lasting",
"antidepressant",
"e... | [
0,
6,
10,
20,
25,
27,
34,
39,
42,
50,
52,
55,
56,
57,
63,
64,
65,
66,
76,
85,
86,
91,
93,
103,
105,
109,
115,
119,
123,
124,
132,
147,
154,
156,
162,
166,
171,
181,
190,
193,
199,
205,
216,
219,
223,
239,
242,
252
] | [
5,
9,
19,
24,
26,
33,
38,
41,
50,
51,
54,
56,
57,
63,
64,
65,
66,
75,
84,
86,
91,
92,
103,
104,
108,
114,
118,
123,
124,
131,
146,
154,
155,
161,
165,
170,
180,
189,
192,
198,
204,
215,
218,
222,
238,
241,
252,
253
] | [
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-drug",
"O",
"O",
"B-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"O",
"O",
"B-physiology",
"I-physiology",
"I-physiology",
"I-physiology",
"I-p... | [
0,
0,
0,
0,
0,
0,
0,
0,
5,
0,
0,
5,
6,
6,
6,
6,
6,
6,
6,
6,
6,
6,
6,
0,
0,
11,
12,
12,
12,
12,
12,
12,
0,
0,
0,
0,
0,
0,
0,
0,
5,
6,
0,
0,
9,
0,
3,
0
] |
MDIEC/23332760 | Derepression of a neuronal inhibitor due to miRNA dysregulation in a schizophrenia-related microdeletion. 22q11.2 microdeletions result in specific cognitive deficits and schizophrenia. Analysis of Df(16)A(+/-) mice, which model this microdeletion, revealed abnormalities in the formation of neuronal dendrites and spine... | T0 gene 69 104 schizophrenia-related microdeletion
T2 physiology 0 36 Derepression of a neuronal inhibitor
T3 disease 148 166 cognitive deficits
T4 disease 171 184 schizophrenia
T5 gene 106 128 22q11.2 microdeletions
T7 disease 258 321 abnormalities in the formation of neuronal dendrites and spines
T8 method 198 215 Df... | [
"Derepression",
"of",
"a",
"neuronal",
"inhibitor",
"due",
"to",
"miRNA",
"dysregulation",
"in",
"a",
"schizophrenia",
"-",
"related",
"microdeletion",
".",
"22q11",
".",
"2",
"microdeletions",
"result",
"in",
"specific",
"cognitive",
"deficits",
"and",
"schizophr... | [
0,
13,
16,
18,
27,
37,
41,
44,
50,
64,
67,
69,
82,
83,
91,
104,
106,
111,
112,
114,
129,
136,
139,
148,
158,
167,
171,
184,
186,
195,
198,
200,
201,
203,
204,
205,
206,
207,
208,
209,
211,
215,
217,
223,
229,
234,
247,
249... | [
12,
15,
17,
26,
36,
40,
43,
49,
63,
66,
68,
82,
83,
90,
104,
105,
111,
112,
113,
128,
135,
138,
147,
157,
166,
170,
184,
185,
194,
197,
200,
201,
203,
204,
205,
206,
207,
208,
209,
210,
215,
216,
222,
228,
233,
247,
248,
2... | [
"B-physiology",
"I-physiology",
"I-physiology",
"I-physiology",
"I-physiology",
"O",
"O",
"B-physiology",
"I-physiology",
"O",
"O",
"B-gene",
"I-gene",
"I-gene",
"I-gene",
"O",
"B-gene",
"I-gene",
"I-gene",
"I-gene",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"... | [
11,
12,
12,
12,
12,
0,
0,
11,
12,
0,
0,
7,
8,
8,
8,
0,
7,
8,
8,
8,
0,
0,
0,
3,
4,
0,
3,
0,
0,
0,
9,
10,
10,
10,
10,
10,
10,
10,
10,
10,
10,
0,
0,
0,
0,
7,
0,
0,
3,
4,
4,
4,
4,
4,
4,
4,
4,
0,
0,
0,
... |
MDIEC/20221122_114 | For this test, conscious values converged toward anesthetized values at higher ages; therefore, there was relatively less depression by halothane at older ages. | T3 method 49 61 anesthetized
T4 Health_factors 72 83 higher ages
T5 Health_factors 149 159 older ages
T6 disease 122 132 depression
T7 drug 136 145 halothane
R1 associated_with Arg1:T6 Arg2:T7
R2 occurs_in Arg1:T7 Arg2:T5
| [
"For",
"this",
"test",
",",
"conscious",
"values",
"converged",
"toward",
"anesthetized",
"values",
"at",
"higher",
"ages",
";",
"therefore",
",",
"there",
"was",
"relatively",
"less",
"depression",
"by",
"halothane",
"at",
"older",
"ages",
"."
] | [
0,
4,
9,
13,
15,
25,
32,
42,
49,
62,
69,
72,
79,
83,
85,
94,
96,
102,
106,
117,
122,
133,
136,
146,
149,
155,
159
] | [
3,
8,
13,
14,
24,
31,
41,
48,
61,
68,
71,
78,
83,
84,
94,
95,
101,
105,
116,
121,
132,
135,
145,
148,
154,
159,
160
] | [
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-method",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"B-drug",
"O",
"B-Health_factors",
"I-Health_factors",
"O"
] | [
0,
0,
0,
0,
0,
0,
0,
0,
9,
0,
0,
1,
2,
0,
0,
0,
0,
0,
0,
0,
3,
0,
5,
0,
1,
2,
0
] |
MDIEC/31910981 | Social disconnectedness, perceived isolation, and symptoms of depression and anxiety among older Americans (NSHAP): a longitudinal mediation analysis. BACKGROUND Research indicates that social isolation and loneliness increase the risk of mental disorders, but less is known about the distinct contributions of different... | T1 disease 62 72 depression
T2 disease 77 84 anxiety
T3 disease 207 217 loneliness
T4 disease 239 255 mental disorders
T5 disease 517 527 loneliness
T6 disease 570 577 anxiety
T8 disease 946 956 depression
T9 disease 1212 1222 depression
T10 disease 1640 1647 anxiety
T11 disease 1906 1925 affective disorders
T16 Health... | [
"Social",
"disconnectedness",
",",
"perceived",
"isolation",
",",
"and",
"symptoms",
"of",
"depression",
"and",
"anxiety",
"among",
"older",
"Americans",
"(",
"NSHAP",
")",
":",
"a",
"longitudinal",
"mediation",
"analysis",
".",
"BACKGROUND",
"Research",
"indicate... | [
0,
7,
23,
25,
35,
44,
46,
50,
59,
62,
73,
77,
85,
91,
97,
107,
108,
113,
114,
116,
118,
131,
141,
149,
151,
162,
171,
181,
186,
193,
203,
207,
218,
227,
231,
236,
239,
246,
255,
257,
261,
266,
269,
275,
281,
285,
294,
308,... | [
6,
23,
24,
34,
44,
45,
49,
58,
61,
72,
76,
84,
90,
96,
106,
108,
113,
114,
115,
117,
130,
140,
149,
150,
161,
170,
180,
185,
192,
202,
206,
217,
226,
230,
235,
238,
245,
255,
256,
260,
265,
268,
274,
280,
284,
293,
307,
31... | [
"B-Health_factors",
"I-Health_factors",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"B-disease",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"B-method",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"O",
"O",
"O",
... | [
1,
2,
0,
1,
2,
0,
0,
0,
0,
3,
0,
3,
0,
1,
2,
0,
9,
0,
0,
0,
9,
10,
10,
0,
0,
0,
0,
0,
1,
2,
0,
3,
0,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
2,
... |
MDIEC/2684085 | National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. We investigated the effectiveness of two brief psychotherapies, interpersonal psychotherapy and cognitive behavior therapy, for the treatment of outpatients with major depression disorder dia... | T1 method 0 90 National Institute of Mental Health Treatment of Depression Collaborative Research Program
T2 disease 291 316 major depression disorder
T3 method 512 561 imipramine hydrochloride plus clinical management
T4 disease 696 715 depressive symptoms
T5 method 844 879 imipramine plus clinical management
#1 Annot... | [
"National",
"Institute",
"of",
"Mental",
"Health",
"Treatment",
"of",
"Depression",
"Collaborative",
"Research",
"Program",
".",
"General",
"effectiveness",
"of",
"treatments",
".",
"We",
"investigated",
"the",
"effectiveness",
"of",
"two",
"brief",
"psychotherapies",... | [
0,
9,
19,
22,
29,
36,
46,
49,
60,
74,
83,
90,
92,
100,
114,
117,
127,
129,
132,
145,
149,
163,
166,
170,
176,
191,
193,
207,
221,
225,
235,
244,
251,
253,
257,
261,
271,
274,
286,
291,
297,
308,
317,
327,
330,
339,
350,
35... | [
8,
18,
21,
28,
35,
45,
48,
59,
73,
82,
90,
91,
99,
113,
116,
127,
128,
131,
144,
148,
162,
165,
169,
175,
191,
192,
206,
220,
224,
234,
243,
251,
252,
256,
260,
270,
273,
285,
290,
296,
307,
316,
326,
329,
338,
349,
358,
3... | [
"B-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-method",
"O",
"B-method",
"I-method",
"O",
"B-method",
"... | [
9,
10,
10,
10,
10,
10,
10,
10,
10,
10,
10,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
0,
9,
10,
0,
9,
10,
10,
0,
0,
0,
0,
0,
0,
0,
3,
4,
4,
0,
0,
9,
10,
10,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0... |
MDIEC/16860895 | Composition of brain oscillations in ongoing EEG during major depression disorder. In the present study, we examined the composition of electroencephalographic (EEG) brain oscillations in 12 unmedicated major depressive outpatients and 10 healthy subjects during resting conditions (closed eyes). The exact composition o... | T1 disease 56 81 major depression disorder
T2 Health_factors 191 231 unmedicated major depressive outpatients
T3 disease 469 479 depression
T4 disease 852 868 major depression
T6 disease 1152 1177 major depressive disorder
#1 AnnotatorNotes T1 C1269683
T7 disease 510 526 major depression
#2 AnnotatorNotes T7 C1269683
T... | [
"Composition",
"of",
"brain",
"oscillations",
"in",
"ongoing",
"EEG",
"during",
"major",
"depression",
"disorder",
".",
"In",
"the",
"present",
"study",
",",
"we",
"examined",
"the",
"composition",
"of",
"electroencephalographic",
"(",
"EEG",
")",
"brain",
"osci... | [
0,
12,
15,
21,
34,
37,
45,
49,
56,
62,
73,
81,
83,
86,
90,
98,
103,
105,
108,
117,
121,
133,
136,
160,
161,
164,
166,
172,
185,
188,
191,
203,
209,
220,
232,
236,
239,
247,
256,
263,
271,
282,
283,
290,
294,
295,
297,
301,... | [
11,
14,
20,
33,
36,
44,
48,
55,
61,
72,
81,
82,
85,
89,
97,
103,
104,
107,
116,
120,
132,
135,
159,
161,
164,
165,
171,
184,
187,
190,
202,
208,
219,
231,
235,
238,
246,
255,
262,
270,
281,
283,
289,
294,
295,
296,
300,
30... | [
"O",
"O",
"B-signs",
"I-signs",
"O",
"B-method",
"I-method",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-signs",
"I-signs",
"I-signs",
"I-signs",
"I-signs",
"I-signs",
"O",
"O",
"B-Health_factors",
... | [
0,
0,
15,
16,
0,
9,
10,
0,
3,
4,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
15,
16,
16,
16,
16,
16,
0,
0,
1,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
13,
0,
0,
0,
0,
0,
0,
15,
16,
0,
0,
0,
0,
9,
10,
10,
10,
1... |
MDIEC/20221103_97 | CONCLUSION: Using a cut-off value of 14, the HADS could be considered a good screening tool to identify hospitalized CAD and ACS patients requiring a more accurate depression assessment, in order to promptly plan the most appropriate treatment strategies and prevent the negative effects of depression in CVD patients. | T2 method 45 49 HADS
T3 method 77 91 screening tool
T4 disease 117 120 CAD
T5 disease 125 128 ACS
T6 disease 164 174 depression
T10 disease 291 301 depression
T11 disease 305 308 CVD
R1 hyponym_of Arg1:T2 Arg2:T3
R2 help_diagnose Arg1:T2 Arg2:T4
R3 help_diagnose Arg1:T2 Arg2:T5
R4 occurs_in Arg1:T10 Arg2:T11
| [
"CONCLUSION",
":",
"Using",
"a",
"cut",
"-",
"off",
"value",
"of",
"14",
",",
"the",
"HADS",
"could",
"be",
"considered",
"a",
"good",
"screening",
"tool",
"to",
"identify",
"hospitalized",
"CAD",
"and",
"ACS",
"patients",
"requiring",
"a",
"more",
"accura... | [
0,
10,
12,
18,
20,
23,
24,
28,
34,
37,
39,
41,
45,
50,
56,
59,
70,
72,
77,
87,
92,
95,
104,
117,
121,
125,
129,
138,
148,
150,
155,
164,
175,
185,
187,
190,
196,
199,
208,
213,
217,
222,
234,
244,
255,
259,
267,
271,
280... | [
10,
11,
17,
19,
23,
24,
27,
33,
36,
39,
40,
44,
49,
55,
58,
69,
71,
76,
86,
91,
94,
103,
116,
120,
124,
128,
137,
147,
149,
154,
163,
174,
185,
186,
189,
195,
198,
207,
212,
216,
221,
233,
243,
254,
258,
266,
270,
279,
2... | [
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-method",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"O",
"O",
"O",
"B-disease",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
... | [
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
0,
0,
0,
0,
0,
9,
10,
0,
0,
0,
3,
0,
3,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
0,
3,
0,
0
] |
MDIEC/20221103_144 | On treatment, these patients were more likely to have psychiatric adverse events (AEs) or start new antidepressants (45 vs. 28%, P=0.02) and to have had early treatment discontinuation (38 vs.13%, P<0.0001); however, sustained virological response (SVR) rates were similar (38 vs. 40%, P=0.79) to those of participants w... | T4 Health_factors 54 80 psychiatric adverse events
T5 drug 100 115 antidepressants
T7 signs 217 247 sustained virological response
T8 signs 249 252 SVR
T10 disease 336 346 depression
T1 Health_factors 82 85 AEs
R1 abbreviation_for Arg1:T1 Arg2:T4
R2 abbreviation_for Arg1:T8 Arg2:T7
T2 Health_factors 159 184 treatment... | [
"On",
"treatment",
",",
"these",
"patients",
"were",
"more",
"likely",
"to",
"have",
"psychiatric",
"adverse",
"events",
"(",
"AEs",
")",
"or",
"start",
"new",
"antidepressants",
"(",
"45",
"vs",
".",
"28",
"%",
",",
"P",
"=",
"0",
".",
"02",
")",
"a... | [
0,
3,
12,
14,
20,
29,
34,
39,
46,
49,
54,
66,
74,
81,
82,
85,
87,
90,
96,
100,
116,
117,
120,
122,
124,
126,
127,
129,
130,
131,
132,
133,
135,
137,
141,
144,
149,
153,
159,
169,
185,
186,
189,
191,
192,
194,
195,
197,
1... | [
2,
12,
13,
19,
28,
33,
38,
45,
48,
53,
65,
73,
80,
82,
85,
86,
89,
95,
99,
115,
117,
119,
122,
123,
126,
127,
128,
130,
131,
132,
133,
135,
136,
140,
143,
148,
152,
158,
168,
184,
186,
188,
191,
192,
194,
195,
196,
198,
... | [
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"I-Health_factors",
"O",
"B-Health_factors",
"O",
"O",
"O",
"O",
"B-drug",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
... | [
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
2,
2,
0,
1,
0,
0,
0,
0,
5,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
15,
16,
16,
0,
15,
0,
0,... |
MDIEC/33096045 | Violence and mental disorders: a structured review of associations by individual diagnoses, risk factors, and risk assessment. In this Review, we summarise evidence on the association between different mental disorders and violence, with emphasis on high quality designs and replicated findings. Relative risks are typic... | T1 disease 13 29 mental disorders
T2 disease 202 218 mental disorders
T3 disease 378 399 psychiatric disorders
T4 disease 429 450 psychiatric disorders
T5 disease 642 656 mental illness
T6 disease 668 689 personality disorders
T7 disease 691 704 schizophrenia
T8 disease 710 726 substance misuse
T9 disease 757 778 perso... | [
"Violence",
"and",
"mental",
"disorders",
":",
"a",
"structured",
"review",
"of",
"associations",
"by",
"individual",
"diagnoses",
",",
"risk",
"factors",
",",
"and",
"risk",
"assessment",
".",
"In",
"this",
"Review",
",",
"we",
"summarise",
"evidence",
"on",
... | [
0,
9,
13,
20,
29,
31,
33,
44,
51,
54,
67,
70,
81,
90,
92,
97,
104,
106,
110,
115,
125,
127,
130,
135,
141,
143,
146,
156,
165,
168,
172,
184,
192,
202,
209,
219,
223,
231,
233,
238,
247,
250,
255,
263,
271,
275,
286,
294,
... | [
8,
12,
19,
29,
30,
32,
43,
50,
53,
66,
69,
80,
90,
91,
96,
104,
105,
109,
114,
125,
126,
129,
134,
141,
142,
145,
155,
164,
167,
171,
183,
191,
201,
208,
218,
222,
231,
232,
237,
246,
249,
254,
262,
270,
274,
285,
294,
295... | [
"B-Health_factors",
"O",
"B-disease",
"I-disease",
"O",
"O",
"B-method",
"I-method",
"O",
"O",
"O",
"B-method",
"I-method",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease"... | [
1,
0,
3,
4,
0,
0,
9,
10,
0,
0,
0,
9,
10,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
0,
0,
0,
0,
0,
1,
2,
0,
0,
0,
3,
4,
0,
... |
MDIEC/20221122_38 | In the final model, 3 PD-specific variables (increased disease duration, more severe motor symptoms, the use of levodopa) and 6 nonspecific variables (female sex, history of anxiety and/or depression, family history of depression, worse functioning on activities of daily living, and worse cognitive status) were maintai... | T2 Health_factors 55 71 disease duration
T3 disease 78 99 severe motor symptoms
T4 Health_factors 151 161 female sex
T5 physiology 290 306 cognitive status
T8 disease 358 368 depression
T9 Health_factors 163 199 history of anxiety and/or depression
T10 Health_factors 201 229 family history of depression
T1 drug 112 120... | [
"In",
"the",
"final",
"model",
",",
"3",
"PD",
"-",
"specific",
"variables",
"(",
"increased",
"disease",
"duration",
",",
"more",
"severe",
"motor",
"symptoms",
",",
"the",
"use",
"of",
"levodopa",
")",
"and",
"6",
"nonspecific",
"variables",
"(",
"female... | [
0,
3,
7,
13,
18,
20,
22,
24,
25,
34,
44,
45,
55,
63,
71,
73,
78,
85,
91,
99,
101,
105,
109,
112,
120,
122,
126,
128,
140,
150,
151,
158,
161,
163,
171,
174,
182,
185,
186,
189,
199,
201,
208,
216,
219,
229,
231,
237,
249... | [
2,
6,
12,
18,
19,
21,
24,
25,
33,
43,
45,
54,
62,
71,
72,
77,
84,
90,
99,
100,
104,
108,
111,
120,
121,
125,
127,
139,
149,
151,
157,
161,
162,
170,
173,
181,
185,
186,
188,
199,
200,
207,
215,
218,
229,
230,
236,
248,
2... | [
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"O",
"B-drug",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Health_factors",
"I-Health_factors... | [
0,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
1,
2,
0,
0,
3,
4,
4,
0,
0,
0,
0,
5,
0,
0,
0,
0,
0,
0,
1,
2,
0,
1,
2,
2,
2,
2,
2,
2,
0,
1,
2,
2,
2,
0,
0,
0,
0,
1,
2,
2,
2,
0,
0,
0,
11,
12,
0,
0,
0,
0,
0,
... |
MDIEC/11978820 | Long-term depression induced by postsynaptic group II metabotropic glutamate receptors linked to phospholipase C and intracellular calcium rises in rat prefrontal cortex. We have previously shown (Otani et al., 1999b) that bath application of (2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG IV), the agonist of g... | T0 gene 32 86 postsynaptic group II metabotropic glutamate receptors
T2 gene 97 112 phospholipase C
T3 drug 117 138 intracellular calcium
T4 physiology 0 20 Long-term depression
T6 region 148 169 rat prefrontal cortex
T8 drug 243 293 (2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine
T9 drug 295 301 DCG IV
T10 gene 319... | [
"Long",
"-",
"term",
"depression",
"induced",
"by",
"postsynaptic",
"group",
"II",
"metabotropic",
"glutamate",
"receptors",
"linked",
"to",
"phospholipase",
"C",
"and",
"intracellular",
"calcium",
"rises",
"in",
"rat",
"prefrontal",
"cortex",
".",
"We",
"have",
... | [
0,
4,
5,
10,
21,
29,
32,
45,
51,
54,
67,
77,
87,
94,
97,
111,
113,
117,
131,
139,
145,
148,
152,
163,
169,
171,
174,
179,
190,
196,
197,
203,
206,
208,
209,
211,
216,
218,
223,
228,
240,
243,
244,
246,
247,
248,
249,
250,
... | [
4,
5,
9,
20,
28,
31,
44,
50,
53,
66,
76,
86,
93,
96,
110,
112,
116,
130,
138,
144,
147,
151,
162,
169,
170,
173,
178,
189,
195,
197,
202,
205,
208,
209,
210,
216,
217,
222,
227,
239,
242,
244,
246,
247,
248,
249,
250,
251,... | [
"B-physiology",
"I-physiology",
"I-physiology",
"I-physiology",
"O",
"O",
"B-gene",
"I-gene",
"I-gene",
"I-gene",
"I-gene",
"I-gene",
"O",
"O",
"B-gene",
"I-gene",
"O",
"B-drug",
"I-drug",
"O",
"O",
"B-region",
"I-region",
"I-region",
"O",
"O",
"O",
"O",
"O",
... | [
11,
12,
12,
12,
0,
0,
7,
8,
8,
8,
8,
8,
0,
0,
7,
8,
0,
5,
6,
0,
0,
13,
14,
14,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
0,
5,
6,
6,
6,
6,
6,
6,
6,
6,
6,
6,
6,
6,
6,
6,
6,
6,
6,
6,
6,
6,
... |
MDIEC/20221122_196 | The aim of this observational study was to clarify the longitudinal association between baseline symptomatic OH (sOH-30) and incident depression in a sample of >3000 older people without baseline depression (mean age: 62 years at baseline). | T1 method 16 35 observational study
T3 disease 134 144 depression
T5 Health_factors 166 171 older
T6 disease 196 206 depression
T7 Health_factors 213 216 age
T2 disease 97 111 symptomatic OH
T4 disease 113 119 sOH-30
| [
"The",
"aim",
"of",
"this",
"observational",
"study",
"was",
"to",
"clarify",
"the",
"longitudinal",
"association",
"between",
"baseline",
"symptomatic",
"OH",
"(",
"sOH",
"-",
"30",
")",
"and",
"incident",
"depression",
"in",
"a",
"sample",
"of",
">",
"3000... | [
0,
4,
8,
11,
16,
30,
36,
40,
43,
51,
55,
68,
80,
88,
97,
109,
112,
113,
116,
117,
119,
121,
125,
134,
145,
148,
150,
157,
160,
161,
166,
172,
179,
187,
196,
207,
208,
213,
216,
218,
221,
227,
230,
238,
239
] | [
3,
7,
10,
15,
29,
35,
39,
42,
50,
54,
67,
79,
87,
96,
108,
111,
113,
116,
117,
119,
120,
124,
133,
144,
147,
149,
156,
159,
161,
165,
171,
178,
186,
195,
206,
208,
212,
216,
217,
220,
226,
229,
238,
239,
240
] | [
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Health_factors",
"O",
"O",
"O",
"... | [
0,
0,
0,
0,
9,
10,
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
0,
3,
4,
4,
0,
0,
0,
3,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
3,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0
] |
MDIEC/20221103_185 | The aim of this review was to examine whether non-pharmacological interventions for sleep problems are effective in reducing symptoms of depression. | T1 method 46 79 non-pharmacological interventions
T2 disease 84 98 sleep problems
T4 disease 137 147 depression
R1 treatment_for Arg1:T1 Arg2:T2
| [
"The",
"aim",
"of",
"this",
"review",
"was",
"to",
"examine",
"whether",
"non",
"-",
"pharmacological",
"interventions",
"for",
"sleep",
"problems",
"are",
"effective",
"in",
"reducing",
"symptoms",
"of",
"depression",
"."
] | [
0,
4,
8,
11,
16,
23,
27,
30,
38,
46,
49,
50,
66,
80,
84,
90,
99,
103,
113,
116,
125,
134,
137,
147
] | [
3,
7,
10,
15,
22,
26,
29,
37,
45,
49,
50,
65,
79,
83,
89,
98,
102,
112,
115,
124,
133,
136,
147,
148
] | [
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O"
] | [
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
10,
10,
0,
3,
4,
0,
0,
0,
0,
0,
0,
3,
0
] |
MDIEC/20221122_63 | Herein, we found that CCH pretreatment significantly attenuated METH-induced hyperthermia, and administration of CCH after METH exposure also inhibited METH-induced depression-like behaviors and reduced the hippocampal synaptic plasticity damage. | T1 disease 64 89 METH-induced hyperthermia
T2 Health_factors 123 136 METH exposure
T3 disease 152 190 METH-induced depression-like behaviors
T4 disease 207 245 hippocampal synaptic plasticity damage
T5 method 22 38 CCH pretreatment
R1 treatment_for Arg1:T5 Arg2:T1
T6 drug 113 116 CCH
R2 treatment_for Arg1:T6 Arg2:T3
... | [
"Herein",
",",
"we",
"found",
"that",
"CCH",
"pretreatment",
"significantly",
"attenuated",
"METH",
"-",
"induced",
"hyperthermia",
",",
"and",
"administration",
"of",
"CCH",
"after",
"METH",
"exposure",
"also",
"inhibited",
"METH",
"-",
"induced",
"depression",
... | [
0,
6,
8,
11,
17,
22,
26,
39,
53,
64,
68,
69,
77,
89,
91,
95,
110,
113,
117,
123,
128,
137,
142,
152,
156,
157,
165,
175,
176,
181,
191,
195,
203,
207,
219,
228,
239,
245
] | [
6,
7,
10,
16,
21,
25,
38,
52,
63,
68,
69,
76,
89,
90,
94,
109,
112,
116,
122,
127,
136,
141,
151,
156,
157,
164,
175,
176,
180,
190,
194,
202,
206,
218,
227,
238,
245,
246
] | [
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"O",
"B-drug",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
... | [
0,
0,
0,
0,
0,
9,
10,
0,
0,
3,
4,
4,
4,
0,
0,
0,
0,
5,
0,
1,
2,
0,
0,
3,
4,
4,
4,
4,
4,
4,
0,
0,
0,
3,
4,
4,
4,
0
] |
MDIEC/20221103_122 | OBJECTIVE: To characterize response among acute-phase non-responders in a randomized controlled trial of deep repetitive transcranial magnetic stimulation (dTMS) monotherapy for medication-resistant depression. | T2 method 74 101 randomized controlled trial
T3 method 105 154 deep repetitive transcranial magnetic stimulation
T5 disease 178 209 medication-resistant depression
T6 method 156 160 dTMS
R1 abbreviation_for Arg1:T6 Arg2:T3
R2 treatment_for Arg1:T3 Arg2:T5
R3 treatment_for Arg1:T6 Arg2:T5
| [
"OBJECTIVE",
":",
"To",
"characterize",
"response",
"among",
"acute",
"-",
"phase",
"non",
"-",
"responders",
"in",
"a",
"randomized",
"controlled",
"trial",
"of",
"deep",
"repetitive",
"transcranial",
"magnetic",
"stimulation",
"(",
"dTMS",
")",
"monotherapy",
... | [
0,
9,
11,
14,
27,
36,
42,
47,
48,
54,
57,
58,
69,
72,
74,
85,
96,
102,
105,
110,
121,
134,
143,
155,
156,
160,
162,
174,
178,
188,
189,
199,
209
] | [
9,
10,
13,
26,
35,
41,
47,
48,
53,
57,
58,
68,
71,
73,
84,
95,
101,
104,
109,
120,
133,
142,
154,
156,
160,
161,
173,
177,
188,
189,
198,
209,
210
] | [
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"I-method",
"O",
"B-method",
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",... | [
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
10,
0,
9,
10,
10,
10,
10,
0,
9,
0,
0,
0,
3,
4,
4,
4,
0
] |
MDIEC/20221103_28 | These results for active conditions extend findings from ALE meta-analyses of resting state and antidepressant treatment studies and emphasize the key role of the anterior insular and rostral anterior cingulate cortex for altered emotion and cognition in MDD. | T2 method 57 74 ALE meta-analyses
T3 method 96 128 antidepressant treatment studies
T5 region 163 179 anterior insular
T6 physiology 230 237 emotion
T8 disease 255 258 MDD
R3 associated_with Arg1:T5 Arg2:T6
R1 occurs_in Arg1:T6 Arg2:T8
T4 physiology 242 251 cognition
R2 associated_with Arg1:T5 Arg2:T4
R4 occurs_in A... | [
"These",
"results",
"for",
"active",
"conditions",
"extend",
"findings",
"from",
"ALE",
"meta",
"-",
"analyses",
"of",
"resting",
"state",
"and",
"antidepressant",
"treatment",
"studies",
"and",
"emphasize",
"the",
"key",
"role",
"of",
"the",
"anterior",
"insula... | [
0,
6,
14,
18,
25,
36,
43,
52,
57,
61,
65,
66,
75,
78,
86,
92,
96,
111,
121,
129,
133,
143,
147,
151,
156,
159,
163,
172,
180,
184,
192,
201,
211,
218,
222,
230,
238,
242,
252,
255,
258
] | [
5,
13,
17,
24,
35,
42,
51,
56,
60,
65,
66,
74,
77,
85,
91,
95,
110,
120,
128,
132,
142,
146,
150,
155,
158,
162,
171,
179,
183,
191,
200,
210,
217,
221,
229,
237,
241,
251,
254,
258,
259
] | [
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-region",
"I-region",
"O",
"B-region",
"I-region",
"I-region",
"I-regio... | [
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
10,
10,
0,
0,
0,
0,
9,
10,
10,
0,
0,
0,
0,
0,
0,
0,
13,
14,
0,
13,
14,
14,
14,
0,
0,
11,
0,
11,
0,
3,
0
] |
MDIEC/20221122_50 | Both agents caused a dose-dependent reduction in the extent of systolic contraction, and a 4.9:1 (lidocaine:bupivacaine) dose ratio produced a 50% depression of contraction. | T2 drug 98 107 lidocaine
T3 drug 108 119 bupivacaine
T4 physiology 63 83 systolic contraction
T1 physiology 147 172 depression of contraction
R1 associated_with Arg1:T2 Arg2:T1
R2 associated_with Arg1:T3 Arg2:T1
T6 drug 5 11 agents
| [
"Both",
"agents",
"caused",
"a",
"dose",
"-",
"dependent",
"reduction",
"in",
"the",
"extent",
"of",
"systolic",
"contraction",
",",
"and",
"a",
"4",
".",
"9",
":",
"1",
"(",
"lidocaine",
":",
"bupivacaine",
")",
"dose",
"ratio",
"produced",
"a",
"50",
... | [
0,
5,
12,
19,
21,
25,
26,
36,
46,
49,
53,
60,
63,
72,
83,
85,
89,
91,
92,
93,
94,
95,
97,
98,
107,
108,
119,
121,
126,
132,
141,
143,
145,
147,
158,
161,
172
] | [
4,
11,
18,
20,
25,
26,
35,
45,
48,
52,
59,
62,
71,
83,
84,
88,
90,
92,
93,
94,
95,
96,
98,
107,
108,
119,
120,
125,
131,
140,
142,
145,
146,
157,
160,
172,
173
] | [
"O",
"B-drug",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-physiology",
"I-physiology",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-drug",
"O",
"B-drug",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-physiology",
"I-physiology",
"I-physiolog... | [
0,
5,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
11,
12,
0,
0,
0,
0,
0,
0,
0,
0,
0,
5,
0,
5,
0,
0,
0,
0,
0,
0,
0,
11,
12,
12,
0
] |
MDIEC/23740050 | Abnormally high degree connectivity of the orbitofrontal cortex in obsessive-compulsive disorder. IMPORTANCE Neurobiological models of obsessive-compulsive disorder (OCD) predict hyperactivity in brain circuits involving the orbitofrontal cortex and the basal ganglia, but it is unclear whether these areas are also char... | T0 disease 67 96 obsessive-compulsive disorder
T2 region 43 63 orbitofrontal cortex
T3 disease 0 35 Abnormally high degree connectivity
T4 disease 135 164 obsessive-compulsive disorder
T5 disease 166 169 OCD
T7 disease 179 192 hyperactivity
T8 region 196 210 brain circuits
T10 region 254 267 basal ganglia
T11 region 34... | [
"Abnormally",
"high",
"degree",
"connectivity",
"of",
"the",
"orbitofrontal",
"cortex",
"in",
"obsessive",
"-",
"compulsive",
"disorder",
".",
"IMPORTANCE",
"Neurobiological",
"models",
"of",
"obsessive",
"-",
"compulsive",
"disorder",
"(",
"OCD",
")",
"predict",
... | [
0,
11,
16,
23,
36,
39,
43,
57,
64,
67,
76,
77,
88,
96,
98,
109,
125,
132,
135,
144,
145,
156,
165,
166,
169,
171,
179,
193,
196,
202,
211,
221,
225,
239,
246,
250,
254,
260,
267,
269,
273,
276,
279,
287,
295,
301,
307,
311... | [
10,
15,
22,
35,
38,
42,
56,
63,
66,
76,
77,
87,
96,
97,
108,
124,
131,
134,
144,
145,
155,
164,
166,
169,
170,
178,
192,
195,
201,
210,
220,
224,
238,
245,
249,
253,
259,
267,
268,
272,
275,
278,
286,
294,
300,
306,
310,
3... | [
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"O",
"B-region",
"I-region",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"O",
"B-method",
"I-method",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"B-disease",
"O",
"O",
"B... | [
3,
4,
4,
4,
0,
0,
13,
14,
0,
3,
4,
4,
4,
0,
0,
9,
10,
0,
3,
4,
4,
4,
0,
3,
0,
0,
3,
0,
13,
14,
0,
0,
13,
14,
0,
0,
13,
14,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
13,
14,
0,
0,
0,
0,
0,
0,
0,
3,
... |
MDIEC/26806518 | Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. BACKGROUND Lithium is a first-line treatment in bipolar disorder, but individual response is variable. Previous studies have suggested that lithium response is a heritable trait. However, no genetic mark... | T0 drug 45 52 lithium
T1 disease 66 82 bipolar disorder
T2 gene 0 16 Genetic variants
T3 method 86 115 genome-wide association study
T4 drug 128 135 Lithium
T5 disease 165 181 bipolar disorder
T6 method 141 161 first-line treatment
T8 symptom 257 273 lithium response
T10 symptom 279 294 heritable trait
T14 symptom 327 ... | [
"Genetic",
"variants",
"associated",
"with",
"response",
"to",
"lithium",
"treatment",
"in",
"bipolar",
"disorder",
":",
"a",
"genome",
"-",
"wide",
"association",
"study",
".",
"BACKGROUND",
"Lithium",
"is",
"a",
"first",
"-",
"line",
"treatment",
"in",
"bipo... | [
0,
8,
17,
28,
33,
42,
45,
53,
63,
66,
74,
82,
84,
86,
92,
93,
98,
110,
115,
117,
128,
136,
139,
141,
146,
147,
152,
162,
165,
173,
181,
183,
187,
198,
207,
210,
218,
220,
229,
237,
242,
252,
257,
265,
274,
277,
279,
289,
... | [
7,
16,
27,
32,
41,
44,
52,
62,
65,
73,
82,
83,
85,
92,
93,
97,
109,
115,
116,
127,
135,
138,
140,
146,
147,
151,
161,
164,
172,
181,
182,
186,
197,
206,
209,
218,
219,
228,
236,
241,
251,
256,
264,
273,
276,
278,
288,
294,... | [
"B-gene",
"I-gene",
"O",
"O",
"O",
"O",
"B-drug",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"I-method",
"O",
"O",
"B-drug",
"O",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"O",
"B-disease",
"I-dis... | [
7,
8,
0,
0,
0,
0,
5,
0,
0,
3,
4,
0,
0,
9,
10,
10,
10,
10,
0,
0,
5,
0,
0,
9,
10,
10,
10,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
17,
18,
0,
0,
17,
18,
0,
0,
0,
0,
15,
16,
0,
17,
18,
0,
0,
0,
0... |
MDIEC/15380965 | Suicide and the unique prevalence pattern of schizophrenia in mainland China: a retrospective observational study. BACKGROUND Unlike almost every other country in the world, the prevalence of both schizophrenia and suicide in China is higher in women than in men. Schizophrenia and suicide are important public-health pr... | T0 disease 45 58 schizophrenia
T1 disease 0 7 Suicide
T3 method 80 113 retrospective observational study
T4 disease 197 210 schizophrenia
T5 disease 215 222 suicide
T7 Health_factors 245 250 women
T8 Health_factors 259 262 men
T9 disease 264 277 Schizophrenia
T10 disease 282 289 suicide
T12 Health_factors 304 326 publi... | [
"Suicide",
"and",
"the",
"unique",
"prevalence",
"pattern",
"of",
"schizophrenia",
"in",
"mainland",
"China",
":",
"a",
"retrospective",
"observational",
"study",
".",
"BACKGROUND",
"Unlike",
"almost",
"every",
"other",
"country",
"in",
"the",
"world",
",",
"the... | [
0,
8,
12,
16,
23,
34,
42,
45,
59,
62,
71,
76,
78,
80,
94,
108,
113,
115,
126,
133,
140,
146,
152,
160,
163,
167,
172,
174,
178,
189,
192,
197,
211,
215,
223,
226,
232,
235,
242,
245,
251,
256,
259,
262,
264,
278,
282,
290,... | [
7,
11,
15,
22,
33,
41,
44,
58,
61,
70,
76,
77,
79,
93,
107,
113,
114,
125,
132,
139,
145,
151,
159,
162,
166,
172,
173,
177,
188,
191,
196,
210,
214,
222,
225,
231,
234,
241,
244,
250,
255,
258,
262,
263,
277,
281,
289,
29... | [
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"B-disease",
"O",
"O",
"O",
"O",... | [
3,
0,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
9,
10,
10,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
0,
3,
0,
0,
0,
0,
0,
1,
0,
0,
1,
0,
3,
0,
3,
0,
0,
1,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
... |
MDIEC/27139058 | Effect of a Web-Based Guided Self-help Intervention for Prevention of Major Depression in Adults With Subthreshold Depression: A Randomized Clinical Trial. IMPORTANCE: Evidence-based treatments for major depressive disorder (MDD) are not very successful in improving functional and health outcomes. Attention has increas... | T1 disease 70 86 Major Depression
T3 disease 198 223 major depressive disorder
T4 disease 225 228 MDD
T5 disease 360 363 MDD
T6 disease 473 476 MDD
T8 disease 922 933 current MDD
T10 disease 1435 1438 MDD
T12 disease 1936 1939 MDD
T13 signs 2047 2074 depressive symptom severity
T14 disease 2210 2213 MDD
T16 disease 242... | [
"Effect",
"of",
"a",
"Web",
"-",
"Based",
"Guided",
"Self",
"-",
"help",
"Intervention",
"for",
"Prevention",
"of",
"Major",
"Depression",
"in",
"Adults",
"With",
"Subthreshold",
"Depression",
":",
"A",
"Randomized",
"Clinical",
"Trial",
".",
"IMPORTANCE",
":"... | [
0,
7,
10,
12,
15,
16,
22,
29,
33,
34,
39,
52,
56,
67,
70,
76,
87,
90,
97,
102,
115,
125,
127,
129,
140,
149,
154,
156,
166,
168,
176,
177,
183,
194,
198,
204,
215,
224,
225,
228,
230,
234,
238,
243,
254,
257,
267,
278,
2... | [
6,
9,
11,
15,
16,
21,
28,
33,
34,
38,
51,
55,
66,
69,
75,
86,
89,
96,
101,
114,
125,
126,
128,
139,
148,
154,
155,
166,
167,
176,
177,
182,
193,
197,
203,
214,
223,
225,
228,
229,
233,
237,
242,
253,
256,
266,
277,
281,
... | [
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"B-Health_factors",
"O",
"B-disease",
"I-disease",
"O",
"O",
"B-method",
"I-method",
"I-method",
"O",
"O"... | [
0,
0,
0,
9,
10,
10,
10,
10,
10,
10,
10,
0,
0,
0,
3,
4,
0,
1,
0,
3,
4,
0,
0,
9,
10,
10,
0,
0,
0,
9,
10,
10,
10,
0,
3,
4,
4,
0,
3,
0,
0,
0,
0,
0,
0,
0,
1,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
... |
MDIEC/34735824 | Associations between plasma fatty acid concentrations and schizophrenia: a two-sample Mendelian randomisation study. BACKGROUND Although studies suggest that concentrations of omega-3 and omega-6 fatty acids are lower in individuals with schizophrenia, evidence for beneficial effects of fatty acid supplementation is sc... | T2 signs 21 53 plasma fatty acid concentrations
T3 disease 58 71 schizophrenia
T4 signs 158 207 concentrations of omega-3 and omega-6 fatty acids
T5 disease 238 251 schizophrenia
T6 method 288 314 fatty acid supplementation
T7 signs 382 427 omega-3 and omega-6 fatty acid concentrations
T8 disease 452 465 schizophrenia
... | [
"Associations",
"between",
"plasma",
"fatty",
"acid",
"concentrations",
"and",
"schizophrenia",
":",
"a",
"two",
"-",
"sample",
"Mendelian",
"randomisation",
"study",
".",
"BACKGROUND",
"Although",
"studies",
"suggest",
"that",
"concentrations",
"of",
"omega",
"-",
... | [
0,
13,
21,
28,
34,
39,
54,
58,
71,
73,
75,
78,
79,
86,
96,
110,
115,
117,
128,
137,
145,
153,
158,
173,
176,
181,
182,
184,
188,
193,
194,
196,
202,
208,
212,
218,
221,
233,
238,
251,
253,
262,
266,
277,
285,
288,
294,
299... | [
12,
20,
27,
33,
38,
53,
57,
71,
72,
74,
78,
79,
85,
95,
109,
115,
116,
127,
136,
144,
152,
157,
172,
175,
181,
182,
183,
187,
193,
194,
195,
201,
207,
211,
217,
220,
232,
237,
251,
252,
261,
265,
276,
284,
287,
293,
298,
3... | [
"O",
"O",
"B-signs",
"I-signs",
"I-signs",
"I-signs",
"O",
"B-disease",
"O",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"O",
"O",
"O",
"O",
"O",
"O",
"B-signs",
"I-signs",
"I-signs",
"I-signs",
"I-signs",
"I-signs",
"I-signs",... | [
0,
0,
15,
16,
16,
16,
0,
3,
0,
0,
9,
10,
10,
10,
10,
10,
0,
0,
0,
0,
0,
0,
15,
16,
16,
16,
16,
16,
16,
16,
16,
16,
16,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
0,
9,
10,
10,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
... |
MDIEC/20221103_59 | TMS has been shown to normalize abnormal functional connectivity of cortico-cortical circuits in depression and baseline functional connectivity of these circuits predicts treatment response. | T1 method 0 3 TMS
T2 disease 32 64 abnormal functional connectivity
T3 region 68 93 cortico-cortical circuits
T4 disease 97 107 depression
T5 physiology 121 144 functional connectivity
R1 treatment_for Arg1:T1 Arg2:T2
T6 region 154 162 circuits
T7 physiology 172 190 treatment response
R2 associated_with Arg1:T5 Arg2:T... | [
"TMS",
"has",
"been",
"shown",
"to",
"normalize",
"abnormal",
"functional",
"connectivity",
"of",
"cortico",
"-",
"cortical",
"circuits",
"in",
"depression",
"and",
"baseline",
"functional",
"connectivity",
"of",
"these",
"circuits",
"predicts",
"treatment",
"respon... | [
0,
4,
8,
13,
19,
22,
32,
41,
52,
65,
68,
75,
76,
85,
94,
97,
108,
112,
121,
132,
145,
148,
154,
163,
172,
182,
190
] | [
3,
7,
12,
18,
21,
31,
40,
51,
64,
67,
75,
76,
84,
93,
96,
107,
111,
120,
131,
144,
147,
153,
162,
171,
181,
190,
191
] | [
"B-method",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"B-region",
"I-region",
"I-region",
"I-region",
"O",
"B-disease",
"O",
"O",
"B-physiology",
"I-physiology",
"O",
"O",
"B-region",
"O",
"B-physiology",
"I-physiology",
"O"
] | [
9,
0,
0,
0,
0,
0,
3,
4,
4,
0,
13,
14,
14,
14,
0,
3,
0,
0,
11,
12,
0,
0,
13,
0,
11,
12,
0
] |
MDIEC/20221122_73 | Six-month poststroke depression (n = 115, 26%) was associated with 6-month impairment on the MoCA (beta = 0.96, standard error [SE] 0.31, p = 0.006) and all individual domains assessed by the OCS: spatial attention (beta = 0.67, SE 0.33, p = 0.041), executive function (beta = 1.37, SE 0.47, p = 0.004), language process... | T1 disease 10 31 poststroke depression
T2 disease 93 97 MoCA
T12 physiology 250 268 executive function
T13 physiology 304 323 language processing
T14 physiology 359 365 memory
T15 physiology 401 418 number processing
R1 associated_with Arg1:T1 Arg2:T2
T3 method 112 126 standard error
T4 method 128 130 SE
R2 abbreviati... | [
"Six",
"-",
"month",
"poststroke",
"depression",
"(",
"n",
"=",
"115",
",",
"26",
"%",
")",
"was",
"associated",
"with",
"6",
"-",
"month",
"impairment",
"on",
"the",
"MoCA",
"(",
"beta",
"=",
"0",
".",
"96",
",",
"standard",
"error",
"[",
"SE",
"]... | [
0,
3,
4,
10,
21,
32,
33,
35,
37,
40,
42,
44,
45,
47,
51,
62,
67,
68,
69,
75,
86,
89,
93,
98,
99,
104,
106,
107,
108,
110,
112,
121,
127,
128,
130,
132,
133,
134,
136,
138,
140,
142,
143,
144,
147,
149,
153,
157,
168,
1... | [
3,
4,
9,
20,
31,
33,
34,
36,
40,
41,
44,
45,
46,
50,
61,
66,
68,
69,
74,
85,
88,
92,
97,
99,
103,
105,
107,
108,
110,
111,
120,
126,
128,
130,
131,
133,
134,
136,
137,
139,
141,
143,
144,
147,
148,
152,
156,
167,
175,
... | [
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"O",
"B-method",
"O",
"O",
"O",
"O",
"O",
... | [
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
0,
0,
9,
10,
0,
9,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
0,
11,
12,
0,
0,
0,
0,
0,
0,
0,
... |
MDIEC/26361000 | Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. BACKGROUND Social anxiety disorder-a chronic and naturally unremitting disease that causes substantial impairment-can be treated with pharmacological, psychological, and self-help interv... | T0 disease 52 75 social anxiety disorder
T2 method 0 47 Psychological and pharmacological interventions
T3 Health_factors 79 85 adults
T4 method 89 106 systematic review
T5 method 111 132 network meta-analysis
T6 disease 145 168 Social anxiety disorder
T8 disease 237 247 impairment
T9 method 268 327 pharmacological, ps... | [
"Psychological",
"and",
"pharmacological",
"interventions",
"for",
"social",
"anxiety",
"disorder",
"in",
"adults",
":",
"a",
"systematic",
"review",
"and",
"network",
"meta",
"-",
"analysis",
".",
"BACKGROUND",
"Social",
"anxiety",
"disorder",
"-",
"a",
"chronic"... | [
0,
14,
18,
34,
48,
52,
59,
67,
76,
79,
85,
87,
89,
100,
107,
111,
119,
123,
124,
132,
134,
145,
152,
160,
168,
169,
171,
179,
183,
193,
205,
213,
218,
225,
237,
247,
248,
252,
255,
263,
268,
283,
285,
298,
300,
304,
308,
3... | [
13,
17,
33,
47,
51,
58,
66,
75,
78,
85,
86,
88,
99,
106,
110,
118,
123,
124,
132,
133,
144,
151,
159,
168,
169,
170,
178,
182,
192,
204,
212,
217,
224,
236,
247,
248,
251,
254,
262,
267,
283,
284,
298,
299,
303,
308,
309,
... | [
"B-method",
"I-method",
"I-method",
"I-method",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"B-Health_factors",
"O",
"O",
"B-method",
"I-method",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"O",
"... | [
9,
10,
10,
10,
0,
3,
4,
4,
0,
1,
0,
0,
9,
10,
0,
9,
10,
10,
10,
0,
0,
3,
4,
4,
0,
0,
3,
4,
4,
4,
4,
0,
0,
0,
3,
0,
0,
0,
0,
0,
9,
10,
10,
10,
10,
10,
10,
10,
10,
0,
0,
0,
0,
0,
0,
9,
0,
0,
0,
0,
0... |
MDIEC/22198573 | Metabotropic glutamate receptor-dependent long-term depression is impaired due to elevated ERK signaling in the RG mouse model of tuberous sclerosis complex. Tuberous sclerosis complex (TSC) and fragile X syndrome (FXS) are caused by mutations in negative regulators of translation. FXS model mice exhibit enhanced metab... | T3 physiology 0 62 Metabotropic glutamate receptor-dependent long-term depression
T4 physiology 82 104 elevated ERK signaling
T6 method 112 126 RG mouse model
T7 disease 158 184 Tuberous sclerosis complex
T8 disease 186 189 TSC
T9 disease 195 213 fragile X syndrome
T10 disease 215 218 FXS
T11 method 283 297 FXS model m... | [
"Metabotropic",
"glutamate",
"receptor",
"-",
"dependent",
"long",
"-",
"term",
"depression",
"is",
"impaired",
"due",
"to",
"elevated",
"ERK",
"signaling",
"in",
"the",
"RG",
"mouse",
"model",
"of",
"tuberous",
"sclerosis",
"complex",
".",
"Tuberous",
"sclerosi... | [
0,
13,
23,
31,
32,
42,
46,
47,
52,
63,
66,
75,
79,
82,
91,
95,
105,
108,
112,
115,
121,
127,
130,
139,
149,
156,
158,
167,
177,
185,
186,
189,
191,
195,
203,
205,
214,
215,
218,
220,
224,
231,
234,
244,
247,
256,
267,
270,... | [
12,
22,
31,
32,
41,
46,
47,
51,
62,
65,
74,
78,
81,
90,
94,
104,
107,
111,
114,
120,
126,
129,
138,
148,
156,
157,
166,
176,
184,
186,
189,
190,
194,
202,
204,
213,
215,
218,
219,
223,
230,
233,
243,
246,
255,
266,
269,
28... | [
"B-physiology",
"I-physiology",
"I-physiology",
"I-physiology",
"I-physiology",
"I-physiology",
"I-physiology",
"I-physiology",
"I-physiology",
"O",
"O",
"O",
"O",
"B-physiology",
"I-physiology",
"I-physiology",
"O",
"O",
"B-method",
"I-method",
"I-method",
"O",
"B-diseas... | [
11,
12,
12,
12,
12,
12,
12,
12,
12,
0,
0,
0,
0,
11,
12,
12,
0,
0,
9,
10,
10,
0,
3,
4,
4,
0,
3,
4,
4,
0,
3,
0,
0,
3,
4,
4,
0,
3,
0,
0,
0,
0,
7,
0,
7,
8,
8,
8,
0,
9,
10,
10,
0,
17,
18,
18,
18,
18,
18,
... |
MDIEC/23232609 | Economic inequalities in the effectiveness of a primary care intervention for depression and suicidal ideation. BACKGROUND Economic disadvantage is associated with depression and suicide. We sought to determine whether economic disadvantage reduces the effectiveness of depression treatments received in primary care. ME... | T0 disease 78 88 depression
T2 method 48 73 primary care intervention
T3 disease 93 110 suicidal ideation
T4 disease 164 174 depression
T5 disease 179 186 suicide
T6 disease 270 280 depression
T7 method 304 316 primary care
T9 disease 498 518 late-life depression
T10 disease 607 623 major depression
T11 disease 650 666... | [
"Economic",
"inequalities",
"in",
"the",
"effectiveness",
"of",
"a",
"primary",
"care",
"intervention",
"for",
"depression",
"and",
"suicidal",
"ideation",
".",
"BACKGROUND",
"Economic",
"disadvantage",
"is",
"associated",
"with",
"depression",
"and",
"suicide",
"."... | [
0,
9,
22,
25,
29,
43,
46,
48,
56,
61,
74,
78,
89,
93,
102,
110,
112,
123,
132,
145,
148,
159,
164,
175,
179,
186,
188,
191,
198,
201,
211,
219,
228,
241,
249,
253,
267,
270,
281,
292,
301,
304,
312,
316,
318,
326,
329,
339... | [
8,
21,
24,
28,
42,
45,
47,
55,
60,
73,
77,
88,
92,
101,
110,
111,
122,
131,
144,
147,
158,
163,
174,
178,
186,
187,
190,
197,
200,
210,
218,
227,
240,
248,
252,
266,
269,
280,
291,
300,
303,
311,
316,
317,
325,
328,
338,
3... | [
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"O",
"B-disease",
"O",
"B-disease",
"I-disease",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"O",
"B-disease",
"O",
"B-disease",
"O",
"O",
"O",
... | [
1,
2,
0,
0,
0,
0,
0,
9,
10,
10,
0,
3,
0,
3,
4,
0,
0,
1,
2,
0,
0,
0,
3,
0,
3,
0,
0,
0,
0,
0,
0,
1,
2,
0,
0,
0,
0,
3,
0,
0,
0,
9,
10,
0,
0,
0,
0,
9,
10,
10,
10,
0,
0,
9,
0,
3,
0,
9,
10,
1,
0,
9,
... |
MDIEC/36073682 | Attention-deficit/hyperactivity disorder as a risk factor for cardiovascular diseases: a nationwide population-based cohort study. Accumulating evidence suggests a higher risk for cardiovascular diseases among individuals with mental disorders, but very little is known about the risk for overall and specific groups of ... | T0 disease 0 40 Attention-deficit/hyperactivity disorder
T1 disease 62 85 cardiovascular diseases
T3 method 89 129 nationwide population-based cohort study
T5 disease 180 203 cardiovascular diseases
T6 disease 227 243 mental disorders
T7 disease 359 399 attention-deficit/hyperactivity disorder
T8 disease 401 405 ADHD
T... | [
"Attention",
"-",
"deficit",
"/",
"hyperactivity",
"disorder",
"as",
"a",
"risk",
"factor",
"for",
"cardiovascular",
"diseases",
":",
"a",
"nationwide",
"population",
"-",
"based",
"cohort",
"study",
".",
"Accumulating",
"evidence",
"suggests",
"a",
"higher",
"r... | [
0,
9,
10,
17,
18,
32,
41,
44,
46,
51,
58,
62,
77,
85,
87,
89,
100,
110,
111,
117,
124,
129,
131,
144,
153,
162,
164,
171,
176,
180,
195,
204,
210,
222,
227,
234,
243,
245,
249,
254,
261,
264,
270,
276,
280,
285,
289,
297,
... | [
9,
10,
17,
18,
31,
40,
43,
45,
50,
57,
61,
76,
85,
86,
88,
99,
110,
111,
116,
123,
129,
130,
143,
152,
161,
163,
170,
175,
179,
194,
203,
209,
221,
226,
233,
243,
244,
248,
253,
260,
263,
269,
275,
279,
284,
288,
296,
300,... | [
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-dise... | [
3,
4,
4,
4,
4,
4,
0,
0,
0,
0,
0,
3,
4,
0,
0,
9,
10,
10,
10,
10,
10,
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
0,
0,
0,
3,
4,
4,
4,
4,
4,
0... |
MDIEC/36436532 | Augmenting trauma-focused psychotherapy for post-traumatic stress disorder with BACKGROUND: Although exposure therapy is central in most front-line psychotherapies of post-traumatic stress disorder (PTSD), many patients do not respond to this treatment. We aimed to investigate the effects of brief aerobic exercise on t... | T0 disease 44 74 post-traumatic stress disorder
T1 disease 167 197 post-traumatic stress disorder
T2 disease 199 203 PTSD
T7 method 137 163 front-line psychotherapies
T8 method 101 117 exposure therapy
T9 method 11 39 trauma-focused psychotherapy
T10 disease 380 384 PTSD
T12 method 335 351 exposure therapy
T14 Health_f... | [
"Augmenting",
"trauma",
"-",
"focused",
"psychotherapy",
"for",
"post",
"-",
"traumatic",
"stress",
"disorder",
"with",
"BACKGROUND",
":",
"Although",
"exposure",
"therapy",
"is",
"central",
"in",
"most",
"front",
"-",
"line",
"psychotherapies",
"of",
"post",
"-... | [
0,
11,
17,
18,
26,
40,
44,
48,
49,
59,
66,
75,
80,
90,
92,
101,
110,
118,
121,
129,
132,
137,
142,
143,
148,
164,
167,
171,
172,
182,
189,
198,
199,
203,
204,
206,
211,
220,
223,
227,
235,
238,
243,
252,
254,
257,
263,
266... | [
10,
17,
18,
25,
39,
43,
48,
49,
58,
65,
74,
79,
90,
91,
100,
109,
117,
120,
128,
131,
136,
142,
143,
147,
163,
166,
171,
172,
181,
188,
197,
199,
203,
204,
205,
210,
219,
222,
226,
234,
237,
242,
252,
253,
256,
262,
265,
2... | [
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"O",
"B-disease",
"I-diseas... | [
0,
9,
10,
10,
10,
0,
3,
4,
4,
4,
4,
0,
0,
0,
0,
9,
10,
0,
0,
0,
0,
9,
10,
10,
10,
0,
3,
4,
4,
4,
4,
0,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
2,
2,
0,
0,
0,
0,
9,
10,
0,
0,
... |
MDIEC/35191924 | Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated IMPORTANCE: Acute agitation is common in patients with bipolar disorder and requires urgent management to relieve distress and to prevent escalation to aggressive behavior. OBJECTIVE: To evaluate the effect of orally absorbed, sublingual dexm... | T0 drug 10 36 Sublingual Dexmedetomidine
T1 disease 133 149 bipolar disorder
T3 disease 192 200 distress
T5 Health_factors 230 249 aggressive behavior
T7 disease 90 105 Acute agitation
T8 disease 51 66 Acute Agitation
T9 drug 305 331 sublingual dexmedetomidine
T10 gene 335 375 selective 2A-adrenergic receptor agonist
T... | [
"Effect",
"of",
"Sublingual",
"Dexmedetomidine",
"vs",
"Placebo",
"on",
"Acute",
"Agitation",
"Associated",
"IMPORTANCE",
":",
"Acute",
"agitation",
"is",
"common",
"in",
"patients",
"with",
"bipolar",
"disorder",
"and",
"requires",
"urgent",
"management",
"to",
"... | [
0,
7,
10,
21,
37,
40,
48,
51,
57,
67,
78,
88,
90,
96,
106,
109,
116,
119,
128,
133,
141,
150,
154,
163,
170,
181,
184,
192,
201,
205,
208,
216,
227,
230,
241,
249,
251,
260,
262,
265,
274,
278,
285,
288,
295,
303,
305,
316... | [
6,
9,
20,
36,
39,
47,
50,
56,
66,
77,
88,
89,
95,
105,
108,
115,
118,
127,
132,
140,
149,
153,
162,
169,
180,
183,
191,
200,
204,
207,
215,
226,
229,
240,
249,
250,
260,
261,
264,
273,
277,
284,
287,
294,
303,
304,
315,
33... | [
"O",
"O",
"B-drug",
"I-drug",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"B-Health_factors",... | [
0,
0,
5,
6,
0,
0,
0,
3,
4,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
1,
2,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
0,
5,
6,
0,
0,
7,
8,
8,
8,
8,
8,
0,
0,
0,
3,
4,
0,
0,
... |
MDIEC/29446381 | Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. The N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine has attracted enormous interest in mental health research owing to its rapid antidepressant actions, but its mechanism of action has remained elusive. Here we show that blockade ... | T1 drug 0 8 Ketamine
T2 gene 84 113 N-methyl-d-aspartate receptor
T3 drug 133 141 ketamine
T7 disease 599 609 depressive
T8 drug 645 653 ketamine
T9 disease 724 733 anhedonia
T10 gene 824 869 low-voltage-sensitive T-type calcium channels
T11 drug 1037 1045 ketamine
T12 disease 68 78 depression
R1 treatment_for Arg1:T1 ... | [
"Ketamine",
"blocks",
"bursting",
"in",
"the",
"lateral",
"habenula",
"to",
"rapidly",
"relieve",
"depression",
".",
"The",
"N",
"-",
"methyl",
"-",
"d",
"-",
"aspartate",
"receptor",
"(",
"NMDAR",
")",
"antagonist",
"ketamine",
"has",
"attracted",
"enormous",... | [
0,
9,
16,
25,
28,
32,
40,
49,
52,
60,
68,
78,
80,
84,
85,
86,
92,
93,
94,
95,
105,
114,
115,
120,
122,
133,
142,
146,
156,
165,
174,
177,
184,
191,
200,
206,
209,
213,
219,
234,
241,
243,
247,
251,
261,
264,
271,
275,
28... | [
8,
15,
24,
27,
31,
39,
48,
51,
59,
67,
78,
79,
83,
85,
86,
92,
93,
94,
95,
104,
113,
115,
120,
121,
132,
141,
145,
155,
164,
173,
176,
183,
190,
199,
205,
208,
212,
218,
233,
241,
242,
246,
250,
260,
263,
270,
274,
283,
... | [
"B-drug",
"O",
"B-physiology",
"O",
"O",
"B-region",
"I-region",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"B-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"I-drug",
"B-drug",
"O",
"O",
"O",
"O",
"O"... | [
5,
0,
11,
0,
0,
13,
14,
0,
0,
0,
3,
0,
0,
5,
6,
6,
6,
6,
6,
6,
6,
6,
6,
6,
6,
5,
0,
0,
0,
0,
0,
9,
10,
10,
0,
0,
0,
11,
12,
12,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
11,
12,
12,
12,
12,
... |
MDIEC/36949192 | Gut enterochromaffin cells drive visceral pain and anxiety. Gastrointestinal (GI) discomfort is a hallmark of most gut disorders and represents an important component of chronic visceral pain(1). For the growing population afflicted by irritable bowel syndrome, GI hypersensitivity and pain persist long after tissue inj... | T0 region 0 26 Gut enterochromaffin cells
T1 disease 33 46 visceral pain
T2 disease 51 58 anxiety
T3 disease 60 92 Gastrointestinal (GI) discomfort
T4 disease 115 128 gut disorders
T5 disease 170 191 chronic visceral pain
T6 disease 236 260 irritable bowel syndrome
T7 disease 262 281 GI hypersensitivity
T8 disease 286 ... | [
"Gut",
"enterochromaffin",
"cells",
"drive",
"visceral",
"pain",
"and",
"anxiety",
".",
"Gastrointestinal",
"(",
"GI",
")",
"discomfort",
"is",
"a",
"hallmark",
"of",
"most",
"gut",
"disorders",
"and",
"represents",
"an",
"important",
"component",
"of",
"chronic... | [
0,
4,
21,
27,
33,
42,
47,
51,
58,
60,
77,
78,
80,
82,
93,
96,
98,
107,
110,
115,
119,
129,
133,
144,
147,
157,
167,
170,
178,
187,
191,
192,
193,
194,
196,
200,
204,
212,
223,
233,
236,
246,
252,
260,
262,
265,
282,
286,
... | [
3,
20,
26,
32,
41,
46,
50,
58,
59,
76,
78,
80,
81,
92,
95,
97,
106,
109,
114,
118,
128,
132,
143,
146,
156,
166,
169,
177,
186,
191,
192,
193,
194,
195,
199,
203,
211,
222,
232,
235,
245,
251,
260,
261,
264,
281,
285,
290,... | [
"B-region",
"I-region",
"I-region",
"O",
"B-disease",
"I-disease",
"O",
"B-disease",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease"... | [
13,
14,
14,
0,
3,
4,
0,
3,
0,
3,
4,
4,
4,
4,
0,
0,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
3,
4,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
4,
0,
3,
4,
0,
3,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
3,
4,
4,
0,
... |
MDIEC/23663951 | Genetics of bipolar disorder. Studies of families and twins show the importance of genetic factors affecting susceptibility to bipolar disorder and suggest substantial genetic and phenotypic complexity. Robust and replicable genome-wide significant associations have recently been reported in genome-wide association stu... | T1 disease 12 28 bipolar disorder
T2 disease 127 143 bipolar disorder
T3 gene 394 401 CACNA1C
T4 gene 403 407 ODZ4
T5 gene 413 417 NCAN
T6 disease 579 595 bipolar disorder
T7 disease 600 613 schizophrenia
T8 disease 752 768 bipolar disorder
T9 disease 785 798 schizophrenia
T10 disease 918 934 bipolar disorder
T11 gene ... | [
"Genetics",
"of",
"bipolar",
"disorder",
".",
"Studies",
"of",
"families",
"and",
"twins",
"show",
"the",
"importance",
"of",
"genetic",
"factors",
"affecting",
"susceptibility",
"to",
"bipolar",
"disorder",
"and",
"suggest",
"substantial",
"genetic",
"and",
"phen... | [
0,
9,
12,
20,
28,
30,
38,
41,
50,
54,
60,
65,
69,
80,
83,
91,
99,
109,
124,
127,
135,
144,
148,
156,
168,
176,
180,
191,
201,
203,
210,
214,
225,
231,
232,
237,
249,
262,
267,
276,
281,
290,
293,
299,
300,
305,
317,
325,
... | [
8,
11,
19,
28,
29,
37,
40,
49,
53,
59,
64,
68,
79,
82,
90,
98,
108,
123,
126,
134,
143,
147,
155,
167,
175,
179,
190,
201,
202,
209,
213,
224,
231,
232,
236,
248,
261,
266,
275,
280,
289,
292,
299,
300,
304,
316,
324,
327,... | [
"B-gene",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"B-Health_factors",
"O",
"O",
"O",
"O",
"B-gene",
"I-gene",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"B-gene",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",... | [
7,
0,
3,
4,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
7,
8,
0,
0,
0,
3,
4,
0,
0,
0,
7,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
10,
10,
10,
0,
0,
0,
7,
0,
0,
0,
0,
0,
7,
7,
0,
7,
0,
0,
7,... |
MDIEC/35093198 | Family interventions for relapse prevention in schizophrenia: a systematic review BACKGROUND: Family interventions are efficacious for relapse prevention in schizophrenia. Multiple different models have been developed. We aimed to compare the efficacy, acceptability, and tolerability of family interventions for relapse... | T1 disease 47 60 schizophrenia
T2 disease 157 170 schizophrenia
T3 disease 335 348 schizophrenia
T4 disease 547 560 schizophrenia
T5 disease 847 879 schizophrenia spectrum disorders
T6 disease 947 989 concurrent medical or psychiatric disorder
T7 disease 1029 1038 psychosis
T8 disease 1204 1217 schizophrenia
T9 disease... | [
"Family",
"interventions",
"for",
"relapse",
"prevention",
"in",
"schizophrenia",
":",
"a",
"systematic",
"review",
"BACKGROUND",
":",
"Family",
"interventions",
"are",
"efficacious",
"for",
"relapse",
"prevention",
"in",
"schizophrenia",
".",
"Multiple",
"different",... | [
0,
7,
21,
25,
33,
44,
47,
60,
62,
64,
75,
82,
92,
94,
101,
115,
119,
131,
135,
143,
154,
157,
170,
172,
181,
191,
198,
203,
208,
217,
219,
222,
228,
231,
239,
243,
251,
253,
266,
268,
272,
285,
288,
295,
309,
313,
321,
332... | [
6,
20,
24,
32,
43,
46,
60,
61,
63,
74,
81,
92,
93,
100,
114,
118,
130,
134,
142,
153,
156,
170,
171,
180,
190,
197,
202,
207,
217,
218,
221,
227,
230,
238,
242,
251,
252,
266,
267,
271,
284,
287,
294,
308,
312,
320,
331,
3... | [
"B-method",
"I-method",
"O",
"B-disease",
"O",
"O",
"B-disease",
"O",
"O",
"B-method",
"I-method",
"O",
"O",
"B-method",
"I-method",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",... | [
9,
10,
0,
3,
0,
0,
3,
0,
0,
9,
10,
0,
0,
9,
10,
0,
0,
0,
3,
0,
0,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
0,
3,
0,
0,
3,
0,
0,
0,
0,
0,
9,
10,
0,
9,
10,
10,
10,
0,
... |
MDIEC/20221122_57 | In short term clinical trials in patients with depression, paroxetine produced clinical improvements that were significantly greater than those with placebo and similar to those achieved with other agents including tricyclic antidepressants (TCAs), maprotiline, nefazodone and the selective serotonin reuptake inhibitors... | T1 method 3 29 short term clinical trials
T3 disease 47 57 depression
T4 drug 59 69 paroxetine
T6 drug 198 204 agents
T7 drug 215 240 tricyclic antidepressants
T8 drug 249 260 maprotiline
T9 drug 262 272 nefazodone
T10 drug 281 320 selective serotonin reuptake inhibitors
T11 drug 322 327 SSRIs
T12 drug 329 339 fluoxeti... | [
"In",
"short",
"term",
"clinical",
"trials",
"in",
"patients",
"with",
"depression",
",",
"paroxetine",
"produced",
"clinical",
"improvements",
"that",
"were",
"significantly",
"greater",
"than",
"those",
"with",
"placebo",
"and",
"similar",
"to",
"those",
"achiev... | [
0,
3,
9,
14,
23,
30,
33,
42,
47,
57,
59,
70,
79,
88,
101,
106,
111,
125,
133,
138,
144,
149,
157,
161,
169,
172,
178,
187,
192,
198,
205,
215,
225,
241,
242,
246,
247,
249,
260,
262,
273,
277,
281,
291,
301,
310,
321,
322,... | [
2,
8,
13,
22,
29,
32,
41,
46,
57,
58,
69,
78,
87,
100,
105,
110,
124,
132,
137,
143,
148,
156,
160,
168,
171,
177,
186,
191,
197,
204,
214,
224,
240,
242,
246,
247,
248,
260,
261,
272,
276,
280,
290,
300,
309,
320,
322,
32... | [
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"O",
"O",
"O",
"B-disease",
"O",
"B-drug",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-drug",
"O",
"B-drug",
"I-drug",
"O",
"B-drug",
"O",
"O"... | [
0,
9,
10,
10,
10,
0,
0,
0,
3,
0,
5,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
5,
0,
5,
6,
0,
5,
0,
0,
5,
0,
5,
0,
0,
5,
6,
6,
6,
0,
5,
0,
5,
0,
5,
0,
5,
0
] |
MDIEC/20221122_133 | Major depressive disorder (MDD) is a prevalent disorder with moderate heritability. | T1 disease 0 25 Major depressive disorder
T2 disease 27 30 MDD
R1 abbreviation_for Arg1:T2 Arg2:T1
T4 Health_factors 61 82 moderate heritability
R4 characteristic_of Arg1:T4 Arg2:T2
R5 characteristic_of Arg1:T4 Arg2:T1
| [
"Major",
"depressive",
"disorder",
"(",
"MDD",
")",
"is",
"a",
"prevalent",
"disorder",
"with",
"moderate",
"heritability",
"."
] | [
0,
6,
17,
26,
27,
30,
32,
35,
37,
47,
56,
61,
70,
82
] | [
5,
16,
25,
27,
30,
31,
34,
36,
46,
55,
60,
69,
82,
83
] | [
"B-disease",
"I-disease",
"I-disease",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"O"
] | [
3,
4,
4,
0,
3,
0,
0,
0,
0,
0,
0,
1,
2,
0
] |
MDIEC/20221103_18 | Here, we show that female mice treated neonatally with a highly selective serotonin reuptake inhibitor, escitalopram, exhibited signs of depression in the form of sleep anomalies, anhedonia, increased helplessness reversed by chronic antidepressant treatment, enhanced response to acute stress, and increased serotoniner... | T2 drug 64 102 selective serotonin reuptake inhibitor
T3 drug 104 116 escitalopram
T4 disease 137 147 depression
T5 disease 180 189 anhedonia
T7 method 226 258 chronic antidepressant treatment
T10 physiology 309 346 serotoninergic autoinhibitory feedbac
T11 disease 163 178 sleep anomalies
R2 characteristic_of Arg1:T11 ... | [
"Here",
",",
"we",
"show",
"that",
"female",
"mice",
"treated",
"neonatally",
"with",
"a",
"highly",
"selective",
"serotonin",
"reuptake",
"inhibitor",
",",
"escitalopram",
",",
"exhibited",
"signs",
"of",
"depression",
"in",
"the",
"form",
"of",
"sleep",
"ano... | [
0,
4,
6,
9,
14,
19,
26,
31,
39,
50,
55,
57,
64,
74,
84,
93,
102,
104,
116,
118,
128,
134,
137,
148,
151,
155,
160,
163,
169,
178,
180,
189,
191,
201,
214,
223,
226,
234,
249,
258,
260,
269,
278,
281,
287,
293,
295,
299,
... | [
4,
5,
8,
13,
18,
25,
30,
38,
49,
54,
56,
63,
73,
83,
92,
102,
103,
116,
117,
127,
133,
136,
147,
150,
154,
159,
162,
168,
178,
179,
189,
190,
200,
213,
222,
225,
233,
248,
258,
259,
268,
277,
280,
286,
293,
294,
298,
308,
... | [
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"O",
"O",
"O",
"O",
"O",
"B-drug",
"I-drug",
"I-drug",
"I-drug",
"O",
"B-drug",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"B-disease",
"O",
"O",
"B-disease",
... | [
0,
0,
0,
0,
0,
9,
10,
0,
0,
0,
0,
0,
5,
6,
6,
6,
0,
5,
0,
0,
0,
0,
3,
0,
0,
0,
0,
3,
4,
0,
3,
0,
0,
3,
0,
0,
9,
10,
10,
0,
0,
11,
12,
12,
12,
0,
0,
0,
11,
12,
12,
0,
0
] |
MDIEC/19293962 | Embodiment and schizophrenia. The essential feature of schizophrenic existence is its being disembodied. This is the feature that unifies the varied dimensions of that existence. The disembodiment of the self, of the self-object relation and of interpersonal relationships all lead to a kind of world in which the schizo... | T0 disease 15 28 schizophrenia
T1 disease 55 68 schizophrenic
T4 disease 314 327 schizophrenic
T5 region 369 373 body
T8 physiology 0 10 Embodiment
T2 physiology 92 103 disembodied
R1 characteristic_of Arg1:T2 Arg2:T1
T3 physiology 183 196 disembodiment
T6 physiology 379 390 disembodied
| [
"Embodiment",
"and",
"schizophrenia",
".",
"The",
"essential",
"feature",
"of",
"schizophrenic",
"existence",
"is",
"its",
"being",
"disembodied",
".",
"This",
"is",
"the",
"feature",
"that",
"unifies",
"the",
"varied",
"dimensions",
"of",
"that",
"existence",
"... | [
0,
11,
15,
28,
30,
34,
44,
52,
55,
69,
79,
82,
86,
92,
103,
105,
110,
113,
117,
125,
130,
138,
142,
149,
160,
163,
168,
177,
179,
183,
197,
200,
204,
208,
210,
213,
217,
221,
222,
229,
238,
242,
245,
259,
273,
277,
282,
28... | [
10,
14,
28,
29,
33,
43,
51,
54,
68,
78,
81,
85,
91,
103,
104,
109,
112,
116,
124,
129,
137,
141,
148,
159,
162,
167,
177,
178,
182,
196,
199,
203,
208,
209,
212,
216,
221,
222,
228,
237,
241,
244,
258,
272,
276,
281,
284,
... | [
"B-physiology",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"B-physiology",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-physiology",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"... | [
11,
0,
3,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
11,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
11,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
0,
0,
13,... |
MDIEC/29289025 | Impact of misclassification error in the estimation of maternal major depression disorder prevalence in home visitation programs. The objective of this study was to measure the bias introduced by misclassification error when estimating the prevalence of MDD among mothers in two community-based studies. Baseline data we... | T1 disease 55 89 maternal major depression disorder
T2 disease 254 257 MDD
T3 disease 479 482 MDD
T4 disease 1009 1012 MDD
T5 disease 1301 1304 MDD
T6 disease 1487 1490 MDD
#1 AnnotatorNotes T1 C1269683
#2 AnnotatorNotes T2 C1269683
T7 method 489 546 Center of Epidemiological Studies-Depression - Short Form
T8 method 5... | [
"Impact",
"of",
"misclassification",
"error",
"in",
"the",
"estimation",
"of",
"maternal",
"major",
"depression",
"disorder",
"prevalence",
"in",
"home",
"visitation",
"programs",
".",
"The",
"objective",
"of",
"this",
"study",
"was",
"to",
"measure",
"the",
"bi... | [
0,
7,
10,
28,
34,
37,
41,
52,
55,
64,
70,
81,
90,
101,
104,
109,
120,
128,
130,
134,
144,
147,
152,
158,
162,
165,
173,
177,
182,
193,
196,
214,
220,
225,
236,
240,
251,
254,
258,
264,
272,
275,
279,
288,
289,
295,
302,
30... | [
6,
9,
27,
33,
36,
40,
51,
54,
63,
69,
80,
89,
100,
103,
108,
119,
128,
129,
133,
143,
146,
151,
157,
161,
164,
172,
176,
181,
192,
195,
213,
219,
224,
235,
239,
250,
253,
257,
263,
271,
274,
278,
288,
289,
294,
302,
303,
3... | [
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"O",
"B-method",
"I-method",
"I-method",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-d... | [
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
4,
4,
0,
0,
9,
10,
10,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
0,
1,
0,
0,
9,
10,
10,
10,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
9,
10,
10,
0,
0,
0,
... |
MDIEC/23663953 | Treatment of bipolar disorder. We review recent developments in the acute and long-term treatment of bipolar disorder and identify promising future routes to therapeutic innovation. Overall, advances in drug treatment remain quite modest. Antipsychotic drugs are effective in the acute treatment of mania; their efficacy... | T1 disease 13 29 bipolar disorder
T2 disease 101 117 bipolar disorder
T3 disease 299 304 mania
T4 disease 341 351 depression
T5 drug 395 405 quetiapine
T6 disease 545 564 depressive episodes
T7 drug 566 573 Lithium
T8 drug 676 686 divalproex
T9 drug 691 702 lamotrigine
T10 disease 967 977 depression
T13 drug 503 523 an... | [
"Treatment",
"of",
"bipolar",
"disorder",
".",
"We",
"review",
"recent",
"developments",
"in",
"the",
"acute",
"and",
"long",
"-",
"term",
"treatment",
"of",
"bipolar",
"disorder",
"and",
"identify",
"promising",
"future",
"routes",
"to",
"therapeutic",
"innovat... | [
0,
10,
13,
21,
29,
31,
34,
41,
48,
61,
64,
68,
74,
78,
82,
83,
88,
98,
101,
109,
118,
122,
131,
141,
148,
155,
158,
170,
180,
182,
189,
191,
200,
203,
208,
218,
225,
231,
237,
239,
253,
259,
263,
273,
276,
280,
286,
296,
... | [
9,
12,
20,
29,
30,
33,
40,
47,
60,
63,
67,
73,
77,
82,
83,
87,
97,
100,
108,
117,
121,
130,
140,
147,
154,
157,
169,
180,
181,
189,
190,
199,
202,
207,
217,
224,
230,
237,
238,
252,
258,
262,
272,
275,
279,
285,
295,
298,
... | [
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-method",... | [
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
9,
10,
10,
10,
10,
10,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
0,
0,
0,
0,
5,
6,
0,
0,
0,
0,
9,
10,
0,
3,
0,
0,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
... |
MDIEC/36108668 | Kidney function in patients with bipolar disorder with and without lithium BACKGROUND: The clinical relevance of lithium nephropathy is subject to debate. Kidney function decreases with age and comorbidities, and this decline might lead to attribution bias when erroneously ascribed to lithium. We aimed to investigate w... | T0 disease 33 49 bipolar disorder
T1 drug 67 74 lithium
T3 disease 113 132 lithium nephropathy
T4 physiology 0 15 Kidney function
T5 drug 286 293 lithium
T6 Health_factors 186 189 age
T7 disease 194 207 comorbidities
T9 physiology 155 170 Kidney function
T10 disease 341 376 bipolar or schizoaffective disorder
T11 drug ... | [
"Kidney",
"function",
"in",
"patients",
"with",
"bipolar",
"disorder",
"with",
"and",
"without",
"lithium",
"BACKGROUND",
":",
"The",
"clinical",
"relevance",
"of",
"lithium",
"nephropathy",
"is",
"subject",
"to",
"debate",
".",
"Kidney",
"function",
"decreases",
... | [
0,
7,
16,
19,
28,
33,
41,
50,
55,
59,
67,
75,
85,
87,
91,
100,
110,
113,
121,
133,
136,
144,
147,
153,
155,
162,
171,
181,
186,
190,
194,
207,
209,
213,
218,
226,
232,
237,
240,
252,
257,
262,
274,
283,
286,
293,
295,
298,... | [
6,
15,
18,
27,
32,
40,
49,
54,
58,
66,
74,
85,
86,
90,
99,
109,
112,
120,
132,
135,
143,
146,
153,
154,
161,
170,
180,
185,
189,
193,
207,
208,
212,
217,
225,
231,
236,
239,
251,
256,
261,
273,
282,
285,
293,
294,
297,
303... | [
"B-physiology",
"I-physiology",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"B-drug",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"B-physiology",
"I-physiology",
"O",
"O",
"B-Health_factors",
"O",
"B-disease... | [
11,
12,
0,
0,
0,
3,
4,
0,
0,
0,
5,
0,
0,
0,
0,
0,
0,
3,
4,
0,
0,
0,
0,
0,
11,
12,
0,
0,
1,
0,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
5,
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
4,
4,
0,
0,
0,
0,
15,
1... |
MDIEC/20221122_61 | CONCLUSIONS: MVPA predicts fewer symptoms of major depression in middle childhood, and increasing MVPA may serve as a complementary method to prevent and treat childhood depression. | T1 method 118 138 complementary method
T2 disease 160 180 childhood depression
T3 disease 45 61 major depression
T4 Health_factors 13 17 MVPA
T5 Health_factors 65 81 middle childhood
T6 Health_factors 98 102 MVPA
R2 treatment_for Arg1:T6 Arg2:T2
R1 associated_with Arg1:T4 Arg2:T3
R3 occurs_in Arg1:T3 Arg2:T5
| [
"CONCLUSIONS",
":",
"MVPA",
"predicts",
"fewer",
"symptoms",
"of",
"major",
"depression",
"in",
"middle",
"childhood",
",",
"and",
"increasing",
"MVPA",
"may",
"serve",
"as",
"a",
"complementary",
"method",
"to",
"prevent",
"and",
"treat",
"childhood",
"depressi... | [
0,
11,
13,
18,
27,
33,
42,
45,
51,
62,
65,
72,
81,
83,
87,
98,
103,
107,
113,
116,
118,
132,
139,
142,
150,
154,
160,
170,
180
] | [
11,
12,
17,
26,
32,
41,
44,
50,
61,
64,
71,
81,
82,
86,
97,
102,
106,
112,
115,
117,
131,
138,
141,
149,
153,
159,
169,
180,
181
] | [
"O",
"O",
"B-Health_factors",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"O",
"B-Health_factors",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O"
] | [
0,
0,
1,
0,
0,
0,
0,
3,
4,
0,
1,
2,
0,
0,
0,
1,
0,
0,
0,
0,
9,
10,
0,
0,
0,
0,
3,
4,
0
] |
MDIEC/29644161 | Sleep Deprivation Therapy Enhanced Via Repetitive Transcranial Magnetic Stimulation in Major Depression. Transcranial magnetic stimulation (rTMS) and sleep deprivation (SD) are two of the latest advances made in the field of psychiatric research. Though yet in development, they present unique opportunities to achieve s... | T1 disease 87 103 Major Depression
T2 method 169 171 SD
T3 method 225 245 psychiatric research
T4 disease 365 390 major depression disorder
T5 disease 392 395 MDD
T6 disease 481 484 MDD
T7 method 573 575 SD
T8 method 769 771 SD
T9 method 0 25 Sleep Deprivation Therapy
T10 method 105 138 Transcranial magnetic stimulatio... | [
"Sleep",
"Deprivation",
"Therapy",
"Enhanced",
"Via",
"Repetitive",
"Transcranial",
"Magnetic",
"Stimulation",
"in",
"Major",
"Depression",
".",
"Transcranial",
"magnetic",
"stimulation",
"(",
"rTMS",
")",
"and",
"sleep",
"deprivation",
"(",
"SD",
")",
"are",
"two... | [
0,
6,
18,
26,
35,
39,
50,
63,
72,
84,
87,
93,
103,
105,
118,
127,
139,
140,
144,
146,
150,
156,
168,
169,
171,
173,
177,
181,
184,
188,
195,
204,
209,
212,
216,
222,
225,
237,
245,
247,
254,
258,
261,
272,
274,
279,
287,
2... | [
5,
17,
25,
34,
38,
49,
62,
71,
83,
86,
92,
103,
104,
117,
126,
138,
140,
144,
145,
149,
155,
167,
169,
171,
172,
176,
180,
183,
187,
194,
203,
208,
211,
215,
221,
224,
236,
245,
246,
253,
257,
260,
272,
273,
278,
286,
293,
... | [
"B-method",
"I-method",
"I-method",
"O",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"O",
"B-disease",
"I-disease",
"O",
"B-method",
"I-method",
"I-method",
"O",
"B-method",
"O",
"O",
"B-method",
"I-method",
"O",
"B-method",
"O",
"O",
"O",
"O",
"O",
... | [
9,
10,
10,
0,
0,
9,
10,
10,
10,
0,
3,
4,
0,
9,
10,
10,
0,
9,
0,
0,
9,
10,
0,
9,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
4,
0,
3,
0,
0,... |
MDIEC/20221103_39 | Importantly, the antidepressant fluoxetine restores both adult neurogenesis and depressive states, and improves most olfactory functions. | T2 physiology 57 75 adult neurogenesis
T3 disease 80 97 depressive states
T4 physiology 117 136 olfactory functions
T5 drug 32 42 fluoxetine
R2 treatment_for Arg1:T5 Arg2:T2
R3 treatment_for Arg1:T5 Arg2:T3
R4 treatment_for Arg1:T5 Arg2:T4
T1 drug 17 31 antidepressant
| [
"Importantly",
",",
"the",
"antidepressant",
"fluoxetine",
"restores",
"both",
"adult",
"neurogenesis",
"and",
"depressive",
"states",
",",
"and",
"improves",
"most",
"olfactory",
"functions",
"."
] | [
0,
11,
13,
17,
32,
43,
52,
57,
63,
76,
80,
91,
97,
99,
103,
112,
117,
127,
136
] | [
11,
12,
16,
31,
42,
51,
56,
62,
75,
79,
90,
97,
98,
102,
111,
116,
126,
136,
137
] | [
"O",
"O",
"O",
"B-drug",
"B-drug",
"O",
"O",
"B-physiology",
"I-physiology",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"B-physiology",
"I-physiology",
"O"
] | [
0,
0,
0,
5,
5,
0,
0,
11,
12,
0,
3,
4,
0,
0,
0,
0,
11,
12,
0
] |
MDIEC/20221103_139 | Episode length and mixed features as predictors of ECT nonresponse in patients with medication-resistant major depression. | T4 disease 84 121 medication-resistant major depression
T1 method 51 54 ECT
| [
"Episode",
"length",
"and",
"mixed",
"features",
"as",
"predictors",
"of",
"ECT",
"nonresponse",
"in",
"patients",
"with",
"medication",
"-",
"resistant",
"major",
"depression",
"."
] | [
0,
8,
15,
19,
25,
34,
37,
48,
51,
55,
67,
70,
79,
84,
94,
95,
105,
111,
121
] | [
7,
14,
18,
24,
33,
36,
47,
50,
54,
66,
69,
78,
83,
94,
95,
104,
110,
121,
122
] | [
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-method",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"O"
] | [
0,
0,
0,
0,
0,
0,
0,
0,
9,
0,
0,
0,
0,
3,
4,
4,
4,
4,
0
] |
MDIEC/20221122_33 | Among EPI subjects, CES-D-based depression was significantly associated with being female, being younger, lower income, worse QOLIE-89 scores, more SDS disability, more social concerns, more adverse drug events, less past-month employment, and fewer working days. | T1 disease 20 42 CES-D-based depression
T2 Health_factors 106 118 lower income
T3 method 126 134 QOLIE-89
T4 disease 148 162 SDS disability
T5 Health_factors 191 210 adverse drug events
T6 disease 6 9 EPI
T7 Health_factors 83 89 female
T8 Health_factors 97 104 younger
T9 Health_factors 169 184 social concerns
T10 Healt... | [
"Among",
"EPI",
"subjects",
",",
"CES",
"-",
"D",
"-",
"based",
"depression",
"was",
"significantly",
"associated",
"with",
"being",
"female",
",",
"being",
"younger",
",",
"lower",
"income",
",",
"worse",
"QOLIE",
"-",
"89",
"scores",
",",
"more",
"SDS",
... | [
0,
6,
10,
18,
20,
23,
24,
25,
26,
32,
43,
47,
61,
72,
77,
83,
89,
91,
97,
104,
106,
112,
118,
120,
126,
131,
132,
135,
141,
143,
148,
152,
162,
164,
169,
176,
184,
186,
191,
199,
204,
210,
212,
217,
221,
222,
228,
238,
2... | [
5,
9,
18,
19,
23,
24,
25,
26,
31,
42,
46,
60,
71,
76,
82,
89,
90,
96,
104,
105,
111,
118,
119,
125,
131,
132,
134,
141,
142,
147,
151,
162,
163,
168,
175,
184,
185,
190,
198,
203,
210,
211,
216,
221,
222,
227,
238,
239,
... | [
"O",
"B-disease",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"B-Health_factors",
"O",
"O",
"B-Health_factors",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"B-method",
"I-method",
"I-m... | [
0,
3,
0,
0,
3,
4,
4,
4,
4,
4,
0,
0,
0,
0,
0,
1,
0,
0,
1,
0,
1,
2,
0,
0,
9,
10,
10,
0,
0,
0,
3,
4,
0,
0,
1,
2,
0,
0,
1,
2,
2,
0,
0,
0,
0,
0,
1,
0,
0,
0,
1,
2,
0
] |
MDIEC/34696940 | Depression in the Postpartum Year and Life Course Economic Trajectories. INTRODUCTION: Perinatal depression affects 13% of childbearing individuals in the U.S. and has been linked to an increased risk of household economic insecurity in the short term. This study aims to assess the relationship between perinatal depres... | T1 disease 0 10 Depression
T2 disease 87 107 Perinatal depression
T3 disease 304 324 perinatal depression
T4 disease 808 827 maternal depression
T5 disease 980 1004 major depressive episode
T6 disease 1028 1047 Maternal depression
T7 disease 1184 1203 Maternal depression
T8 disease 1358 1377 maternal depression
T9 dise... | [
"Depression",
"in",
"the",
"Postpartum",
"Year",
"and",
"Life",
"Course",
"Economic",
"Trajectories",
".",
"INTRODUCTION",
":",
"Perinatal",
"depression",
"affects",
"13",
"%",
"of",
"childbearing",
"individuals",
"in",
"the",
"U",
".",
"S",
".",
"and",
"has",... | [
0,
11,
14,
18,
29,
34,
38,
43,
50,
59,
71,
73,
85,
87,
97,
108,
116,
118,
120,
123,
136,
148,
151,
155,
156,
157,
158,
160,
164,
168,
173,
180,
183,
186,
196,
201,
204,
214,
223,
234,
237,
241,
247,
251,
253,
258,
264,
269... | [
10,
13,
17,
28,
33,
37,
42,
49,
58,
71,
72,
85,
86,
96,
107,
115,
118,
119,
122,
135,
147,
150,
154,
156,
157,
158,
159,
163,
167,
172,
179,
182,
185,
195,
200,
203,
213,
222,
233,
236,
240,
246,
251,
252,
257,
263,
268,
2... | [
"B-disease",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"... | [
3,
0,
0,
1,
2,
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
0,
0,
0,
0,
1,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
0,
1,
2,
2,
2,
2,
0,
0,
0,
0... |
MDIEC/31816349 | Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. Circulating microRNAs (cimiRNAs) are a class of non-encoding RNAs found in bodily fluids such as blood, cerebrospinal fluid (CSF) and tears. CimiRNAs have been implicated as promising biomarkers for central nervous system (CN... | T1 disease 50 93 psychiatric and neurodegenerative disorders
T2 disease 294 332 central nervous system (CNS) disorders
T3 disease 783 796 CNS disorders
T4 disease 860 880 cognitive impairment
T5 disease 886 899 CNS disorders
T6 disease 908 933 Major depression disorder
T7 disease 935 938 MDD
T8 disease 941 957 Bipolar ... | [
"Circulating",
"microRNAs",
"as",
"potential",
"biomarkers",
"for",
"psychiatric",
"and",
"neurodegenerative",
"disorders",
".",
"Circulating",
"microRNAs",
"(",
"cimiRNAs",
")",
"are",
"a",
"class",
"of",
"non",
"-",
"encoding",
"RNAs",
"found",
"in",
"bodily",
... | [
0,
12,
22,
25,
35,
46,
50,
62,
66,
84,
93,
95,
107,
117,
118,
126,
128,
132,
134,
140,
143,
146,
147,
156,
161,
167,
170,
177,
184,
189,
192,
197,
199,
213,
219,
220,
223,
225,
229,
234,
236,
245,
250,
255,
266,
269,
279,
... | [
11,
21,
24,
34,
45,
49,
61,
65,
83,
93,
94,
106,
116,
118,
126,
127,
131,
133,
139,
142,
146,
147,
155,
160,
166,
169,
176,
183,
188,
191,
197,
198,
212,
218,
220,
223,
224,
228,
234,
235,
244,
249,
254,
265,
268,
278,
289,
... | [
"B-gene",
"I-gene",
"O",
"O",
"B-signs",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"B-gene",
"I-gene",
"O",
"B-gene",
"O",
"O",
"O",
"O",
"O",
"B-gene",
"I-gene",
"I-gene",
"I-gene",
"O",
"O",
"B-region",
"I-region",
"O",
"O",
"B-region... | [
7,
8,
0,
0,
15,
0,
3,
4,
4,
4,
0,
7,
8,
0,
7,
0,
0,
0,
0,
0,
7,
8,
8,
8,
0,
0,
13,
14,
0,
0,
13,
0,
13,
14,
0,
13,
0,
0,
13,
0,
7,
0,
0,
0,
0,
0,
15,
0,
3,
4,
4,
4,
4,
4,
4,
0,
0,
0,
0,
0,
0,
0,... |
MDIEC/30244163 | Social brain, social dysfunction and social withdrawal. The human social brain is complex. Current knowledge fails to define the neurobiological processes underlying social behaviour involving the (patho-) physiological mechanisms that link system-level phenomena to the multiple hierarchies of brain function. Unfortuna... | T1 disease 14 32 social dysfunction
T2 disease 37 54 social withdrawal
T3 disease 450 465 social deficits
T4 disease 517 543 neuropsychiatric disorders
T5 disease 554 567 schizophrenia
T6 disease 575 594 Alzheimer's disease
T7 disease 596 598 AD
T8 disease 604 629 major depressive disorder
T9 disease 631 634 MDD
T10 di... | [
"Social",
"brain",
",",
"social",
"dysfunction",
"and",
"social",
"withdrawal",
".",
"The",
"human",
"social",
"brain",
"is",
"complex",
".",
"Current",
"knowledge",
"fails",
"to",
"define",
"the",
"neurobiological",
"processes",
"underlying",
"social",
"behaviour... | [
0,
7,
12,
14,
21,
33,
37,
44,
54,
56,
60,
66,
73,
79,
82,
89,
91,
99,
109,
115,
118,
125,
129,
145,
155,
166,
173,
183,
193,
197,
198,
203,
204,
206,
220,
231,
236,
241,
247,
248,
254,
264,
267,
271,
280,
292,
295,
301,
... | [
6,
12,
13,
20,
32,
36,
43,
54,
55,
59,
65,
72,
78,
81,
89,
90,
98,
108,
114,
117,
124,
128,
144,
154,
165,
172,
182,
192,
196,
198,
203,
204,
205,
219,
230,
235,
240,
247,
248,
253,
263,
266,
270,
279,
291,
294,
300,
309,
... | [
"B-region",
"I-region",
"O",
"B-disease",
"I-disease",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"B-region",
"I-region",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-physiology",
"I-physiology",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"... | [
13,
14,
0,
3,
4,
0,
3,
4,
0,
0,
0,
13,
14,
0,
0,
0,
0,
0,
0,
0,
0,
0,
11,
12,
0,
1,
2,
0,
0,
11,
12,
12,
12,
12,
12,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
11,
12,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,... |
MDIEC/33181098 | Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62354 COVID-19 cases in the USA. BACKGROUND Adverse mental health consequences of COVID-19, including anxiety and depression, have been widely predicted but not yet accurately measured. There are a range of physical he... | T1 disease 35 43 COVID-19
T2 disease 48 68 psychiatric disorder
T3 disease 108 116 COVID-19
T5 disease 204 211 anxiety
T6 disease 216 226 depression
T7 method 424 469 electronic health record network cohort study
T8 disease 543 551 COVID-19
T9 disease 588 596 COVID-19
T10 disease 810 818 COVID-19
T11 disease 1080 1088 ... | [
"Bidirectional",
"associations",
"between",
"COVID",
"-",
"19",
"and",
"psychiatric",
"disorder",
":",
"retrospective",
"cohort",
"studies",
"of",
"62354",
"COVID",
"-",
"19",
"cases",
"in",
"the",
"USA",
".",
"BACKGROUND",
"Adverse",
"mental",
"health",
"conseq... | [
0,
14,
27,
35,
40,
41,
44,
48,
60,
68,
70,
84,
91,
99,
102,
108,
113,
114,
117,
123,
126,
130,
133,
135,
146,
154,
161,
168,
181,
184,
189,
190,
192,
194,
204,
212,
216,
226,
228,
233,
238,
245,
255,
259,
263,
267,
278,
28... | [
13,
26,
34,
40,
41,
43,
47,
59,
68,
69,
83,
90,
98,
101,
107,
113,
114,
116,
122,
125,
129,
133,
134,
145,
153,
160,
167,
180,
183,
189,
190,
192,
193,
203,
211,
215,
226,
227,
232,
237,
244,
254,
258,
262,
266,
277,
286,
... | [
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"B-disease",
"I-disease",
"O",
"B-method",
"I-method",
"I-method",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"I-... | [
0,
0,
0,
3,
4,
4,
0,
3,
4,
0,
9,
10,
10,
0,
0,
3,
4,
4,
0,
0,
0,
0,
0,
0,
3,
4,
4,
4,
4,
4,
4,
4,
0,
0,
3,
0,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
2,
0,
0,
0,
3,
4,
4,
0,
0,
... |
MDIEC/30669122 | Probing prefrontal cortex hemodynamic alterations during facial emotion recognition for major depression disorder through functional near-infrared spectroscopy. OBJECTIVE: A serious issue in psychiatric practice is a lack of specific, objective biomarker to assist clinicians in establishing differential diagnosis and i... | T1 disease 88 113 major depression disorder
T2 disease 355 380 Major depression disorder
T3 disease 382 385 MDD
T5 disease 680 683 MDD
T6 disease 809 812 MDD
T7 gene 910 931 oxygenated hemoglobin
T8 gene 945 968 deoxygenated hemoglobin
T9 method 1036 1038 HC
T10 disease 1144 1147 MDD
T11 gene 1239 1245 oxy-Hb
T12 gene ... | [
"Probing",
"prefrontal",
"cortex",
"hemodynamic",
"alterations",
"during",
"facial",
"emotion",
"recognition",
"for",
"major",
"depression",
"disorder",
"through",
"functional",
"near",
"-",
"infrared",
"spectroscopy",
".",
"OBJECTIVE",
":",
"A",
"serious",
"issue",
... | [
0,
8,
19,
26,
38,
50,
57,
64,
72,
84,
88,
94,
105,
114,
122,
133,
137,
138,
147,
159,
161,
170,
172,
174,
182,
188,
191,
203,
212,
215,
217,
222,
225,
233,
235,
245,
255,
258,
265,
276,
279,
292,
305,
315,
319,
329,
344,
3... | [
7,
18,
25,
37,
49,
56,
63,
71,
83,
87,
93,
104,
113,
121,
132,
137,
138,
146,
159,
160,
170,
171,
173,
181,
187,
190,
202,
211,
214,
216,
221,
224,
233,
234,
244,
254,
257,
264,
275,
278,
291,
304,
314,
318,
328,
343,
353,
... | [
"O",
"B-symptom",
"I-symptom",
"I-symptom",
"I-symptom",
"O",
"B-physiology",
"I-physiology",
"I-physiology",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"I-method",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O"... | [
0,
17,
18,
18,
18,
0,
11,
12,
12,
0,
3,
4,
4,
0,
9,
10,
10,
10,
10,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
15,
0,
0,
1,
0,
0,
0,
0,
0,
0,
9,
10,
0,
3,
4,
4,
0,
3,
0,
0,
0,
0,
0,
0,
0,
17,... |
MDIEC/19965435 | The schizophrenia susceptibility gene dysbindin controls synaptic homeostasis. The molecular mechanisms that achieve homeostatic stabilization of neural function remain largely unknown. To better understand how neural function is stabilized during development and throughout life, we used an electrophysiology-based forw... | T1 gene 38 47 dysbindin
T2 gene 4 37 schizophrenia susceptibility gene
T3 physiology 57 77 synaptic homeostasis
T4 physiology 83 103 molecular mechanisms
T6 physiology 117 161 homeostatic stabilization of neural function
T7 method 292 338 electrophysiology-based forward genetic screen
T8 gene 382 408 neuronally express... | [
"The",
"schizophrenia",
"susceptibility",
"gene",
"dysbindin",
"controls",
"synaptic",
"homeostasis",
".",
"The",
"molecular",
"mechanisms",
"that",
"achieve",
"homeostatic",
"stabilization",
"of",
"neural",
"function",
"remain",
"largely",
"unknown",
".",
"To",
"bett... | [
0,
4,
18,
33,
38,
48,
57,
66,
77,
79,
83,
93,
104,
109,
117,
129,
143,
146,
153,
162,
169,
177,
184,
186,
189,
196,
207,
211,
218,
227,
230,
241,
248,
260,
264,
275,
279,
281,
284,
289,
292,
309,
310,
316,
324,
332,
339,
3... | [
3,
17,
32,
37,
47,
56,
65,
77,
78,
82,
92,
103,
108,
116,
128,
142,
145,
152,
161,
168,
176,
184,
185,
188,
195,
206,
210,
217,
226,
229,
240,
247,
259,
263,
274,
279,
280,
283,
288,
291,
309,
310,
315,
323,
331,
338,
342,
... | [
"O",
"B-gene",
"I-gene",
"I-gene",
"B-gene",
"O",
"B-physiology",
"I-physiology",
"O",
"O",
"B-physiology",
"I-physiology",
"O",
"O",
"B-physiology",
"I-physiology",
"I-physiology",
"I-physiology",
"I-physiology",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-physi... | [
0,
7,
8,
8,
7,
0,
11,
12,
0,
0,
11,
12,
0,
0,
11,
12,
12,
12,
12,
0,
0,
0,
0,
0,
0,
0,
0,
11,
12,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
10,
10,
10,
10,
0,
0,
0,
0,
0,
0,
0,
0,
7,
8,
8,
0,
0,
0,
... |
MDIEC/31675497 | Stress-Induced Metabolic Disorder in Peripheral CD4+ T Cells Leads to Anxiety-like Behavior. Physical or mental stress leads to neuroplasticity in the brain and increases the risk of depression and anxiety. Stress exposure causes the dysfunction of peripheral T lymphocytes. However, the pathological role and underlying... | T0 disease 0 33 Stress-Induced Metabolic Disorder
T1 region 37 60 Peripheral CD4+ T Cells
T2 disease 70 91 Anxiety-like Behavior
T3 disease 183 193 depression
T4 disease 198 205 anxiety
T6 physiology 128 143 neuroplasticity
T7 region 151 156 brain
T9 Health_factors 93 118 Physical or mental stress
T10 disease 234 273 d... | [
"Stress",
"-",
"Induced",
"Metabolic",
"Disorder",
"in",
"Peripheral",
"CD4",
"+",
"T",
"Cells",
"Leads",
"to",
"Anxiety",
"-",
"like",
"Behavior",
".",
"Physical",
"or",
"mental",
"stress",
"leads",
"to",
"neuroplasticity",
"in",
"the",
"brain",
"and",
"inc... | [
0,
6,
7,
15,
25,
34,
37,
48,
51,
53,
55,
61,
67,
70,
77,
78,
83,
91,
93,
102,
105,
112,
119,
125,
128,
144,
147,
151,
157,
161,
171,
175,
180,
183,
194,
198,
205,
207,
214,
223,
230,
234,
246,
249,
260,
262,
273,
275,
28... | [
6,
7,
14,
24,
33,
36,
47,
51,
52,
54,
60,
66,
69,
77,
78,
82,
91,
92,
101,
104,
111,
118,
124,
127,
143,
146,
150,
156,
160,
170,
174,
179,
182,
193,
197,
205,
206,
213,
222,
229,
233,
245,
248,
259,
261,
273,
274,
282,
... | [
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"B-region",
"I-region",
"I-region",
"I-region",
"I-region",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"B-Health_factors",
"I-Health_factors",
"I-Health_factors",
"I-Health_factors... | [
3,
4,
4,
4,
4,
0,
13,
14,
14,
14,
14,
0,
0,
3,
4,
4,
4,
0,
1,
2,
2,
2,
0,
0,
11,
0,
0,
13,
0,
0,
0,
0,
0,
3,
0,
3,
0,
1,
2,
0,
0,
3,
4,
4,
4,
4,
0,
0,
0,
0,
0,
0,
0,
0,
11,
12,
0,
13,
14,
14,
0,
... |
MDIEC/20221103_102 | Within mothers with a psychiatric disorder (n=173), we estimated the association between antidepressant treatment in pregnancy and postnatal depressive symptom severity, as standardized EPDS mean scores, via the inverse probability of treatment weight (association analysis). | T2 disease 22 42 psychiatric disorder
T5 method 89 113 antidepressant treatment
T6 physiology 117 126 pregnancy
T7 disease 131 159 postnatal depressive symptom
T8 method 186 190 EPDS
T10 method 253 273 association analysis
T1 Health_factors 7 14 mothers
R1 occurs_in Arg1:T1 Arg2:T2
| [
"Within",
"mothers",
"with",
"a",
"psychiatric",
"disorder",
"(",
"n",
"=",
"173",
")",
",",
"we",
"estimated",
"the",
"association",
"between",
"antidepressant",
"treatment",
"in",
"pregnancy",
"and",
"postnatal",
"depressive",
"symptom",
"severity",
",",
"as",... | [
0,
7,
15,
20,
22,
34,
43,
44,
45,
46,
49,
50,
52,
55,
65,
69,
81,
89,
104,
114,
117,
127,
131,
141,
152,
160,
168,
170,
173,
186,
191,
196,
202,
204,
208,
212,
220,
232,
235,
245,
252,
253,
265,
273,
274
] | [
6,
14,
19,
21,
33,
42,
44,
45,
46,
49,
50,
51,
54,
64,
68,
80,
88,
103,
113,
116,
126,
130,
140,
151,
159,
168,
169,
172,
185,
190,
195,
202,
203,
207,
211,
219,
231,
234,
244,
251,
253,
264,
273,
274,
275
] | [
"O",
"B-Health_factors",
"O",
"O",
"B-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"O",
"B-physiology",
"O",
"B-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"O",
"B-method",
"O",
"O",
"O",
... | [
0,
1,
0,
0,
3,
4,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
0,
11,
0,
3,
4,
4,
0,
0,
0,
0,
9,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
0,
0
] |
MDIEC/24352232 | CNVs conferring risk of autism or schizophrenia affect cognition in controls. In a small fraction of patients with schizophrenia or autism, alleles of copy-number variants (CNVs) in their genomes are probably the strongest factors contributing to the pathogenesis of the disease. These CNVs may provide an entry point fo... | T0 disease 24 30 autism
T1 disease 34 47 schizophrenia
T2 symptom 55 64 cognition
T3 disease 115 128 schizophrenia
T4 disease 132 138 autism
T6 disease 251 263 pathogenesis
T9 gene 140 171 alleles of copy-number variants
T11 physiology 360 374 brain function
T12 disease 379 390 dysfunction
T15 Health_factors 625 633 ch... | [
"CNVs",
"conferring",
"risk",
"of",
"autism",
"or",
"schizophrenia",
"affect",
"cognition",
"in",
"controls",
".",
"In",
"a",
"small",
"fraction",
"of",
"patients",
"with",
"schizophrenia",
"or",
"autism",
",",
"alleles",
"of",
"copy",
"-",
"number",
"variants... | [
0,
5,
16,
21,
24,
31,
34,
48,
55,
65,
68,
76,
78,
81,
83,
89,
98,
101,
110,
115,
129,
132,
138,
140,
148,
151,
155,
156,
163,
172,
173,
177,
179,
182,
188,
196,
200,
209,
213,
223,
231,
244,
247,
251,
264,
267,
271,
278,
... | [
4,
15,
20,
23,
30,
33,
47,
54,
64,
67,
76,
77,
80,
82,
88,
97,
100,
109,
114,
128,
131,
138,
139,
147,
150,
155,
156,
162,
171,
173,
177,
178,
181,
187,
195,
199,
208,
212,
222,
230,
243,
246,
250,
263,
266,
270,
278,
279,... | [
"B-gene",
"O",
"O",
"O",
"B-disease",
"O",
"B-disease",
"O",
"B-symptom",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"B-disease",
"O",
"B-gene",
"I-gene",
"I-gene",
"I-gene",
"I-gene",
"I-gene",
"O",
"B-gene",
"O",
"O",
"O",
... | [
7,
0,
0,
0,
3,
0,
3,
0,
17,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
0,
3,
0,
7,
8,
8,
8,
8,
8,
0,
7,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
7,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
11,
12,
... |
MDIEC/16023516 | Attention-deficit hyperactivity disorder. Attention-deficit hyperactivity disorder (ADHD) is a disorder of inattention, impulsivity, and hyperactivity that affects 8-12% of children worldwide. Although the rate of ADHD falls with age, at least half of children with the disorder will have impairing symptoms in adulthood... | T0 disease 0 40 Attention-deficit hyperactivity disorder
T1 disease 42 82 Attention-deficit hyperactivity disorder
T2 disease 84 88 ADHD
T3 disease 107 118 inattention
T4 disease 120 131 impulsivity
T5 disease 137 150 hyperactivity
T7 disease 214 218 ADHD
T8 Health_factors 230 233 age
T9 Health_factors 252 260 children... | [
"Attention",
"-",
"deficit",
"hyperactivity",
"disorder",
".",
"Attention",
"-",
"deficit",
"hyperactivity",
"disorder",
"(",
"ADHD",
")",
"is",
"a",
"disorder",
"of",
"inattention",
",",
"impulsivity",
",",
"and",
"hyperactivity",
"that",
"affects",
"8",
"-",
... | [
0,
9,
10,
18,
32,
40,
42,
51,
52,
60,
74,
83,
84,
88,
90,
93,
95,
104,
107,
118,
120,
131,
133,
137,
151,
156,
164,
165,
166,
168,
170,
173,
182,
191,
193,
202,
206,
211,
214,
219,
225,
230,
233,
235,
238,
244,
249,
252,
... | [
9,
10,
17,
31,
40,
41,
51,
52,
59,
73,
82,
84,
88,
89,
92,
94,
103,
106,
118,
119,
131,
132,
136,
150,
155,
163,
165,
166,
168,
169,
172,
181,
191,
192,
201,
205,
210,
213,
218,
224,
229,
233,
234,
237,
243,
248,
251,
260,... | [
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"O",
"B-disease",
"O",
"O",
"B-disease",
"O",
"O",
"O",
"O",
"O",
"... | [
3,
4,
4,
4,
4,
0,
3,
4,
4,
4,
4,
0,
3,
0,
0,
0,
0,
0,
3,
0,
3,
0,
0,
3,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
3,
0,
0,
1,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
3,
4,
0,
1,
0,
9,
10,
10,
10,
10,... |
MDIEC/31133831 | Altered Resting-State Functional Activity in Medication-Naive Patients With First-Episode Major Depression Disorder vs. Healthy Control: A Quantitative Meta-Analysis. Background: There is an urgent need for a meta-analysis that characterizes the brain states of major depression disorder (MDD) patients and potentially p... | T1 disease 76 115 First-Episode Major Depression Disorder
T2 disease 262 287 major depression disorder
T3 disease 289 292 MDD
T4 disease 644 670 first-episode unipolar MDD
T5 disease 943 946 MDD
T6 disease 1089 1132 first-episode medication-naive unipolar MDD
T7 disease 1422 1441 depressive symptoms
T8 disease 1503 150... | [
"Altered",
"Resting",
"-",
"State",
"Functional",
"Activity",
"in",
"Medication",
"-",
"Naive",
"Patients",
"With",
"First",
"-",
"Episode",
"Major",
"Depression",
"Disorder",
"vs",
".",
"Healthy",
"Control",
":",
"A",
"Quantitative",
"Meta",
"-",
"Analysis",
... | [
0,
8,
15,
16,
22,
33,
42,
45,
55,
56,
62,
71,
76,
81,
82,
90,
96,
107,
116,
118,
120,
128,
135,
137,
139,
152,
156,
157,
165,
167,
177,
179,
185,
188,
191,
198,
203,
207,
209,
213,
214,
223,
228,
242,
246,
252,
259,
262,
... | [
7,
15,
16,
21,
32,
41,
44,
55,
56,
61,
70,
75,
81,
82,
89,
95,
106,
115,
118,
119,
127,
135,
136,
138,
151,
156,
157,
165,
166,
177,
178,
184,
187,
190,
197,
202,
206,
208,
213,
214,
222,
227,
241,
245,
251,
258,
261,
267,... | [
"B-symptom",
"I-symptom",
"I-symptom",
"I-symptom",
"I-symptom",
"I-symptom",
"O",
"B-Health_factors",
"I-Health_factors",
"I-Health_factors",
"I-Health_factors",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"O",
"B-method",
"I-met... | [
17,
18,
18,
18,
18,
18,
0,
1,
2,
2,
2,
0,
3,
4,
4,
4,
4,
4,
0,
0,
9,
10,
0,
0,
9,
10,
10,
10,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
10,
0,
0,
0,
15,
16,
0,
3,
4,
4,
0,
3,
0,
0,
0,
0,
0,
0,
15,
0,
0... |
MDIEC/20221103_117 | AIMS: To arrive at recommendations for addressing co-occurring psychiatric and substance use disorders in the development of the Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-V) criteria. | T2 disease 50 102 co-occurring psychiatric and substance use disorders
T4 method 129 196 Diagnostic and Statistical Manual of Mental Disorders fifth edition
T5 method 198 203 DSM-V
R1 abbreviation_for Arg1:T5 Arg2:T4
| [
"AIMS",
":",
"To",
"arrive",
"at",
"recommendations",
"for",
"addressing",
"co",
"-",
"occurring",
"psychiatric",
"and",
"substance",
"use",
"disorders",
"in",
"the",
"development",
"of",
"the",
"Diagnostic",
"and",
"Statistical",
"Manual",
"of",
"Mental",
"Diso... | [
0,
4,
6,
9,
16,
19,
35,
39,
50,
52,
53,
63,
75,
79,
89,
93,
103,
106,
110,
122,
125,
129,
140,
144,
156,
163,
166,
173,
183,
189,
197,
198,
201,
202,
203,
205,
213
] | [
4,
5,
8,
15,
18,
34,
38,
49,
52,
53,
62,
74,
78,
88,
92,
102,
105,
109,
121,
124,
128,
139,
143,
155,
162,
165,
172,
182,
188,
196,
198,
201,
202,
203,
204,
213,
214
] | [
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"O",
"O",
"O",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-method",
"I-meth... | [
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
4,
4,
4,
4,
4,
4,
0,
0,
0,
0,
0,
9,
10,
10,
10,
10,
10,
10,
10,
10,
0,
9,
10,
10,
0,
0,
0
] |
MDIEC/15800331 | Study of anxiety disorder and depression in long-term survivors of testicular cancer. PURPOSE To increase our knowledge of the prevalence of anxiety disorder and depression in long-term testicular cancer survivors (TCSs), and to identify variables associated with such caseness. PATIENTS AND METHODS Participants were ... | T0 disease 9 25 anxiety disorder
T1 disease 30 40 depression
T3 Health_factors 44 84 long-term survivors of testicular cancer
T4 disease 141 157 anxiety disorder
T5 disease 162 172 depression
T6 Health_factors 176 213 long-term testicular cancer survivors
T7 Health_factors 215 219 TCSs
T10 method 463 476 questionnaire
... | [
"Study",
"of",
"anxiety",
"disorder",
"and",
"depression",
"in",
"long",
"-",
"term",
"survivors",
"of",
"testicular",
"cancer",
".",
"PURPOSE",
"To",
"increase",
"our",
"knowledge",
"of",
"the",
"prevalence",
"of",
"anxiety",
"disorder",
"and",
"depression",
... | [
0,
6,
9,
17,
26,
30,
41,
44,
48,
49,
54,
64,
67,
78,
84,
86,
94,
97,
106,
110,
120,
123,
127,
138,
141,
149,
158,
162,
173,
176,
180,
181,
186,
197,
204,
214,
215,
219,
220,
222,
226,
229,
238,
248,
259,
264,
269,
277,
2... | [
5,
8,
16,
25,
29,
40,
43,
48,
49,
53,
63,
66,
77,
84,
85,
93,
96,
105,
109,
119,
122,
126,
137,
140,
148,
157,
161,
172,
175,
180,
181,
185,
196,
203,
213,
215,
219,
220,
221,
225,
228,
237,
247,
258,
263,
268,
277,
278,
... | [
"O",
"O",
"B-disease",
"I-disease",
"O",
"B-disease",
"O",
"B-Health_factors",
"I-Health_factors",
"I-Health_factors",
"I-Health_factors",
"I-Health_factors",
"I-Health_factors",
"I-Health_factors",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-d... | [
0,
0,
3,
4,
0,
3,
0,
1,
2,
2,
2,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
4,
0,
3,
0,
1,
2,
2,
2,
2,
2,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0... |
MDIEC/20221103_109 | METHODS: Adults receiving blended CBT (10 online sessions in combination with 5 face-to-face sessions) for depression in routine mental health care were recruited in the context of the European implementation project MasterMind. | T2 method 26 37 blended CBT
T3 Health_factors 42 57 online sessions
T4 Health_factors 80 101 face-to-face sessions
T5 disease 107 117 depression
T6 Health_factors 121 147 routine mental health care
T1 Health_factors 9 15 Adults
T7 method 185 227 European implementation project MasterMind
R1 treatment_for Arg1:T2 Arg2:T... | [
"METHODS",
":",
"Adults",
"receiving",
"blended",
"CBT",
"(",
"10",
"online",
"sessions",
"in",
"combination",
"with",
"5",
"face",
"-",
"to",
"-",
"face",
"sessions",
")",
"for",
"depression",
"in",
"routine",
"mental",
"health",
"care",
"were",
"recruited"... | [
0,
7,
9,
16,
26,
34,
38,
39,
42,
49,
58,
61,
73,
78,
80,
84,
85,
87,
88,
93,
101,
103,
107,
118,
121,
129,
136,
143,
148,
153,
163,
166,
170,
178,
181,
185,
194,
209,
217,
227
] | [
7,
8,
15,
25,
33,
37,
39,
41,
48,
57,
60,
72,
77,
79,
84,
85,
87,
88,
92,
101,
102,
106,
117,
120,
128,
135,
142,
147,
152,
162,
165,
169,
177,
180,
184,
193,
208,
216,
227,
228
] | [
"O",
"O",
"B-Health_factors",
"O",
"B-method",
"I-method",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"O",
"O",
"O",
"O",
"B-Health_factors",
"I-Health_factors",
"I-Health_factors",
"I-Health_factors",
"I-Health_factors",
"I-Health_factors",
"O",
"O",
"B-disease",
... | [
0,
0,
1,
0,
9,
10,
0,
0,
1,
2,
0,
0,
0,
0,
1,
2,
2,
2,
2,
2,
0,
0,
3,
0,
1,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
9,
10,
10,
10,
0
] |
MDIEC/18180336 | Corpus callosum in patients with obsessive-compulsive disorder: diffusion-tensor imaging study. PURPOSE To prospectively examine microstructural white matter abnormalities in the corpus callosum (CC) of patients with obsessive-compulsive disorder (OCD), as compared with control subjects, and to investigate the relation... | T0 disease 33 62 obsessive-compulsive disorder
T2 method 64 94 diffusion-tensor imaging study
T3 region 0 15 Corpus callosum
T4 disease 129 171 microstructural white matter abnormalities
T5 disease 217 246 obsessive-compulsive disorder
T6 disease 248 251 OCD
T7 disease 414 417 OCD
T8 method 351 353 DT
T9 method 355 371... | [
"Corpus",
"callosum",
"in",
"patients",
"with",
"obsessive",
"-",
"compulsive",
"disorder",
":",
"diffusion",
"-",
"tensor",
"imaging",
"study",
".",
"PURPOSE",
"To",
"prospectively",
"examine",
"microstructural",
"white",
"matter",
"abnormalities",
"in",
"the",
"... | [
0,
7,
16,
19,
28,
33,
42,
43,
54,
62,
64,
73,
74,
81,
89,
94,
96,
104,
107,
121,
129,
145,
151,
158,
172,
175,
179,
186,
195,
196,
198,
200,
203,
212,
217,
226,
227,
238,
247,
248,
251,
252,
254,
257,
266,
271,
279,
287,
... | [
6,
15,
18,
27,
32,
42,
43,
53,
62,
63,
73,
74,
80,
88,
94,
95,
103,
106,
120,
128,
144,
150,
157,
171,
174,
178,
185,
194,
196,
198,
199,
202,
211,
216,
226,
227,
237,
246,
248,
251,
252,
253,
256,
265,
270,
278,
287,
288,... | [
"B-region",
"I-region",
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"B-method",
"I-method",
"I-method",
"I-method",
"I-method",
"O",
"O",
"O",
"O",
"O",
"B-disease",
"I-disease",
"I-disease",
"I-disease",
"O",
"O",
"B-region",
"I-regi... | [
13,
14,
0,
0,
0,
3,
4,
4,
4,
0,
9,
10,
10,
10,
10,
0,
0,
0,
0,
0,
3,
4,
4,
4,
0,
0,
13,
14,
0,
13,
0,
0,
0,
0,
3,
4,
4,
4,
0,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
9,
10,
10,
0,
9,
0,
9,
... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.